Page last updated: 2024-11-05

ticlopidine and Coronary Thrombosis

ticlopidine has been researched along with Coronary Thrombosis in 496 studies

Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.

Coronary Thrombosis: Coagulation of blood in any of the CORONARY VESSELS. The presence of a blood clot (THROMBUS) often leads to MYOCARDIAL INFARCTION.

Research Excerpts

ExcerptRelevanceReference
"In smokers, a double-dose clopidogrel regimen reduced major cardiovascular events and stent thrombosis after percutaneous coronary intervention, with no increase in major bleeding."9.24Double-Dose Versus Standard-Dose Clopidogrel According to Smoking Status Among Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. ( Bossard, M; Faxon, DP; Fox, KAA; Gao, P; Granger, CB; Jolly, SS; Mehta, SR; Montalescot, G; Natarajan, MK; Niemela, K; Steg, PG; Tanguay, JF; Widimsky, P; Yusuf, S, 2017)
"In CHAMPION PHOENIX, cangrelor reduced ischaemic events with no significant increase in GUSTO-defined severe bleeding."9.22The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX. ( Bhatt, DL; Blankenship, JC; Deliargyris, EN; Généreux, P; Gibson, CM; Gutierrez, JA; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD, 2016)
"The CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention) trial demonstrated that cangrelor significantly reduced periprocedural ischemic events in all-comer percutaneous coronary intervention with a modest increase in mild and moderate bleeding."9.22Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial. ( Abnousi, F; Abtan, J; Bhatt, DL; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD, 2016)
"Ticagrelor reduces thrombotic events compared with clopidogrel in patients with acute coronary syndrome, but may also increase bleeding complications."9.19Coronary artery bypass grafting-related bleeding complications in real-life acute coronary syndrome patients treated with clopidogrel or ticagrelor. ( Albertsson, P; Dellborg, M; Hansson, EC; Jeppsson, A; Rexius, H, 2014)
"Ticagrelor compared with clopidogrel reduces the incidence of stent thrombosis in patients with acute coronary syndromes, with consistent benefit across a broad range of patient, stent, and treatment characteristics."9.17Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial. ( Emanuelsson, H; Harrington, RA; James, SK; Katus, HA; Lewis, BS; Mahaffey, KW; Maurer, G; Meier, B; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, DM, 2013)
"The study aimed to compare the antiplatelet action of ticagrelor with prasugrel in acute coronary syndrome (ACS) patients with high on-treatment platelet reactivity (HTPR) while on clopidogrel after percutaneous coronary intervention (PCI)."9.16Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study. ( Alexopoulos, D; Damelou, A; Davlouros, P; Galati, A; Hahalis, G; Kassimis, G; Makris, G; Mavronasiou, E; Theodoropoulos, KC; Tsigkas, G; Xanthopoulou, I, 2012)
"Residual platelet reactivity (RPR) after clopidogrel loading, measured by the VerifyNow assay, has been shown to predict 12-month clinical events in patients with acute coronary syndromes."9.15Residual platelet reactivity after clopidogrel loading in patients with ST-elevation myocardial infarction undergoing an unexpectedly delayed primary percutaneous coronary intervention. - Impact on intracoronary thrombus burden and myocardial perfusion-. ( Archontakis, S; Gafou, A; Kalogeras, KI; Kariori, MG; Moldovan, C; Papaioannou, TG; Stefanadis, C; Tzamalis, P; Vavuranakis, M; Vrachatis, DA, 2011)
" On-clopidogrel platelet reactivity was investigated in patients with previous angiographically confirmed STh, myocardial infarction (MI), and controls."9.15Relationship between clopidogrel-induced platelet P2Y12 inhibition and stent thrombosis or myocardial infarction after percutaneous coronary intervention-a case-control study. ( Erlinge, D; James, S; Koul, S; Lagerqvist, B; Siegbahn, A; Varenhorst, C; Wallentin, L, 2011)
"The aim of this analysis was to evaluate whether routine pre-hospital administration of high-dose tirofiban in ST-segment elevation myocardial infarction (STEMI) decreases the incidence of early stent thrombosis after primary PCI."9.14Marked reduction of early stent thrombosis with pre-hospital initiation of high-dose Tirofiban in ST-segment elevation myocardial infarction. ( De Boer, MJ; Dill, T; Gosselink, AT; Hamm, C; Heestermans, AA; Hoorntje, JC; Koopmans, PC; Ten Berg, JM; Van 't Hof, AW; Van Houwelingen, G; Van Werkum, JW, 2009)
"Aspirin and clopidogrel are recommended for patients with acute coronary syndromes (ACS) or undergoing coronary stenting."9.14Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. ( Ardissino, D; Becker, RC; Cannon, CP; Emanuelsson, H; Finkelstein, A; Harrington, RA; Husted, S; James, S; Katus, H; Kilhamn, J; Olofsson, S; Steg, PG; Storey, RF; Wallentin, L; Weaver, WD, 2010)
"Dual antiplatelet therapy with aspirin plus a P2Y(12) receptor inhibitor is the cornerstone of treatment for patients with acute coronary syndrome and in those undergoing percutaneous coronary intervention."8.89Switching antiplatelet regimens: alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI: a review of the literature and practical considerations for the interventional cardiologist. ( Angiolillo, DJ; Azmoon, S, 2013)
" In this article we focus on the use of clopidogrel in the contemporary management of coronary artery disease."8.84Contemporary use of clopidogrel in patients with coronary artery disease. ( Beckman, JA; Parikh, SA, 2007)
"One of the most unusual causes of thrombotic thrombocytopenic purpura (TTP), a life-threatening disease, is ticlopidine hydrochloride, an antiplatelet agent used to prevent strokes in high-risk populations or following coronary artery stent placement."8.80Thrombotic thrombocytopenic purpura associated with ticlopidine in the setting of coronary artery stents and stroke prevention. ( Bennett, CL; Bennett, RH; Davidson, CJ; Feldman, MD; Raisch, DW; Weinberg, PD, 1999)
"PROMETHEUS was a multicentre observational study that compared clopidogrel vs prasugrel in acute coronary syndrome patients who underwent PCI (n = 19,914)."7.88Associations Between Complex PCI and Prasugrel or Clopidogrel Use in Patients With Acute Coronary Syndrome Who Undergo PCI: From the PROMETHEUS Study. ( Aquino, M; Baber, U; Baker, BA; Chandrasekhar, J; Dangas, G; DeFranco, A; Effron, MB; Farhan, S; Ge, Z; Henry, TD; Kapadia, S; Keller, S; Kini, AS; Mehran, R; Muhlestein, JB; Pocock, S; Rao, S; Sartori, S; Sorrentino, S; Strauss, C; Toma, C; Vogel, B; Weintraub, W; Weiss, S, 2018)
"Among patients in the CHAMPION trials with a prior cerebrovascular event at least 1 year before the percutaneous coronary intervention, the efficacy and bleeding profile of cangrelor compared with clopidogrel was similar to that in the overall trial."7.85Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention. ( Bhatt, DL; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Sawlani, NN; Steg, PG; Stone, GW; White, HD, 2017)
"There are limited data about long-term outcomes for biodegradable polymer biolimus-eluting stent (BES) versus durable polymer everolimus-eluting stent (EES) in patients undergoing percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI)."7.81Biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent in patients with acute myocardial infarction. ( Choi, JH; Choi, RK; Choi, SH; Choi, YJ; Gwon, HC; Hahn, JY; Jang, HJ; Kim, JS; Kim, TH; Lee, HJ; Lee, SH; Park, JS; Park, TK; Roh, YM; Shim, WH; Song, YB; Yang, JH; Yu, CW, 2015)
"This study sought to assess the usefulness of clopidogrel-pathway genotyping and on-treatment platelet reactivity (OTR) testing in predicting major adverse cardiac events (MACE) in stable coronary artery disease (CAD) patients receiving drug-eluting stents (DES) under dual antiplatelet (clopidogrel plus aspirin) therapy."7.79Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease. ( Briguori, C; Condorelli, G; De Micco, F; Focaccio, A; Latronico, MV; Pagnotta, P; Papa, L; Roncarati, R; Visconti, G; Viviani Anselmi, C, 2013)
"CYP2C19*17 carrier status is significantly associated with enhanced response to clopidogrel and an increased risk of bleeding."7.76Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. ( Braun, S; Gebhard, D; Kastrati, A; Koch, W; Morath, T; Schömig, A; Schuster, T; Sibbing, D; Stegherr, J; von Beckerath, N, 2010)
" The present study was designed to assess the predictive value of adenosine diphosphate (ADP)-induced platelet aggregation (ADP-Ag) and the Platelet Reactivity Index of vasodilator-stimulated phosphoprotein for the occurrence of stent thrombosis in patients admitted for non-ST-elevation acute coronary syndrome undergoing percutaneous coronary intervention."7.75Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients. ( Alessi, MC; Bali, L; Bonnet, JL; Castelli, C; Cuisset, T; Frere, C; Gaborit, B; Morange, PE; Poyet, R; Quilici, J, 2009)
"The incidence of subacute stent thrombosis (SAT) within 30 days after stenting with a sirolimus-eluting stent (Cypher) for acute myocardial infarction (AMI) was retrospectively compared to that with bare-metal stents (BMS)."7.73Documented subacute stent thrombosis within thirty days after stenting with sirolimus-eluting stent (Cypher) for acute myocardial infarction: a Japanese single center retrospective non-randomized study. ( Enta, K; Fuda, Y; Higashitani, M; Horie, T; Imai, K; Ishikawa, T; Mochizuki, S; Mutoh, M; Nakano, Y; Okada, H; Sakamoto, H; Satoh, T; Yamaguchi, J, 2006)
"The antiplatelet effect of clopidogrel was studied prospectively in 60 consecutive patients who underwent primary angioplasty (percutaneous coronary intervention [PCI]) with stenting for acute ST-segment-elevation myocardial infarction (STEMI) to determine whether variability in response to clopidogrel affects clinical outcomes."7.72Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. ( Beinart, R; Bienart, R; Goldenberg, I; Guetta, V; Hod, H; Matetzky, S; Novikov, I; Pres, H; Savion, N; Shechter, M; Shenkman, B; Varon, D, 2004)
"We report 3 cases of fatal neutropenia and thrombocytopenia associated with ticlopidine after coronary stenting."7.70Fatal neutropenia and thrombocytopenia associated with ticlopidine after stenting. ( Ball, MW; Linnemeier, TJ; Szto, GY, 1999)
" We report the successful use of ticlopidine, together with aspirin, in a 7-month-old infant with Kawasaki disease complicated by a thrombus in a giant coronary aneurysm that failed to resolve with thrombolytic therapy."7.70Ticlopidine plus aspirin for coronary thrombosis in Kawasaki disease. ( Baker, AL; Neufeld, EJ; Newburger, JW; O'Brien, M; Parness, IA; Sundel, RP, 2000)
"The incidence of thrombocytopenia with ticlopidine and clopidogrel when used in conjunction with abciximab has not been systematically addressed."7.70Incidence of thrombocytopenia following coronary stent placement using abciximab plus clopidogrel or ticlopidine. ( Dillon, JC; Dillon, WC; Eckert, GJ; Ritchie, ME, 2000)
"We examined the antithrombotic effect of ticlopidine on occlusive thrombi of small coronary arteries in (NZWxBXSB)F1 [(WxB)F1] male mice with myocardial infarction (MI) and systemic lupus erythematosus (SLE)."7.69Antithrombotic effect of ticlopidine on occlusive thrombi of small coronary arteries in (NZWxBXSB)F1 male mice with myocardial infarction and systemic lupus erythematosus. ( Fujiwara, H; Nakamura, Y; Shibata, Y; Suzuka, H; Tanaka, M; Yoshifusa, H, 1995)
" The primary end point was major adverse cardiac events (death, MI, and ischemia-driven target vessel revascularization) at 12 months."6.74Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction. ( Cheong, SS; Cho, YH; Hong, MK; Hong, TJ; Jeong, MH; Kim, JJ; Kim, KS; Kim, YH; Lee, CW; Lee, JH; Lee, NH; Lee, SG; Lee, SH; Lim, DS; Park, DW; Park, SJ; Park, SW; Seong, IW; Seung, KB; Yang, JY; Yoon, J; Yun, SC, 2009)
"In conclusion, in a dog coronary thrombosis model, ticagrelor blocks ADP-induced platelet activation and aggregation; prevents platelet-mediated thrombosis; prolongs reperfusion time and reduces re-occlusion and cyclic flow variation; and significantly decreases infarct size and rapidly restores myocardial tissue perfusion."5.36Adjunctive treatment with ticagrelor, but not clopidogrel, added to tPA enables sustained coronary artery recanalisation with recovery of myocardium perfusion in a canine coronary thrombosis model. ( Huang, Y; Khalil, M; Penn, MS; van Giezen, JJ; Wang, K; Wiktor, D; Zhou, X, 2010)
"Tirofiban was administered for 24 h and the IABP was withdrawn after 60 h."5.35Reversible clopidogrel resistance due to right ventricular myocardial infarction: risk factor of recurrent stent thrombosis? ( Braun-Dullaeus, RC; Hass, N; Ibrahim, K; Kolschmann, S; Strasser, RH, 2008)
"The DAPT (Dual Antiplatelet Therapy) study randomized 11,648 patients free from ischemic and bleeding events 12 months after coronary stenting to continued thienopyridine plus aspirin therapy for an additional 18 months versus aspirin therapy alone."5.24Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study. ( Apruzzese, PK; Cutlip, DE; Kereiakes, DJ; Massaro, JM; Mauri, L; Secemsky, EA; Steg, PG; Yeh, RW, 2017)
"The ITALIC (Is There a Life for DES After Discontinuation of Clopidogrel) trial showed that rates of bleeding and thrombotic events at 1 year were much the same with 6 versus 12 months of DAPT after percutaneous coronary intervention with second-generation drug-eluting stents."5.246- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin: Final Results of the ITALIC Trial (Is There a Life for DES After Discontinuation of Clopidogrel). ( Armengaud, J; Barragan, P; Ben Amer, H; Berlan, J; Blanchard, D; Bressolette, E; Carrie, D; Cassat, C; Castellant, P; Cazaux, P; Champagnac, D; Darremont, O; Dauphin, R; Delarche, N; Didier, R; Druelles, P; Dupouy, P; Furber, A; Gilard, M; Gommeaux, A; Hovasse, T; Jouve, B; Kermarrec, A; Kiss, RG; Le Breton, H; Levy, G; Lyuycx-Bore, A; Maillard, L; Majwal, T; Morice, MC; Noor, HA; Noryani, AAL; Ohlmann, P; Ormezzano, O; Paganelli, F; Sainsous, J; Schneeberger, M; Ungi, I; Wojcik, J, 2017)
"In smokers, a double-dose clopidogrel regimen reduced major cardiovascular events and stent thrombosis after percutaneous coronary intervention, with no increase in major bleeding."5.24Double-Dose Versus Standard-Dose Clopidogrel According to Smoking Status Among Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. ( Bossard, M; Faxon, DP; Fox, KAA; Gao, P; Granger, CB; Jolly, SS; Mehta, SR; Montalescot, G; Natarajan, MK; Niemela, K; Steg, PG; Tanguay, JF; Widimsky, P; Yusuf, S, 2017)
"Thienopyridine plus aspirin beyond 1 year after coronary stenting reduces myocardial infarction (MI) risk and increases bleeding risk in comparison with aspirin alone."5.24Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy). ( Cutlip, DE; D'Agostino, RB; Hsieh, WH; Kereiakes, DJ; Massaro, JM; Mauri, L; Stefanescu Schmidt, AC; Yeh, RW, 2017)
"In CHAMPION PHOENIX, cangrelor reduced ischaemic events with no significant increase in GUSTO-defined severe bleeding."5.22The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX. ( Bhatt, DL; Blankenship, JC; Deliargyris, EN; Généreux, P; Gibson, CM; Gutierrez, JA; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD, 2016)
"Among patients with STEMI undergoing PPCI, ticagrelor reduces the incidence of MACCE and the composite end point of cardiovascular death, nonfatal MI, and stroke compared with clopidogrel."5.22Assessment of Ticagrelor Versus Clopidogrel Treatment in Patients With ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. ( Jing, Q; Li, R; Liu, P; Liu, Y; Tang, X; Wang, Q; Zhang, P, 2016)
"Compared with 12-month DAPT, 6-month DAPT did not increase the composite events of cardiac death, myocardial infarction, stroke, or TIMI major bleeding at 1 year in patients who underwent everolimus-eluting stent implantation."5.226-Month Versus 12-Month Dual-Antiplatelet Therapy Following Long Everolimus-Eluting Stent Implantation: The IVUS-XPL Randomized Clinical Trial. ( Choi, D; Her, AY; Hong, MK; Hong, SJ; Jang, Y; Kim, BK; Kim, JS; Kim, YH; Ko, YG; Shin, DH, 2016)
"Despite broad differences in clinical profiles and indications for percutaneous coronary intervention by region in a large global cardiovascular clinical trial, cangrelor consistently reduced rates of ischemic end points compared with clopidogrel without an excess in severe bleeding in both the US and non-US subgroups."5.22Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial. ( Bhatt, DL; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; Vaduganathan, M; White, HD, 2016)
"The CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention) trial demonstrated that cangrelor significantly reduced periprocedural ischemic events in all-comer percutaneous coronary intervention with a modest increase in mild and moderate bleeding."5.22Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial. ( Abnousi, F; Abtan, J; Bhatt, DL; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD, 2016)
"We evaluated the impact of clopidogrel 150 mg/d in patients with chronic kidney disease (CKD) having clopidogrel resistance (CR) after percutaneous coronary intervention (PCI); 1076 consecutive patients with coronary artery disease (CAD) having CKD were enrolled."5.20High clopidogrel dose in patients with chronic kidney disease having clopidogrel resistance after percutaneous coronary intervention. ( Han, H; Li, Y; Liang, J; Liu, W; Liu, Y; Shi, D; Wang, Z; Yang, L; Zhang, L; Zhao, Y; Zhou, Y, 2015)
"The aim of this study was to examine the efficacy and bleeding outcomes of cangrelor in patients in the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]) who underwent percutaneous coronary intervention with bivalirudin."5.20Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]). ( Bhatt, DL; Cortese, B; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Liu, T; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD; Wilensky, M, 2015)
"The relationships between Q waves that appear during the acute phase of ST-elevation myocardial infarction (STEMI), clinical characteristics, ST-segment resolution (STRes), and clopidogrel therapy in patients treated with fibrinolysis are not well described."5.19Clinical implications and correlates of Q waves in patients with ST-elevation myocardial infarction treated with fibrinolysis: observations from the CLARITY-TIMI 28 trial. ( Cannon, CP; Gibson, CM; Giugliano, RP; Morrow, DA; Sabatine, MS; Scirica, BM; Sloan, S; Waks, JW; Wiviott, SD, 2014)
"Ticagrelor reduces thrombotic events compared with clopidogrel in patients with acute coronary syndrome, but may also increase bleeding complications."5.19Coronary artery bypass grafting-related bleeding complications in real-life acute coronary syndrome patients treated with clopidogrel or ticagrelor. ( Albertsson, P; Dellborg, M; Hansson, EC; Jeppsson, A; Rexius, H, 2014)
"Definite/probable ST and MB (TIMI major and Bleeding Academic Research Consortium (BARC) ≥ 3) were compared in 2 subsequent trials with similar inclusion criteria but different DAPT duration, that is, BASKET (6 months; n = 557) and BASKET-PROVE (12 months; n = 2,314), between months 0 to 6 (DAPT in both trials), 7 to 12 (DAPT in BASKET-PROVE only), and 13 to 24 (aspirin in both trials) using propensity score-adjusted, time-stratified Cox proportional hazard models."5.19Tradeoff between bleeding and stent thrombosis in different dual antiplatelet therapy regimes: Importance of case fatality rates and effective treatment durations. ( Alber, H; Bonetti, PO; Eberli, F; Erne, P; Galatius, S; Jeger, RV; Kaiser, CA; Pedrazzini, G; Pfisterer, ME; Rickli, H; Sørensen, R; von Felten, S, 2014)
"The PLATO (Platelet Inhibition and Patient Outcomes) angiographic substudy sought to compare the efficacy of ticagrelor versus clopidogrel with respect to angiographic outcomes before and after PCI in the setting of acute coronary syndrome."5.17Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes). ( Emanuelsson, H; Gibson, CM; Harrington, RA; Horrow, J; James, SK; Katus, H; Kunadian, V; Maya, J; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, DM; Wu, J; Zorkun, C, 2013)
"Ticagrelor compared with clopidogrel reduces the incidence of stent thrombosis in patients with acute coronary syndromes, with consistent benefit across a broad range of patient, stent, and treatment characteristics."5.17Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial. ( Emanuelsson, H; Harrington, RA; James, SK; Katus, HA; Lewis, BS; Mahaffey, KW; Maurer, G; Meier, B; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, DM, 2013)
"The study aimed to compare the antiplatelet action of ticagrelor with prasugrel in acute coronary syndrome (ACS) patients with high on-treatment platelet reactivity (HTPR) while on clopidogrel after percutaneous coronary intervention (PCI)."5.16Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study. ( Alexopoulos, D; Damelou, A; Davlouros, P; Galati, A; Hahalis, G; Kassimis, G; Makris, G; Mavronasiou, E; Theodoropoulos, KC; Tsigkas, G; Xanthopoulou, I, 2012)
"The Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial included 3602 patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention who were randomized to heparin plus a glycoprotein IIb/IIIa inhibitor (GPI) (n=1802) versus bivalirudin monotherapy (n=1800)."5.15Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction. ( Brodie, BR; Caixeta, A; Cristea, E; Dangas, GD; Dudek, D; Guagliumi, G; Lansky, AJ; Mehran, R; Möeckel, M; Parise, H; Peruga, JZ; Stone, GW; Witzenbichler, B, 2011)
"Residual platelet reactivity (RPR) after clopidogrel loading, measured by the VerifyNow assay, has been shown to predict 12-month clinical events in patients with acute coronary syndromes."5.15Residual platelet reactivity after clopidogrel loading in patients with ST-elevation myocardial infarction undergoing an unexpectedly delayed primary percutaneous coronary intervention. - Impact on intracoronary thrombus burden and myocardial perfusion-. ( Archontakis, S; Gafou, A; Kalogeras, KI; Kariori, MG; Moldovan, C; Papaioannou, TG; Stefanadis, C; Tzamalis, P; Vavuranakis, M; Vrachatis, DA, 2011)
" On-clopidogrel platelet reactivity was investigated in patients with previous angiographically confirmed STh, myocardial infarction (MI), and controls."5.15Relationship between clopidogrel-induced platelet P2Y12 inhibition and stent thrombosis or myocardial infarction after percutaneous coronary intervention-a case-control study. ( Erlinge, D; James, S; Koul, S; Lagerqvist, B; Siegbahn, A; Varenhorst, C; Wallentin, L, 2011)
"We screened 1277 patients to enroll 93 aspirin, 147 clopidogrel, and 23 dual poor responders, based on a point-of-care assay, who underwent elective coronary angioplasty at 10 European sites for stable or low-risk unstable coronary artery disease."5.14Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho ( Angiolillo, DJ; Brugaletta, S; Campo, G; Colangelo, S; de Cesare, N; Ferrari, R; Furgieri, A; Hamon, M; Meliga, E; Parrinello, G; Percoco, G; Repetto, A; Sabatè, M; Valgimigli, M; Vranckx, P, 2009)
"The aim of this analysis was to evaluate whether routine pre-hospital administration of high-dose tirofiban in ST-segment elevation myocardial infarction (STEMI) decreases the incidence of early stent thrombosis after primary PCI."5.14Marked reduction of early stent thrombosis with pre-hospital initiation of high-dose Tirofiban in ST-segment elevation myocardial infarction. ( De Boer, MJ; Dill, T; Gosselink, AT; Hamm, C; Heestermans, AA; Hoorntje, JC; Koopmans, PC; Ten Berg, JM; Van 't Hof, AW; Van Houwelingen, G; Van Werkum, JW, 2009)
"Aspirin and clopidogrel are recommended for patients with acute coronary syndromes (ACS) or undergoing coronary stenting."5.14Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. ( Ardissino, D; Becker, RC; Cannon, CP; Emanuelsson, H; Finkelstein, A; Harrington, RA; Husted, S; James, S; Katus, H; Kilhamn, J; Olofsson, S; Steg, PG; Storey, RF; Wallentin, L; Weaver, WD, 2010)
" The Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38) showed an overall reduction in ischemic events with more intensive antiplatelet therapy with prasugrel than with clopidogrel but with more bleeding."5.13Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial I ( Angiolillo, DJ; Antman, EM; Braunwald, E; Corbalan, R; Dalby, AJ; Goodman, SG; McCabe, CH; Meisel, S; Murphy, SA; Purdy, DA; Verheugt, FW; Wiviott, SD, 2008)
"In elective stenting without clopidogrel pretreatment, use of a GPIIb/IIIa inhibitor produces superior platelet inhibition and lower myocardial necrosis compared with high-dose (600 mg) or standard-dose (300 mg) clopidogrel loading alone."5.11Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. ( Bliden, KP; Gurbel, PA; Hayes, KM; Tantry, US; Yoho, JA; Zaman, KA, 2005)
" Furthermore, the simpler dosing regimen, the absence of neutropenia, and the lower frequency of other side effects make it a safe alternative to ticlopidine."5.09Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. ( Collins, M; Colombo, A; Iyer, S; Kreps, E; Maida, R; Moses, JW; Moussa, I; Oetgen, M; Roubin, G; Wang, X, 1999)
"Compared with standard clopidogrel therapy, individualized intensified antiplatelet therapy on the basis of platelet reactivity testing reduces the incidence of cardiovascular events in patient undergoing PCI, without increasing the risk of bleeding."4.95Individualized dual antiplatelet therapy based on platelet function testing in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials. ( Huang, C; Wang, Y; Wu, Y; Xu, W; Yan, H; Zhang, L; Zhou, Y; Zhu, J; Zhu, W, 2017)
"The association between DAPT interruption and the rates of stent thrombosis (ST) and cardiac death/target-vessel myocardial infarction (CD/TVMI) in patients receiving a Resolute zotarolimus-eluting stent (R-ZES) was analysed in 4896 patients from the pooled RESOLUTE clinical programme."4.90Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation. ( Belardi, JA; Brar, S; Kirtane, AJ; Liu, M; Rothman, M; Silber, S; Windecker, S, 2014)
"Dual antiplatelet therapy with aspirin plus a P2Y(12) receptor inhibitor is the cornerstone of treatment for patients with acute coronary syndrome and in those undergoing percutaneous coronary intervention."4.89Switching antiplatelet regimens: alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI: a review of the literature and practical considerations for the interventional cardiologist. ( Angiolillo, DJ; Azmoon, S, 2013)
"P2Y12 adenosine di-phosphate (ADP) receptor antagonists are critical to reduce thrombotic recurrences in acute coronary syndromes patients and for those undergoing percutaneous coronary revascularization."4.88Tailoring antiplatelet therapy: a step toward individualized therapy to improve clinical outcome? ( Bessereau, J; Bonello, L; Camoin-Jau, L; Laine, M; Paganelli, F; Sébastien, A, 2012)
"Clopidogrel has become part of the mainstay of therapy for acute coronary syndromes and in patients post stenting."4.87Proton pump inhibitors, genetic polymorphisms and response to clopidogrel therapy. ( Dart, AM; Fernando, H; Peter, K; Shaw, JA, 2011)
" In this article we focus on the use of clopidogrel in the contemporary management of coronary artery disease."4.84Contemporary use of clopidogrel in patients with coronary artery disease. ( Beckman, JA; Parikh, SA, 2007)
"The clinical benefit of the combination of aspirin plus clopidogrel over aspirin alone to prevent recurrent events after acute coronary syndrome is obviously a key step of the past few years in the management of coronary artery disease."4.84[Management coronary syndrome in the acute phase]. ( Collet, JP; Montalescot, G, 2007)
"The purpose of this article was to determine the incidence of in-stent thrombosis (IST) after coronary stent implantation in patients with cocaine abuse."4.84Increased incidence of in-stent thrombosis related to cocaine use: case series and review of literature. ( Arora, R; Bahekar, A; Handa, K; Khosla, S; Khraisat, A; Singh, S; Trivedi, A, 2007)
"The current standard of care for the treatment of arterial thrombosis includes anticoagulants and three classes of antiplatelet agents--aspirin, thienopyridines and glycoprotein IIb-IIIa antagonists."4.82Therapeutic approaches in arterial thrombosis. ( Andre, P; Conley, PB; Phillips, DR; Sinha, U, 2005)
"One of the most unusual causes of thrombotic thrombocytopenic purpura (TTP), a life-threatening disease, is ticlopidine hydrochloride, an antiplatelet agent used to prevent strokes in high-risk populations or following coronary artery stent placement."4.80Thrombotic thrombocytopenic purpura associated with ticlopidine in the setting of coronary artery stents and stroke prevention. ( Bennett, CL; Bennett, RH; Davidson, CJ; Feldman, MD; Raisch, DW; Weinberg, PD, 1999)
"PROMETHEUS was a multicentre observational study that compared clopidogrel vs prasugrel in acute coronary syndrome patients who underwent PCI (n = 19,914)."3.88Associations Between Complex PCI and Prasugrel or Clopidogrel Use in Patients With Acute Coronary Syndrome Who Undergo PCI: From the PROMETHEUS Study. ( Aquino, M; Baber, U; Baker, BA; Chandrasekhar, J; Dangas, G; DeFranco, A; Effron, MB; Farhan, S; Ge, Z; Henry, TD; Kapadia, S; Keller, S; Kini, AS; Mehran, R; Muhlestein, JB; Pocock, S; Rao, S; Sartori, S; Sorrentino, S; Strauss, C; Toma, C; Vogel, B; Weintraub, W; Weiss, S, 2018)
"The present study confirms the strong relationship of high platelet reactivity on clopidogrel to 2-year ischemic and bleeding outcomes after DES."3.85Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated With Drug-Eluting Stents: 2-Year Results of a Prospective, Multicenter Registry Study. ( Ben-Yehuda, O; Brodie, BR; Cox, DA; Duffy, PL; Généreux, P; Gurbel, PA; Henry, TD; Kirtane, AJ; Litherland, C; Mazzaferri, EL; Mehran, R; Metzger, DC; Neumann, FJ; Rinaldi, MJ; Simonton, CA; Stone, GW; Stuckey, TD; Weisz, G; Witzenbichler, B, 2017)
"In clopidogrel treated PCI patients, the 2-year adjusted risk of MACE and NACE was significantly higher in PPI users driven by higher TLR compared to non-PPI users, without a difference in bleeding."3.85Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry. ( Aquino, M; Ariti, C; Baber, U; Bansilal, S; Chandrasekhar, J; Chieffo, A; Cohen, D; Colombo, A; Dangas, G; Faggioni, M; Farhan, S; Gabriel Steg, P; Giustino, G; Henry, T; Kini, A; Mehran, R; Michael Gibson, C; Moliterno, D; Pocock, S; Saporito, R; Sartori, S; Stuckey, T; Vogel, B; Witzenbichler, B, 2017)
"Among patients in the CHAMPION trials with a prior cerebrovascular event at least 1 year before the percutaneous coronary intervention, the efficacy and bleeding profile of cangrelor compared with clopidogrel was similar to that in the overall trial."3.85Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention. ( Bhatt, DL; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Sawlani, NN; Steg, PG; Stone, GW; White, HD, 2017)
"Dual-antiplatelet therapy with aspirin and clopidogrel after percutaneous coronary intervention reduces the risk for coronary thrombotic events (CTEs) at the expense of increasing risk for major bleeding (MB)."3.83Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS. ( Ariti, C; Baber, U; Chieffo, A; Cohen, DJ; Colombo, A; Dangas, G; Gibson, CM; Giustino, G; Henry, TD; Kini, AS; Kirtane, AJ; Krucoff, MW; Litherland, C; Mehran, R; Moliterno, DJ; Pocock, S; Sartori, S; Steg, PG; Stone, GW; Weisz, G; Witzenbichler, B, 2016)
"There are limited data about long-term outcomes for biodegradable polymer biolimus-eluting stent (BES) versus durable polymer everolimus-eluting stent (EES) in patients undergoing percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI)."3.81Biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent in patients with acute myocardial infarction. ( Choi, JH; Choi, RK; Choi, SH; Choi, YJ; Gwon, HC; Hahn, JY; Jang, HJ; Kim, JS; Kim, TH; Lee, HJ; Lee, SH; Park, JS; Park, TK; Roh, YM; Shim, WH; Song, YB; Yang, JH; Yu, CW, 2015)
"Patients with high PR on clopidogrel have a greater incidence of adverse ischemic events after stent implantation, whereas low PR may increase bleeding."3.81Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: "Window" Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents). ( Brodie, BR; Cox, DA; Duffy, PL; Généreux, P; Henry, TD; Kirtane, AJ; Maehara, A; Mazzaferri, EL; Mehran, R; Metzger, DC; Neumann, FJ; Parikh, PB; Parvataneni, R; Rinaldi, MJ; Stone, GW; Stuckey, TD; Weisz, G; Witzenbichler, B; Xu, K, 2015)
" This investigation aimed to evaluate the effect of hypothermia on the pharmacodynamic response of aspirin and clopidogrel in patients (n = 20) with ST elevation myocardial infarction undergoing primary PCI."3.80Impact of mild hypothermia on platelet responsiveness to aspirin and clopidogrel: an in vitro pharmacodynamic investigation. ( Angiolillo, DJ; Ariza, A; Cequier, A; Ferreiro, JL; Gómez-Hospital, JA; Gómez-Lara, J; Gracida, M; Homs, S; Lorente, V; Marcano, AL; Rivera, K; Romaguera, R; Roura, G; Sánchez-Elvira, G; Sánchez-Salado, JC; Sosa, SG; Teruel, L, 2014)
"The choice of antiplatelet therapy after acute coronary syndrome (ACS) is complicated: Ticagrelor and prasugrel are novel alternatives to clopidogrel, patients with some genotypes may not respond to clopidogrel, and low-cost generic formulations of clopidogrel are available."3.80Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome. ( Boothroyd, DB; Dudley, RA; Garber, AM; Hlatky, MA; Kazi, DS; Mell, MW; Moshkevich, S; Owens, DK; Rhee, C; Shah, RU, 2014)
"A 36 year-old man, who had undergone a paclitaxel-eluting stent deployment into the left main (LM) coronary artery three years before, was admitted after successful resuscitation following out-of-hospital cardiac arrest due to an acute ST-segment elevation myocardial infarction."3.79Thrombocytosis as a potential cause of a very late stent thrombosis in the left main coronary artery. ( Janus, M; Lesiak, M; Lukawski, K; Prech, M, 2013)
" Whether the bolus dose alone is sufficient for ST-elevation myocardial infarction patients receiving a high loading dose of clopidogrel is unknown."3.79Abciximab bolus with optional infusion in intervention for ST-elevation myocardial infarction. ( Berglund, U; Janzon, M; Nilsson, L, 2013)
"The current study sought to evaluate the clinical impact of newly reported genetic variations and their association with clopidogrel high on-treatment platelet reactivity (HTPR) in acute coronary syndrome (ACS) patients after drug-eluting stent (DES) implantation."3.79The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation. ( Han, YL; Kang, J; Li, Y; Liang, ZY; Yan, CH; Zhang, XL, 2013)
"This study sought to assess the usefulness of clopidogrel-pathway genotyping and on-treatment platelet reactivity (OTR) testing in predicting major adverse cardiac events (MACE) in stable coronary artery disease (CAD) patients receiving drug-eluting stents (DES) under dual antiplatelet (clopidogrel plus aspirin) therapy."3.79Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease. ( Briguori, C; Condorelli, G; De Micco, F; Focaccio, A; Latronico, MV; Pagnotta, P; Papa, L; Roncarati, R; Visconti, G; Viviani Anselmi, C, 2013)
" We examined the influence of previously described polymorphisms, related to aspirin and clopidogrel resistance, on treatment outcome in a real life unselected population of patients presenting with ST-segment elevation myocardial infarction (STEMI) treated with percutaneous coronary intervention."3.79Value of platelet pharmacogenetics in common clinical practice of patients with ST-segment elevation myocardial infarction. ( Boden, H; Guchelaar, HJ; Heijmans, BT; Jukema, JW; Putter, H; Schalij, MJ; Trompet, S; van der Hoeven, BL; Verschuren, JJ; Wessels, JA, 2013)
"CYP2C19*17 carrier status is significantly associated with enhanced response to clopidogrel and an increased risk of bleeding."3.76Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. ( Braun, S; Gebhard, D; Kastrati, A; Koch, W; Morath, T; Schömig, A; Schuster, T; Sibbing, D; Stegherr, J; von Beckerath, N, 2010)
" The present study was designed to assess the predictive value of adenosine diphosphate (ADP)-induced platelet aggregation (ADP-Ag) and the Platelet Reactivity Index of vasodilator-stimulated phosphoprotein for the occurrence of stent thrombosis in patients admitted for non-ST-elevation acute coronary syndrome undergoing percutaneous coronary intervention."3.75Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients. ( Alessi, MC; Bali, L; Bonnet, JL; Castelli, C; Cuisset, T; Frere, C; Gaborit, B; Morange, PE; Poyet, R; Quilici, J, 2009)
"Clopidogrel is widely used in patients with acute coronary syndromes and following percutaneous coronary intervention with stent implantation."3.75Potential Interaction between clopidogrel and proton pump inhibitors. ( Howard, PA; Vacek, JL, 2009)
" We describe a case of very late paclitaxel-eluting stent thrombosis despite 21 months of clopidogrel treatment, which occurred just 2 weeks after its withdrawal, causing an acute coronary syndrome that was promptly resolved with an urgent invasive strategy."3.74Very late paclitaxel-eluting stent thrombosis despite 21 months of clopidogrel treatment after percutaneous coronary intervention. ( Bucciarelli-Ducci, C; Colantonio, R; Fedele, F; Mancone, M; Sangiorgi, GM; Sardella, G, 2007)
"We describe a case of an 81-year-old man with acute ST-elevation myocardial infarction (STEMI), who received a loading dose of clopidogrel (300 mg) and aspirin (ASA) (300 mg) prior to primary coronary intervention of critical left anterior descending coronary artery stenosis."3.74[Suspected clopidogrel resistance associated with recurrent coronary stent thrombosis--a case report]. ( Knapp, M; Musiał, WJ; Prokop, JB; Sawicki, R; Sobkowicz, B; Tomaszuk-Kazberuk, A; Usowicz-Szaryńska, M, 2007)
"To model the 2-year cost-effectiveness of secondary prevention with clopidogrel versus aspirin (acetylsalicylic acid) (ASS) in German patients with myocardial infarction (MI), ischaemic stroke (IS) or diagnosed with peripheral arterial disease (PAD), based on CAPRIE trial data and from the perspective of German third party payers (TPP)."3.74Clopidogrel versus aspirin in patients with atherothrombosis: CAPRIE-based calculation of cost-effectiveness for Germany. ( Berger, K; Diener, HC; Hessel, F; Kreuzer, J; Smala, A, 2008)
"The incidence of subacute stent thrombosis (SAT) within 30 days after stenting with a sirolimus-eluting stent (Cypher) for acute myocardial infarction (AMI) was retrospectively compared to that with bare-metal stents (BMS)."3.73Documented subacute stent thrombosis within thirty days after stenting with sirolimus-eluting stent (Cypher) for acute myocardial infarction: a Japanese single center retrospective non-randomized study. ( Enta, K; Fuda, Y; Higashitani, M; Horie, T; Imai, K; Ishikawa, T; Mochizuki, S; Mutoh, M; Nakano, Y; Okada, H; Sakamoto, H; Satoh, T; Yamaguchi, J, 2006)
"The antiplatelet effect of clopidogrel was studied prospectively in 60 consecutive patients who underwent primary angioplasty (percutaneous coronary intervention [PCI]) with stenting for acute ST-segment-elevation myocardial infarction (STEMI) to determine whether variability in response to clopidogrel affects clinical outcomes."3.72Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. ( Beinart, R; Bienart, R; Goldenberg, I; Guetta, V; Hod, H; Matetzky, S; Novikov, I; Pres, H; Savion, N; Shechter, M; Shenkman, B; Varon, D, 2004)
"We report 3 cases of fatal neutropenia and thrombocytopenia associated with ticlopidine after coronary stenting."3.70Fatal neutropenia and thrombocytopenia associated with ticlopidine after stenting. ( Ball, MW; Linnemeier, TJ; Szto, GY, 1999)
" We report the successful use of ticlopidine, together with aspirin, in a 7-month-old infant with Kawasaki disease complicated by a thrombus in a giant coronary aneurysm that failed to resolve with thrombolytic therapy."3.70Ticlopidine plus aspirin for coronary thrombosis in Kawasaki disease. ( Baker, AL; Neufeld, EJ; Newburger, JW; O'Brien, M; Parness, IA; Sundel, RP, 2000)
"The incidence of thrombocytopenia with ticlopidine and clopidogrel when used in conjunction with abciximab has not been systematically addressed."3.70Incidence of thrombocytopenia following coronary stent placement using abciximab plus clopidogrel or ticlopidine. ( Dillon, JC; Dillon, WC; Eckert, GJ; Ritchie, ME, 2000)
"We examined the antithrombotic effect of ticlopidine on occlusive thrombi of small coronary arteries in (NZWxBXSB)F1 [(WxB)F1] male mice with myocardial infarction (MI) and systemic lupus erythematosus (SLE)."3.69Antithrombotic effect of ticlopidine on occlusive thrombi of small coronary arteries in (NZWxBXSB)F1 male mice with myocardial infarction and systemic lupus erythematosus. ( Fujiwara, H; Nakamura, Y; Shibata, Y; Suzuka, H; Tanaka, M; Yoshifusa, H, 1995)
"Aspirin was to be given indefinitely, and clopidogrel/ticlopidine for ≥ 3 months or up to 12 months after implantation."2.79Modifying effect of dual antiplatelet therapy on incidence of stent thrombosis according to implanted drug-eluting stent type. ( Al Kurdi, M; Boersma, E; Camenzind, E; Mauri, L; Ordoubadi, FF; Rademaker-Havinga, T; Steg, PG; Suttorp, MJ; Wijns, W, 2014)
" Following this randomized pilot study, it may be justified to perform a large-scale randomized study comparing 50- and 75-mg dosing of clopidogrel in Japanese patients undergoing coronary stent implantation."2.79Efficacy and safety of low-dose clopidogrel in Japanese patients after drug-eluting stent implantation: a randomized pilot trial. ( Fujimoto, Y; Iwata, Y; Kadohira, T; Kitahara, H; Kobayashi, Y; Morino, T; Ohkubo, K; Sugimoto, K, 2014)
" Two 7-day treatments were separated by 14-day washout periods: (a) PA32540 + clopidogrel (300 mg loading/75 mg maintenance) 10 hours later and (b) synchronous dosing of clopidogrel + EC aspirin (81 mg) + EC omeprazole (40 mg)."2.78Spaced administration of PA32540 and clopidogrel results in greater platelet inhibition than synchronous administration of enteric-coated aspirin and enteric-coated omeprazole and clopidogrel. ( Antonino, M; Bliden, KP; Chai, S; Fort, JG; Gesheff, M; Gesheff, T; Gurbel, PA; Jeong, YH; Shuldiner, A; Tantry, US; Zhang, Y, 2013)
"Pantoprazole treatment does not impair the efficacy of dual antiplatelet therapy in patients with SAP after PCI."2.77Effects of pantoprazole on dual antiplatelet therapy in stable angina pectoris patients after percutaneous coronary intervention. ( Chmiel, A; Gąsior, Z; Gieszczyk, K; Haberka, M; Kunecki, M; Kyrcz-Krzemień, S; Lasota, B; Mizia, M; Mizia-Stec, K; Najda, J, 2012)
" (2) Clopidogrel may be under dosed in obese patients."2.75Clopidogrel affects leukocyte dependent platelet aggregation by P2Y12 expressing leukocytes. ( Bode, C; Diehl, P; Halscheid, C; Helbing, T; Moser, M; Olivier, C, 2010)
"tirofiban may allow temporary withdrawal of oral clopidogrel without increasing the risk of bleeding."2.75Urgent surgery in patients with a recently implanted coronary drug-eluting stent: a phase II study of 'bridging' antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel. ( Barlocco, F; Caracciolo, M; D'Urbano, M; De Servi, S; Klugmann, S; Mariani, G; Nichelatti, M; Savonitto, S, 2010)
" Some recent studies have suggested that a higher clopidogrel maintenance dosage could enhance ex vivo platelet inhibition and thereby overcome resistance to clopidogrel."2.75High maintenance dosage of clopidogrel is associated with a reduced risk of stent thrombosis in clopidogrel-resistant patients. ( Carrie, D; Galinier, M; Lapeyre-Mestre, M; Montastruc, JL; Pathak, A; Tavassoli, N; Voisin, S, 2010)
" The primary end point was major adverse cardiac events (death, MI, and ischemia-driven target vessel revascularization) at 12 months."2.74Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction. ( Cheong, SS; Cho, YH; Hong, MK; Hong, TJ; Jeong, MH; Kim, JJ; Kim, KS; Kim, YH; Lee, CW; Lee, JH; Lee, NH; Lee, SG; Lee, SH; Lim, DS; Park, DW; Park, SJ; Park, SW; Seong, IW; Seung, KB; Yang, JY; Yoon, J; Yun, SC, 2009)
"Cilostazol is a potent antiplatelet agent with less serious side effects."2.69Comparison of cilostazol versus ticlopidine therapy after stent implantation. ( Hong, MK; Kim, HS; Kim, JJ; Lee, CW; Lee, HJ; Park, HK; Park, SJ; Park, SW, 1999)
"Ticlopidine-plus-aspirin has become standard antiplatelet therapy for the prevention of thrombotic complications after coronary stenting."2.69Clopidogrel as adjunctive antiplatelet therapy during coronary stenting. ( Aguirre, FV; Ligon, RW; Lucore, CL; Mishkel, GJ; Rocha-Singh, KJ, 1999)
" A new therapeutic regimen of ticlopidine and aspirin without further heparin after coronary stenting in patients without AMI has been shown to be safe and reduce the incidence of stent thrombosis."2.69A safe and effective regimen without heparin therapy after successful primary coronary stenting in patients with acute myocardial infarction. ( Chang, HW; Chen, MC; Fang, CY; Hang, CL; Hsieh, KY; Wu, CJ; Yip, HK, 2000)
"Ticlopidine therapy was discontinued in 1."2.68Combined antiplatelet therapy with ticlopidine and aspirin. A simplified approach to intracoronary stent management. ( Bauters, C; Bedossa, M; Bertrand, ME; Bonnet, JL; Danchin, N; Grollier, G; Lablanche, JM; Leclercq, C; McFadden, EP; Vahanian, A; Van Belle, E, 1996)
"Ticagrelor is a novel ADP receptor blocker that has shown greater, more rapid and more consistent platelet inhibition than clopidogrel."2.53Ticagrelor: a safe and effective approach for overcoming clopidogrel resistance in patients with stent thrombosis? ( Duraj, L; Fedor, M; Galajda, P; Kovář, F; Kubisz, P; Mokáň, M; Samoš, M; Stančiaková, L; Staško, J, 2016)
"Clinical trials enrolling STEMI patients were identified and relevant data was extracted."2.53Optimal P2Y12 Inhibitor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Network Meta-Analysis. ( Baber, U; Berger, PB; Currier, J; Dave, RH; Henry, TD; Mehran, R; Nayyar, P; Rafique, AM; Tobis, J; Wang, TY, 2016)
" The included end-points were major adverse cardiovascular event (MACE), target lesion revascularization (TLR), target vessel revascularization (TVR), death, myocardial infarction (MI), stent thrombosis, bleeding and other drug adverse events."2.50Long-term clinical efficacy and safety of adding cilostazol to dual antiplatelet therapy for patients undergoing PCI: a meta-analysis of randomized trials with adjusted indirect comparisons. ( Chen, Y; Huang, X; Tang, Y; Xie, Y; Zhang, Y, 2014)
" In contrast to aspirin, the response to clopidogrel is highly variable and reflects the bioavailability of the active metabolite and not "resistance" of the receptor to inhibition."2.44Aspirin and clopidogrel resistance. ( Fitzgerald, DJ; Maree, A, 2007)
" This approach may be in the future influenced by further progress in drug-eluting stents development and by prospectively acquired information on long-term administration of clopidogrel to such patients."2.44[Late coronary stent thrombosis and clopidogrel]. ( Herman, A; Matejka, J; Varvarovský, I, 2007)
"Ticlopidine is an inhibitor of platelets function in vivo."2.43[Place of ticlopidine in antiplatelet treatment]. ( Goch, A; Goch, JH; Wlazłowski, R, 2005)
"We report a case of multiple coronary thrombosis involving the left anterior descending artery and circumflex artery and stent implantation to the subtotally stenotic right renal artery in a women with unstable angina pectoris, essential thrombocytosis and previous history of renal artery trombosis."2.43Multiple coronary thrombosis and stent implantation to the subtotally occluded right renal artery in a patient with essential thrombocytosis: a case report with review. ( Bugra, Z; Ekmekci, A; Meric, M; Ozben, B; Umman, S, 2006)
"Aspirin is a weak antiplatelet agent; however, its side effects can cause in tolerance, and between 15% and 45% of patients are resistant to its antiplatelet effects."2.40The thienopyridines in coronary artery disease. ( Berger, PB, 1999)
"Major bleeding was a significant correlate of DAPT ANA within 6 months."1.42Thrombotic complications associated with early and late nonadherence to dual antiplatelet therapy. ( Cutlip, DE; Dauerman, HL; Kereiakes, DJ; Mauri, L; Stoler, R, 2015)
" Use of β-adrenergic blockers is recommended in most guidelines, but the clinical trials to support this recommendation were performed more than 30 years ago, and routine long-term use may not be relevant to modern treatment, except when there is cardiac failure or left ventricular dysfunction."1.40Optimising pharmacotherapy for secondary prevention of non-invasively managed acute coronary syndrome. ( Judkins, C; Thompson, AG; Thompson, PL, 2014)
" In conclusion, compared with immediate PCI, d-PCI after ATT in selected, stabilized patients with ACS and a large intracoronary thrombus and without an urgent need for revascularization is probably safe and associated with a reduction in thrombotic burden, angiographic complications, and the need of revascularization."1.39Safety and efficacy of intense antithrombotic treatment and percutaneous coronary intervention deferral in patients with large intracoronary thrombus. ( Alfonso, F; Bañuelos, C; Echavarría-Pinto, M; Escaned, J; Fernández, C; Fernandez-Ortiz, A; García, E; Gonzalo, N; Gorgadze, T; Hernández, R; Ibañez, B; Jiménez-Quevedo, P; Lopes, R; Macaya, C; Nuñez-Gil, IJ, 2013)
"Bleeding has emerged as a predictor of early and late mortality after percutaneous coronary interventions."1.38Prognostic implications of early and long-term bleeding events in patients on one-year dual antiplatelet therapy following drug-eluting stent implantation. ( Angiolillo, DJ; Capodanno, D; Gavazzi, A; Guagliumi, G; Lettieri, C; Musumeci, G; Romano, M; Rosiello, R; Rossini, R; Valsecchi, O, 2012)
" The aim of this study was to assess the impact of CCB therapy on the pharmacodynamic effect and the clinical efficacy of clopidogrel after drug-eluting stent placement."1.37Lack of impact of calcium-channel blockers on the pharmacodynamic effect and the clinical efficacy of clopidogrel after drug-eluting stenting. ( Bernlochner, I; Kastrati, A; Mehilli, J; Morath, T; Neumann, L; Sarafoff, N; Schömig, A; Sibbing, D, 2011)
"Systemic lupus erythematosus is a chronic inflammatory disorder that predisposes to acute coronary thrombosis."1.37Effective management of acute coronary thrombosis in a young woman with lupus using aggressive medical therapy. ( Matthai, WH; Patel, PJ; Untereker, WJ, 2011)
"Needle injury induces atherosclerotic plaque rupture with exposure of plaque material and formation of a thrombus that is larger, nearly occlusive and more stable as compared to that formed by application of ultrasounds."1.37Comparison of two murine models of thrombosis induced by atherosclerotic plaque injury. ( Gachet, C; Hechler, B, 2011)
" The effect of aspirin dosing was evaluated using χ(2) , Cochran-Mantel-Haenszel, and homogeneity testing."1.37Influence of low-dose aspirin (81 mg) on the incidence of definite stent thrombosis in patients receiving bare-metal and drug-eluting stents. ( Columbo, J; Cui, J; Davis, M; Giugliano, GR; Lotfi, A; Mulvey, S; Schweiger, M; Wartak, S, 2011)
"The TRUE registry demonstrated that SES in the treatment of bare-metal stent ISR is efficacious (5% of target lesion revascularization [TLR]) and safe (stent thrombosis <1%) at 9 months."1.36Long-term effectiveness and safety of sirolimus stent implantation for coronary in-stent restenosis results of the TRUE (Tuscany Registry of sirolimus for unselected in-stent restenosis) registry at 4 years. ( Angioli, P; Bolognese, L; Carrera, A; Ducci, K; Falsini, G; Fineschi, M; Gori, T; Grotti, S; Liistro, F; Pierli, C, 2010)
"Only amlodipine was associated with clopidogrel poor-response."1.36The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response. ( Breet, NJ; de Boer, A; Deneer, VH; Hackeng, CM; Harmsze, AM; Klungel, OH; Robijns, K; Ruven, HJ; Ten Berg, JM; van Werkum, JW, 2010)
"In conclusion, in a dog coronary thrombosis model, ticagrelor blocks ADP-induced platelet activation and aggregation; prevents platelet-mediated thrombosis; prolongs reperfusion time and reduces re-occlusion and cyclic flow variation; and significantly decreases infarct size and rapidly restores myocardial tissue perfusion."1.36Adjunctive treatment with ticagrelor, but not clopidogrel, added to tPA enables sustained coronary artery recanalisation with recovery of myocardium perfusion in a canine coronary thrombosis model. ( Huang, Y; Khalil, M; Penn, MS; van Giezen, JJ; Wang, K; Wiktor, D; Zhou, X, 2010)
"The underlying disease was paroxysmal nocturnal hemoglobinuria (PNH), a stem cell defect characterized by episodes of complement-induced hemolysis and thromboembolic events."1.36[Between thrombosis and bleeding - a case of paroxysmal nocturnal hemoglobinuria]. ( Reinhart, WH, 2010)
" In 199 patients treated with DAT alone (control group) and 103 patients treated with rabeprazole plus DAT (rabeprazole group), we examined the incidences of GI bleeding and major adverse cardiac events (MACE) including stent thrombosis."1.36[Efficacy and safety of concomitant use of rabeprazole during dual-antiplatelet therapy with clopidogrel and aspirin after drug-eluting stent implantation: a retrospective cohort study]. ( Chubachi, H; Ikee, R; Miyasaka, Y; Saito, S; Yasu, T, 2010)
"Tirofiban was administered for 24 h and the IABP was withdrawn after 60 h."1.35Reversible clopidogrel resistance due to right ventricular myocardial infarction: risk factor of recurrent stent thrombosis? ( Braun-Dullaeus, RC; Hass, N; Ibrahim, K; Kolschmann, S; Strasser, RH, 2008)
"Myocardial infarction is common in patients with a history of coronary artery disease."1.35[Severe myocardial infarction due to late and very late stent thrombosis after coronary artery stenting with drug-eluting stents]. ( Erdmann, E; Flesch, M; Krausgrill, B, 2008)
"Aspirin effect was assessed using the VerifyNow Aspirin Assay, and the effect of clopidogrel was assessed using the VerifyNow P2Y12 Assay and vasodilator-stimulated phosphoprotein phosphorylation (VASP-P)."1.35Prevalence of aspirin and clopidogrel resistance among patients with and without drug-eluting stent thrombosis. ( Beauzile, P; Bonello, L; Gavini, R; Gurbel, P; Kaneshige, K; Kent, K; Pichard, AD; Pinto Slottow, TL; Satler, LF; Scheinowitz, M; Suddath, WO; Sushinsky, SJ; Tantry, U; Torguson, R; Waksman, R; Xue, Z, 2009)
" Investigation of alternative clopidogrel dosing regimens to reduce ischaemic events in high-risk patients identified by this assay is warranted."1.35Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. ( Endemann, S; Ernst, A; Gollapudi, RR; Levisay, JP; Price, MJ; Sawhney, NS; Schatz, RA; Stinis, CT; Teirstein, PS; Valencia, R, 2008)
"Ticlopidine can cause rare but serious side effects, especially during the first 3 months of treatment."1.34Optimal antiplatelet treatment for percutaneous coronary intervention: clopidogrel vs. ticlopidine. ( Almsherqi, ZA; Deng, Y; McLachlan, CS; Mossop, P, 2007)
"Ticlopidine has a relative high rate of side-effects."1.34Incidence of side-effects of ticlopidine after sirolimus-eluting stent implantation. ( Fukushima, K; Kobayashi, Y; Komuro, I; Kuroda, N; Miyazaki, A; Nakamura, Y; Nakayama, T; Okuno, T; Sakakibara, M; Shimizu, Y, 2007)
" We assessed the cumulative incidence of major adverse cardiac events (death, acute myocardial infarction, and target-vessel revascularization) and angiographic stent thrombosis during 2-year follow-up."1.34Long-term safety and efficacy of drug-eluting stents: two-year results of the REAL (REgistro AngiopLastiche dell'Emilia Romagna) multicenter registry. ( Aurier, E; Benassi, A; Cremonesi, A; Grilli, R; Guastaroba, P; Magnavacchi, P; Manari, A; Maresta, A; Marzocchi, A; Percoco, G; Piovaccari, G; Saia, F; Varani, E, 2007)
" Prasugrel is orally more potent and acts more rapidly than clopidogrel, allowing lower oral dosing despite of similar in vitro activity of the active metabolites."1.34[Prasugrel, a new thienopyridine]. ( Huber, K; Schrör, K, 2007)
"ticlopidine) treatment remained the sole predictor of TSO (OR: 5."1.33Increased long term rates of stent thrombosis and mortality in patients given clopidogrel as compared to ticlopidine following coronary stent implantation. ( Amit, G; Cafri, C; Gilutz, H; Ilia, R; Wolak, A; Zahger, D, 2005)
" Clopidogrel was studied in two dosing regimens representing either a clinical pretreatment regimen (PTR) of 4."1.33Pharmacologic inhibition of platelet vWF-GPIb alpha interaction prevents coronary artery thrombosis. ( Brooks, JM; Crandall, DL; Hennan, JK; Leik, CE; Morgan, GA; Schaub, RG; Shaw, GD; Swillo, RE; Vlasuk, GP, 2006)
" An adequate dosage of ticlopidine (250 mg twice daily) and aspirin (100 mg/day) led to a lower rate of stent thrombosis (6 of 2,189 cases) than inadequate dosages or missing therapy (12 of 343 cases)."1.32Influence of residual stenosis after percutaneous coronary intervention with stent implantation on development of restenosis and stent thrombosis. ( Hambrecht, R; Hentschel, B; Hüttl, T; Lauer, B; Niebauer, J; Schuler, G; Sick, P; Thiele, H, 2003)
" We sought to establish an optimal clopidogrel dosing regimen for sustained platelet inhibition in stented patients."1.32Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial. ( Alford, AB; Bell, CR; Cummings, CC; Gurbel, PA; Meister, AF; Serebruany, VL, 2003)
"Reduced anticoagulation with antiplatelet therapy alone after coronary stenting, despite infrequent use of intravascular ultrasound, is an effective and safe strategy with a low rate of vascular complications, a relatively short hospital stay and a low incidence of clinical manifestations of stent thrombosis."1.30Antiplatelet therapy alone is safe and effective after coronary stenting: observations of a transition in practice. ( Buller, CE; Chauhan, A; Moscovich, MD; Penn, IM; Ricci, DR; Zubaid, M, 1997)

Research

Studies (496)

TimeframeStudies, this research(%)All Research%
pre-19902 (0.40)18.7374
1990's49 (9.88)18.2507
2000's229 (46.17)29.6817
2010's215 (43.35)24.3611
2020's1 (0.20)2.80

Authors

AuthorsStudies
Capodanno, D3
Stefanini, GG1
Vicenzi, M1
Nikolaou, NI1
Secemsky, EA1
Yeh, RW2
Kereiakes, DJ4
Cutlip, DE6
Steg, PG14
Massaro, JM2
Apruzzese, PK1
Mauri, L4
Felix, CM1
Vlachojannis, GJ1
IJsselmuiden, AJJ1
Fam, JM1
Smits, PC1
Lansink, WJ1
Diletti, R1
Zijlstra, F3
Regar, ES1
Boersma, E2
Onuma, Y2
van Geuns, RJM1
Zhou, Y2
Wang, Y1
Wu, Y1
Huang, C1
Yan, H1
Zhu, W1
Xu, W1
Zhang, L3
Zhu, J2
Didier, R1
Morice, MC3
Barragan, P7
Noryani, AAL1
Noor, HA1
Majwal, T1
Hovasse, T1
Castellant, P1
Schneeberger, M1
Maillard, L1
Bressolette, E1
Wojcik, J1
Delarche, N2
Blanchard, D1
Jouve, B1
Ormezzano, O2
Paganelli, F7
Levy, G1
Sainsous, J3
Carrie, D3
Furber, A1
Berlan, J1
Darremont, O1
Le Breton, H1
Lyuycx-Bore, A1
Gommeaux, A1
Cassat, C1
Kermarrec, A1
Cazaux, P2
Druelles, P1
Dauphin, R1
Armengaud, J1
Dupouy, P2
Champagnac, D1
Ohlmann, P1
Ben Amer, H1
Kiss, RG2
Ungi, I1
Gilard, M2
Jiang, M1
You, JHS1
Baber, U8
Chandrasekhar, J3
Sartori, S5
Aquino, M3
Kini, AS3
Kapadia, S2
Weintraub, W2
Muhlestein, JB3
Vogel, B3
Faggioni, M2
Farhan, S3
Weiss, S2
Strauss, C2
Toma, C2
DeFranco, A2
Baker, BA2
Keller, S2
Effron, MB3
Henry, TD8
Rao, S2
Pocock, S4
Dangas, G6
Mehran, R13
Stuckey, TD5
Kirtane, AJ10
Brodie, BR6
Witzenbichler, B8
Litherland, C2
Weisz, G6
Rinaldi, MJ6
Neumann, FJ7
Metzger, DC5
Cox, DA4
Duffy, PL4
Mazzaferri, EL4
Gurbel, PA9
Généreux, P5
Ben-Yehuda, O3
Simonton, CA2
Stone, GW16
Harada, Y1
Michel, J1
Lohaus, R1
Mayer, K3
Emmer, R1
Lahmann, AL1
Colleran, R1
Giacoppo, D1
Wolk, A1
Ten Berg, JM8
Han, Y1
Adriaenssens, T1
Tölg, R1
Seyfarth, M2
Maeng, M2
Zrenner, B1
Jacobshagen, C1
Wöhrle, J1
Kufner, S1
Morath, T6
Ibrahim, T1
Bernlochner, I4
Fischer, M1
Schunkert, H3
Laugwitz, KL4
Mehilli, J5
Byrne, RA4
Kastrati, A9
Schulz-Schüpke, S1
Zafar, MU1
Smith, DA1
Contreras, J1
Rey-Mendoza, J1
Linares-Koloffon, CA1
Escolar, G1
Fuster, V1
Badimon, JJ1
Piccolo, R2
Feres, F2
Abizaid, A3
Hong, MK7
Kim, HS3
Colombo, A17
Bhatt, DL10
Palmerini, T3
Windecker, S4
Valgimigli, M7
Bossard, M1
Granger, CB2
Tanguay, JF1
Montalescot, G8
Faxon, DP2
Jolly, SS1
Widimsky, P3
Niemela, K1
Natarajan, MK1
Gao, P1
Fox, KAA1
Yusuf, S2
Mehta, SR2
Sorrentino, S1
Ge, Z1
Almalla, M1
Schröder, J1
Hennings, V1
Marx, N1
Hoffmann, R1
Rinfret, S1
Rodés-Cabau, J2
Bagur, R1
Déry, JP2
Dorais, M1
Larose, E2
Barbeau, G1
Gleeton, O2
Nguyen, CM2
Noël, B2
Proulx, G2
Roy, L2
Taillon, I1
De Larochellière, R2
Bertrand, OF2
Echavarría-Pinto, M1
Lopes, R1
Gorgadze, T1
Gonzalo, N1
Hernández, R3
Jiménez-Quevedo, P4
Alfonso, F5
Bañuelos, C3
Nuñez-Gil, IJ1
Ibañez, B1
Fernández, C2
Fernandez-Ortiz, A3
García, E1
Macaya, C5
Escaned, J3
Prech, M1
Janus, M1
Lukawski, K1
Lesiak, M1
Storey, RF6
Park, J1
Shin, DH2
Kim, BK2
Her, AY2
Kim, YH4
Choi, HH1
Kim, JS3
Ko, YG2
Choi, D2
Jang, Y2
Berglund, U1
Nilsson, L1
Janzon, M1
Cano, P1
Consuegra-Sánchez, L1
Conesa, P1
Torres-Moreno, D1
Jaulent, L1
Dau, D1
Picó, F1
Villegas, M1
Tantry, US7
Kunadian, V1
James, SK3
Wojdyla, DM3
Zorkun, C1
Wu, J1
Katus, H2
Emanuelsson, H5
Horrow, J1
Maya, J1
Wallentin, L6
Harrington, RA11
Gibson, CM11
Liang, ZY1
Han, YL2
Zhang, XL1
Li, Y4
Yan, CH1
Kang, J1
Katus, HA3
Mahaffey, KW9
Meier, B3
Lewis, BS2
Maurer, G2
Cuisset, T6
Grosdidier, C1
Loundou, AD1
Quilici, J4
Loosveld, M1
Camoin, L2
Pankert, M2
Beguin, S1
Lambert, M1
Morange, PE2
Bonnet, JL5
Alessi, MC3
Suh, SY1
Kang, WC1
Oh, PC1
Choi, H1
Moon, CI1
Lee, K1
Han, SH1
Ahn, T1
Choi, IS1
Shin, EK1
Park, KW1
Kang, SH1
Park, JJ1
Yang, HM1
Kang, HJ1
Koo, BK2
Park, BE1
Cha, KS1
Rhew, JY1
Jeon, HK1
Shin, ES1
Oh, JH1
Jeong, MH5
Kim, S1
Hwang, KK1
Yoon, JH2
Lee, SY1
Park, TH1
Moon, KW1
Kwon, HM1
Chae, IH2
Mao, L1
Jian, C1
Changzhi, L1
Dan, H1
Suihua, H1
Wenyi, T1
Wei, W1
Chen, Y1
Zhang, Y2
Tang, Y1
Huang, X1
Xie, Y1
Musumeci, G2
Limbruno, U2
Viviani Anselmi, C1
Briguori, C2
Roncarati, R1
Papa, L1
Visconti, G1
Focaccio, A1
De Micco, F1
Latronico, MV1
Pagnotta, P1
Condorelli, G1
Tebaldi, M2
Borghesi, M1
Vranckx, P3
Campo, G4
Tumscitz, C1
Cangiano, E1
Minarelli, M1
Scalone, A1
Cavazza, C1
Marchesini, J1
Parrinello, G2
Ferreiro, JL1
Sánchez-Salado, JC1
Gracida, M1
Marcano, AL1
Roura, G1
Ariza, A1
Gómez-Lara, J1
Lorente, V1
Romaguera, R1
Homs, S1
Sánchez-Elvira, G1
Teruel, L1
Rivera, K1
Sosa, SG1
Gómez-Hospital, JA1
Angiolillo, DJ12
Cequier, A2
Deharo, P1
Bonnet, G1
Verdier, V1
Morange, P1
Waks, JW1
Sabatine, MS3
Cannon, CP4
Morrow, DA2
Wiviott, SD2
Giugliano, RP1
Sloan, S1
Scirica, BM1
Hansson, EC1
Rexius, H1
Dellborg, M2
Albertsson, P1
Jeppsson, A1
Silber, S1
Belardi, JA1
Liu, M1
Brar, S1
Rothman, M1
Camenzind, E1
Wijns, W3
Rademaker-Havinga, T1
Ordoubadi, FF1
Suttorp, MJ3
Al Kurdi, M1
Sabouret, P2
Taiel-Sartral, M1
Murray, AM1
Keville, N1
Gray, S1
Schulz, S5
Braun, S4
Hausleiter, J3
Massberg, S4
Sibbing, D8
Kazi, DS1
Garber, AM1
Shah, RU1
Dudley, RA1
Mell, MW1
Rhee, C1
Moshkevich, S1
Boothroyd, DB1
Owens, DK1
Hlatky, MA1
Ho, HH1
Er Ching, M1
Ong, PJ1
Ooi, YW1
Rangé, G2
Yayehd, K1
Belle, L2
Thuaire, C1
Richard, P1
Barbou, F1
Köning, R1
Chassaing, S1
Teiger, E1
Berthier, R1
Decomis, MP1
Claudel, JP1
Brunel, P1
De Poli, F1
Beygui, F3
Albert, F1
Collet, JP6
Davlouros, P2
Gkizas, V1
Deftereos, S1
Giannopoulos, G1
Alexopoulos, D2
Ayers, J1
Mandell, R1
Sanghvi, K1
Aboujaoude, R1
Hsi, DH1
Roguin, A1
Musallam, A1
Liang, J1
Wang, Z1
Shi, D1
Liu, Y2
Zhao, Y1
Han, H1
Liu, W1
Yang, L1
Legrand, V1
Chenu, P1
Vrolix, M1
Martinez, C1
Dens, J1
Gach, O1
Boland, J1
Claeys, MJ1
Magne, J1
Barbato, E1
Parekh, P1
Agrawal, N1
Vasavada, A1
Vinchurkar, M1
Thim, T1
Johansen, MB1
Chisholm, GE1
Schmidt, M1
Kaltoft, A1
Sørensen, HT1
Thuesen, L2
Kristensen, SD3
Bøtker, HE1
Krusell, LR1
Lassen, JF1
Thayssen, P1
Jensen, LO1
Tilsted, HH1
Orban, M2
Hadamitzky, M1
Hoppmann, P1
Tiroch, K1
Ramaiola, I1
Padró, T1
Peña, E1
Juan-Babot, O1
Cubedo, J1
Martin-Yuste, V1
Sabate, M7
Badimon, L1
Siller-Matula, JM1
Trenk, D2
Schrör, K3
Gawaz, M6
Huber, K4
Calabrò, P1
Piscione, F2
De Servi, S2
Cattaneo, M3
Maffeo, D1
Toso, A1
Bartorelli, A1
Palmieri, C1
De Carlo, M2
Barozzi, C1
Tomasi, L1
Della Riva, D1
Mariani, A1
Taglieri, N1
Reggiani, LB1
Bianchi, R1
De Rosa, R1
Mariani, M1
Podda, G1
Thompson, PL1
Thompson, AG1
Judkins, C1
Mendolicchio, GL1
Zavalloni, D2
Bacci, M1
Roveda, M1
Quagliuolo, V1
Anselmi, CV1
Rota, LL1
Ruggeri, ZM1
Jeger, RV1
Pfisterer, ME1
Sørensen, R1
von Felten, S1
Alber, H1
Bonetti, PO1
Eberli, F1
Erne, P1
Pedrazzini, G1
Rickli, H1
Galatius, S1
Kaiser, CA1
Shimohama, T1
Ako, J2
Lee, HJ2
Park, TK1
Song, YB1
Choi, YJ1
Yu, CW1
Yang, JH1
Hahn, JY1
Choi, SH1
Choi, RK1
Choi, JH1
Park, JS1
Kim, TH1
Jang, HJ1
Lee, SH2
Shim, WH1
Roh, YM1
Gwon, HC1
Stoler, R1
Dauerman, HL3
White, HD6
Hamm, CW5
Price, MJ9
Cortese, B2
Wilensky, M1
Deliargyris, EN5
Liu, T1
Prats, J5
Zalewski, J1
Bogaert, J1
Sadowski, M1
Woznicka, O1
Doulaptsis, K1
Ntoumpanaki, M1
Ząbczyk, M1
Nessler, J1
Undas, A1
Ichikawa, M1
Takei, Y1
Hamasaki, T1
Kijima, Y1
Sueta, D1
Hokimoto, S2
Enomoto, K1
Ono, T1
Tabata, T1
Kajiwara, I1
Kaikita, K1
Saruwatari, J1
Oniki, K1
Nakagawa, K1
Ogawa, H2
Perzborn, E1
Heitmeier, S1
Laux, V1
Rutledge, DR1
Caixeta, A2
Kedhi, E1
Hermiller, JB1
Wang, J2
Krucoff, MW2
Jones-McMeans, J1
Sudhir, K1
Serruys, PW1
Mele, M1
Martimucci, M1
Maggi, A1
Villella, A1
Villella, M1
Langialonga, T1
Azzalini, L1
Al-Hawwas, M1
L'Allier, PL3
Wei, YQ1
Wang, DG1
Yang, H1
Cao, H1
Samoš, M1
Fedor, M1
Kovář, F1
Duraj, L1
Stančiaková, L1
Galajda, P1
Staško, J1
Kubisz, P1
Mokáň, M1
Valenti, R3
Marcucci, R4
Comito, V1
Marrani, M1
Cantini, G1
Migliorini, A2
Parodi, G2
Gensini, GF3
Abbate, R3
Antoniucci, D4
Gutierrez, JA1
Blankenship, JC1
Kim, YS1
Lee, SR1
Yahagi, K1
Virmani, R2
Kesavamoorthy, B1
Khalaf, H1
Al Meman, AA1
Rasool, S1
Gouffran, G1
Rosencher, J1
Bougouin, W1
Jakamy, R1
Joffre, J1
Lamhaut, L1
Dumas, F1
Cariou, A1
Varenne, O1
Parikh, PB1
Xu, K2
Parvataneni, R2
Maehara, A3
Bonello, L9
Dignat-George, F4
Laine, M3
Tang, X1
Li, R1
Jing, Q1
Wang, Q1
Liu, P1
Zhang, P1
Crimi, G1
Leonardi, S1
Costa, F1
Adamo, M1
Ariotti, S2
Giustino, G2
Cohen, DJ3
Ariti, C2
Moliterno, DJ2
Chieffo, A3
Rafique, AM1
Nayyar, P1
Wang, TY1
Berger, PB8
Tobis, J3
Currier, J1
Dave, RH1
Hong, SJ1
Vaduganathan, M1
Brener, SJ1
Essandoh, MK1
Dalia, AA1
George, BS1
Flores, AS1
Otey, AJ1
Broderick, TM1
Rao, SV1
Gargiulo, G1
Santucci, A1
Baldo, A1
Franzone, A1
Magnani, G1
Marino, M1
Esposito, G1
Ren, F1
Mu, N1
Zhang, X2
Tan, J2
Li, L1
Zhang, C1
Dong, M1
Bansilal, S1
Kini, A2
Saporito, R1
Michael Gibson, C1
Cohen, D1
Moliterno, D1
Stuckey, T2
Henry, T1
Gabriel Steg, P1
Abtan, J2
Abnousi, F1
Kukula, K1
Klopotowski, M1
Kunicki, P1
Jamiolkowski, J1
Debski, A1
Bekta, P1
Chmielak, Z1
Witkowski, A1
Sawlani, NN1
Yu, J1
Ooi, SY1
Stefanescu Schmidt, AC1
D'Agostino, RB1
Hsieh, WH1
Jiménez-Brítez, G1
Freixa, X1
Flores-Umanzor, E1
San Antonio, R1
Caixal, G1
Garcia, J1
Hernandez-Enriquez, M1
Andrea, R1
Regueiro, A1
Masotti, M1
Brugaletta, S3
Martin, V1
Gupta, R1
Ozan, MO1
Lim, SY1
Kim, KS3
Joo, SJ1
Jeong, YH3
Kim, IS1
Choi, BR1
Kwak, CH2
Hwang, JY2
Camoin-Jau, L4
Antonino, MJ1
Acar, G1
Sökmen, G1
Nacar, AB1
Tuncer, C1
Newsome, LT1
Weller, RS1
Gerancher, JC1
Kutcher, MA1
Royster, RL1
Fukushima, K3
Kobayashi, Y4
Kitahara, H3
Iwata, Y3
Nakayama, T2
Kuroda, N3
Ooyama, M1
Nomura, F1
Komuro, I3
Ibrahim, K1
Hass, N1
Kolschmann, S1
Strasser, RH1
Braun-Dullaeus, RC1
Barthwal, R1
Herman, BA1
Braunwald, E2
Meisel, S1
Dalby, AJ1
Verheugt, FW1
Goodman, SG2
Corbalan, R1
Purdy, DA1
Murphy, SA4
McCabe, CH2
Antman, EM3
Asano, T1
Ishio, N1
Maltz, LA1
Gauvreau, K1
Connor, JA1
Jenkins, KJ1
Williams, DO1
Abbott, JD1
Krausgrill, B1
Erdmann, E3
Flesch, M1
Horowitz, JD1
Chirkov, YY1
Biondi-Zoccai, G1
Lotrionte, M1
Sheiban, I3
Ivandic, BT1
Kurz, K1
Keck, F1
Staritz, P1
Lehrke, S1
Giannitsis, E1
Vlaar, PJ1
Svilaas, T1
Damman, K1
de Smet, BJ1
Tijssen, JG1
Hillege, HL1
Serebruany, VL4
Goto, S1
Pérez-Vizcayno, MJ2
Bethencourt, A1
Martí, V1
López-Mínguez, JR1
Angel, J1
Iñiguez, A2
Morís, C1
Suárez, A2
Wang, ZJ1
Zhou, YJ1
Liu, YY1
Yu, M1
Shi, DM1
Zhao, YX1
Guo, YH1
Cheng, WJ1
Jia, de A1
Cao, Z1
Nie, B1
Ge, HL1
Yang, SW1
Yan, ZX1
Armero, S2
Com, O1
Arques, S1
Burignat-Bonello, C1
Giacomoni, MP1
Bonello, R1
Collet, F1
Rossi, P1
Jang, SW1
Kim, DB1
Kwon, BJ1
Shin, D1
Her, SH1
Park, CS1
Park, HJ1
Park, MW1
Cho, EJ1
Rho, TH1
Kim, JH2
De Labriolle, A1
Scheinowitz, M2
Lemesle, G1
Roy, P3
Steinberg, DH3
Pinto Slottow, TL4
Pakala, R1
Pichard, AD5
Waksman, R7
Conroy, MM1
Bolsin, SN2
Kremneva, LV1
Shalaev, SV1
Lozano, I1
Martín, D1
Torres, F1
Avanzas, P1
Rondán, J1
García-Ruiz, JM1
Hernández, E2
Bayón, J1
Vegas, JM1
Espolita, A1
Torguson, R3
Okabe, T2
Kaneshige, K2
Xue, Z3
Satler, LF3
Kent, KM1
Suddath, WO2
Lindsay, J1
Giusti, B1
Gori, AM1
Saracini, C1
Sestini, I1
Paniccia, R1
Buonamici, P2
Pattullo, SJ1
Jayasinghe, R1
Iijima, R1
Schömig, A8
Merkely, B1
Tóth-Zsamboki, E1
Becker, D1
Beres, BJ1
Szabó, G1
Vargova, K1
Fülöp, G1
Kerecsen, G1
Preda, I1
Spaulding, C1
Micheli, A1
Picchi, A1
Ben-Dor, I2
Ikari, Y2
Kotani, J2
Kozuma, K2
Kyo, E2
Nakamura, M3
Yokoi, H2
Wozakowska-Kapłon, B1
Młodnicki, M1
Gutkowski, W1
Cola, C1
Martín Yuste, V1
Campos, B1
Costa, JR1
Costa, R1
Tanajura, LF1
Mattos, LA1
Staico, R1
Siqueira, D1
Sousa, AG1
Bonan, R1
Sousa, JE1
Liu, X1
Doi, H1
Mintz, GS2
Costa, Jde R1
Sano, K1
Dangas, GD2
Lansky, AJ3
Kreps, EM1
Collins, M2
Fahy, M1
Moses, JW4
Leon, MB2
Otake, H2
Shite, J2
Shinke, T2
Tanino, Y2
Ogasawara, D2
Sawada, T2
Miyoshi, N1
Kato, H2
Honda, Y1
Fitzgerald, PJ1
Hirata, K2
Motovska, Z2
Ruiz, M2
Cazares, M1
Makarov, LM1
Güray, Y1
Güray, U1
Korkmaz, S1
Carrescia, C1
Carletti, R1
Ferrari, R2
de Cesare, N1
Meliga, E1
Furgieri, A1
Hamon, M2
Repetto, A1
Colangelo, S1
Percoco, G2
Chen, KY1
Rha, SW1
Li, YJ1
Poddar, KL1
Jin, Z1
Minami, Y1
Wang, L1
Kim, EJ1
Park, CG1
Seo, HS1
Oh, DJ2
Ahn, YK1
Hong, TJ2
Kim, YJ1
Hur, SH1
Seong, IW2
Chae, JK1
Cho, MC1
Bae, JH1
Choi, DH1
Jang, YS2
Kim, CJ1
Chung, WS1
Seung, KB2
Park, SJ5
Perez, G1
Rodriguez-Granillo, AM1
Mieres, J1
Llaurado, C1
Rubilar, B1
Risau, G1
Fernandez-Pereira, C1
Rodriguez, AE1
Milicic, D1
Skoric, B1
Lovric, D1
Gavini, R1
Beauzile, P1
Sushinsky, SJ1
Tantry, U1
Kent, K1
Gurbel, P1
Heestermans, AA2
Van Werkum, JW8
Hamm, C2
Dill, T1
Gosselink, AT2
De Boer, MJ1
Van Houwelingen, G1
Hoorntje, JC1
Koopmans, PC1
Van 't Hof, AW2
El-Menyar, A1
Hussein, H1
Al Suwaidi, J1
Ergelen, M1
Uyarel, H1
Osmonov, D1
Ayhan, E1
Akkaya, E1
Soylu, O1
Orhan, AL1
Sayar, N1
Bozbay, M1
Turer, A1
Yildirim, E1
Yekeler, I1
Santiago-Díaz, P1
Arrebola-Moreno, AL1
Ramírez-Hernández, JA1
Melgares-Moreno, R1
Frere, C1
Gaborit, B1
Castelli, C1
Poyet, R1
Bali, L1
Zomer, AC1
Zwart, B1
Tanzilli, G1
Greco, C1
Pelliccia, F1
Pasceri, V2
Barillà, F1
Paravati, V1
Pannitteri, G1
Gaudio, C1
Mangieri, E1
Lee, CW3
Park, DW1
Kim, JJ4
Park, SW4
Yun, SC1
Lee, JH1
Lee, NH1
Cho, YH1
Cheong, SS1
Lim, DS1
Yang, JY1
Lee, SG1
Yoon, J1
Popescu, WM1
Giuliani, G1
Cerisano, G1
Carrabba, N1
Howard, PA1
Vacek, JL1
Diehl, P1
Olivier, C1
Halscheid, C1
Helbing, T1
Bode, C1
Moser, M1
Chhatriwalla, AK1
Gerber, RT1
Savonitto, S1
D'Urbano, M1
Caracciolo, M1
Barlocco, F1
Mariani, G1
Nichelatti, M1
Klugmann, S1
Sielski, J2
Wałek, P1
Polewczyk, A2
Janion, M2
Xue, F1
Yang, XJ1
Cheng, XJ1
Hui, J1
Jiang, TB1
Chen, T1
Liu, ZH1
Song, JP1
Jiang, WP1
Koch, W1
Gebhard, D1
Schuster, T1
Stegherr, J1
von Beckerath, N1
Steinhubl, SR7
Tavassoli, N1
Voisin, S1
Lapeyre-Mestre, M1
Galinier, M1
Montastruc, JL1
Pathak, A1
Akhter, M1
Kothari, S1
Sharma, SK1
Nie, R1
Luo, N1
Liistro, F2
Fineschi, M2
Grotti, S1
Angioli, P1
Carrera, A1
Ducci, K1
Gori, T2
Falsini, G1
Pierli, C1
Bolognese, L1
Balbi, M1
Fedele, M1
Bezante, GP1
Brunelli, C1
Barsotti, A1
Harmsze, AM1
Robijns, K1
Breet, NJ3
Hackeng, CM2
Ruven, HJ1
Klungel, OH1
de Boer, A1
Deneer, VH1
Johansen, M1
Afshari, A1
Kristensen, BB1
Piatek, L1
Piatek, K1
Saidi, Y1
Guesmi, F1
Landolsi, M1
Trabelsi, S1
Khemiri, K1
Ounalli, K1
Dziri, C1
Houissa, M1
Schwartz, RS1
Eshtehardi, P2
Cook, S1
Billinger, M1
Togni, M1
Garachemani, A1
Hess, OM1
Wenaweser, P1
Shen, WF1
Chen, JL1
Gao, LJ1
Yang, YJ1
Li, JJ1
Qiao, SB1
Xu, B2
Huang, JH1
Yao, M1
Qin, XW1
Liu, HB1
Wu, YJ1
Yuan, JQ1
Chen, J2
You, SJ1
Dai, J1
Gao, RL2
Geisler, T3
Mueller, K1
Aichele, S1
Bigalke, B3
Stellos, K1
Htun, P1
Ninci, E1
Fateh-Moghadam, S1
May, AE2
Paikin, JS1
Eikelboom, JW1
Cairns, JA1
Hirsh, J2
Hulot, JS2
Silvain, J3
Pena, A1
Bellemain-Appaix, A1
Barthélémy, O2
Cayla, G3
Hövelborn, T1
Wessely, R1
Karabay, CY1
Can, MM1
Tanboğa, IH1
Ahmet, G1
Bitigen, A1
Serebruany, V1
Wang, K1
Zhou, X1
Huang, Y1
Khalil, M1
Wiktor, D1
van Giezen, JJ1
Penn, MS1
Blindt, R1
Becker, R1
Gachet, C2
Jennings, LK1
Kereiakes, D1
Llau, JV1
Ferrandis, R1
Sierra, P1
Gómez-Luque, A1
Solheim, S1
Seljeflot, I1
Lunde, K1
Bjørnerheim, R1
Aakhus, S1
Forfang, K1
Arnesen, H1
James, S2
Ardissino, D1
Becker, RC3
Finkelstein, A1
Husted, S1
Kilhamn, J1
Olofsson, S1
Weaver, WD1
Reinhart, WH1
Gentilomo, C1
Huang, YS1
Raffini, L1
Yasu, T1
Ikee, R1
Miyasaka, Y1
Chubachi, H1
Saito, S1
Tomasello, SD1
Tello-Montoliu, A2
Park, KH1
Lee, MG1
Ko, JS1
Sim, DS1
Yoon, NS1
Yoon, HJ1
Hong, YJ1
Kim, KH1
Park, HW1
Ahn, Y1
Cho, JG1
Park, JC1
Kang, JC2
Rechner, AR1
Ivandic, B1
Frey, N1
Ota, Y1
Nagai, Y1
Katsuta, Y1
Nozaki, E1
Onodera, T1
Dolgin, E1
Campbell, KL1
Cohn, JR1
Fischman, DL1
Walinsky, P1
Mallya, R1
Jaffrani, W1
Savage, MP1
Patti, G2
Vizzi, V1
Ricottini, E1
Di Sciascio, G1
Jung, HJ1
Sir, JJ1
Barison, A1
Bellini, F1
Capozza, PF1
Lunardini, A1
Petronio, AS1
Bakhai, A1
Ferrieres, J1
Schmitt, C1
Sartral, M1
Belger, M1
Zeymer, U1
Juel, J1
Jensen, SE1
Bouman, HJ1
ten Cate, H1
Sarafoff, N1
Neumann, L1
Patel, PJ1
Matthai, WH1
Untereker, WJ1
Hara, M1
Nishino, M1
Taniike, M1
Makino, N1
Egami, Y1
Shutta, R1
Tanouchi, J1
Yamada, Y1
Hechler, B1
Parise, H1
Cristea, E1
Guagliumi, G3
Peruga, JZ1
Dudek, D1
Möeckel, M1
Briongos Figuero, S1
Salido-Tahoces, L1
de Juan-Bagudá, J1
Martí-Sánchez, D1
Grove, EL1
Würtz, M1
Hvas, AM1
Fernando, H1
Dart, AM1
Peter, K1
Shaw, JA1
Vavuranakis, M1
Vrachatis, DA1
Papaioannou, TG1
Archontakis, S1
Kalogeras, KI1
Kariori, MG1
Gafou, A1
Moldovan, C1
Tzamalis, P1
Stefanadis, C1
Cassese, S1
De Luca, G1
Villari, B1
Berti, S1
Bellone, P1
Alfieri, A1
Montinaro, A1
Quaranta, G1
Marraccini, P1
Lotfi, A1
Cui, J1
Wartak, S1
Columbo, J1
Mulvey, S1
Davis, M1
Schweiger, M1
Giugliano, GR1
Yan, BP1
Ajani, AE1
Clark, DJ1
Duffy, SJ1
Andrianopoulos, N1
Brennan, AL1
Loane, P1
Reid, CM1
Nusca, A1
Curzen, N2
Sambu, N2
Varenhorst, C1
Koul, S1
Erlinge, D1
Lagerqvist, B1
Siegbahn, A1
Barone-Rochette, G2
Foote, A1
Motreff, P2
Vanzetto, G2
Quesada, JL1
Danchin, N2
Machecourt, J2
Zakhem, B1
Garg, P1
Davis, G1
Wilson, JI1
Sivananthan, M1
Sharma, S1
Forrester, JS2
Rossini, R1
Lettieri, C1
Romano, M1
Rosiello, R1
Valsecchi, O1
Gavazzi, A1
Luo, Y1
Zhao, YT1
Verdo, A1
Qi, WG1
Zhang, DF1
Hu, B1
Odvodyova, D1
Fischerova, M1
Stepankova, S1
Maly, M1
Morawska, P1
Hermanides, RS1
Ottervanger, JP1
van Houwelingen, KG1
Dambrink, JH1
Ishida, M1
Watanabe, H1
Iino, K1
Okawa, M1
Kosaka, T1
Ito, H1
Granada, JF1
French, PA1
Smyth, SS2
Kern, MJ1
Parrett, BM1
Woo, A1
Buntic, R1
Singer, M1
Elmariah, S1
Jang, IK1
Warner, TD1
Mitchell, JA1
Kirkby, NS1
Radhakrishnan, A1
Dent, H1
Calver, AL1
Corbett, S1
Gray, H1
Simpson, IA1
Subban, V1
Kalidoss, L1
Sankardas, MA1
Azmoon, S1
Park, Y1
Muse, WC1
Kwon, TJ1
Koh, JS1
Hwang, SJ1
Canpolat, U1
Yorgun, H1
Atalar, E1
Mizia-Stec, K1
Haberka, M1
Mizia, M1
Lasota, B1
Kunecki, M1
Gieszczyk, K1
Chmiel, A1
Najda, J1
Kyrcz-Krzemień, S1
Gąsior, Z1
O'Connor, SA2
Bessereau, J1
Sébastien, A1
Galati, A1
Xanthopoulou, I1
Mavronasiou, E1
Kassimis, G1
Theodoropoulos, KC1
Makris, G1
Damelou, A1
Tsigkas, G1
Hahalis, G1
Tai, BC1
Sia, W1
Phua, QH1
Richards, MA1
Low, A1
Chan, KH1
Teo, SG1
Sim, TB1
Lee, CH1
Roe, MT1
Yeo, TC1
Tan, HC1
Chan, MY1
Colantonio, R2
Rotolo, F1
Monti, F1
Boggi, A1
Serdoz, R2
Rollini, F1
El Mallah, W1
Klein, AJ1
Brilakis, ES1
Verschuren, JJ1
Boden, H1
Wessels, JA1
van der Hoeven, BL1
Trompet, S1
Heijmans, BT1
Putter, H1
Guchelaar, HJ1
Schalij, MJ2
Jukema, JW1
Zou, JJ1
Xie, HG1
Chen, SL1
Lin, L1
Zhao, YY1
Xu, HM1
Lin, S1
Zhang, J1
Wang, GJ1
Brodie, B1
Pokharel, Y1
Garg, A1
Kissling, G1
Hansen, C1
Milks, S1
Cooper, M1
McAlhany, C1
Biscaglia, S1
Elhadad, S1
Pouillot, C1
Henry, P1
Boueri, Z1
Van Belle, E2
Rousseau, H1
Aubry, P2
Monségu, J1
Kerneis, M1
Saint-Etienne, C1
Vicaut, E1
Peyrol, M1
Sbragia, P1
Thuny, F1
Bennett, MR1
Yang, LX1
Liu, HL1
Qu, P1
Li, WM1
Jiang, TM1
Li, SM1
Jing, QM1
Zhang, QY1
Aradi, D1
Komócsi, A1
Vorobcsuk, A1
Yamagishi, M1
Ueno, T1
Hara, K2
Ishiwata, S1
Itoh, T1
Hamanaka, I1
Wakatsuki, T2
Sugano, T1
Kawai, K1
Kimura, T1
Ohkubo, K1
Fujimoto, Y1
Kadohira, T1
Sugimoto, K1
Morino, T1
Bliden, KP3
Fort, JG1
Shuldiner, A1
Chai, S1
Gesheff, T1
Antonino, M1
Gesheff, M1
Carlquist, JF1
Knight, S1
Horne, BD1
Huntinghouse, JA1
Rollo, JS1
May, H1
Anderson, JL1
Singh, M1
Bolla, VH1
Berg, R1
Shatin, D1
Schech, SD1
Brinker, A1
Mahadevan, VS1
Khan, MM1
Adgey, JA1
Burzotta, F1
Sabatier, R1
Prati, F1
Boccanelli, A1
Grollier, G2
Orford, JL1
Lennon, R1
Melby, S2
Fasseas, P1
Bell, MR2
Rihal, CS2
Holmes, DR6
Fitchett, D1
Gupta, M1
Langer, A1
Krötz, F1
Schiele, TM1
Zahler, S1
König, A1
Rieber, J1
Kantlehner, R1
Pöllinger, B1
Dühmke, E1
Theisen, K1
Sohn, HY1
Klauss, V1
Sick, P1
Hüttl, T1
Niebauer, J1
Thiele, H1
Lauer, B1
Hambrecht, R1
Hentschel, B1
Schuler, G1
Cummings, CC1
Bell, CR1
Alford, AB1
Meister, AF1
Boden, WE1
Pepine, CJ1
Bouvier, JL3
Roquebert, PO2
Macaluso, G1
Commeau, P1
Comet, B3
Lafont, A1
Walter, U1
Eigenthaler, M2
Voskoboĭ, VI1
Rebrov, AP1
Rogan, SV1
Arablinskiĭ, AV1
Solov'ev, OP1
Rott, D1
Dai, H1
Tao, Q1
Zhang, F1
Zheng, L1
Qiu, Y1
Lee, SW1
Song, JM1
Han, KH1
Kang, DH1
Song, JK1
Ludwig, J1
Spanos, V1
Louvard, Y1
Desmedt, B1
Di Mario, C4
Weltermann, A1
Fritsch, P1
Kyrle, PA1
Schoenauer, V1
Heinze, G1
Wojta, J1
Christ, G1
Schömig, E1
Lepäntalo, A1
Virtanen, KS1
Heikkilä, J1
Wartiovaara, U1
Lassila, R1
Bernardo, E2
Stranieri, C1
Trabetti, E1
Pignatti, PF1
Helø, OH1
Madsen, JK1
Kastrup, J1
Matetzky, S2
Shenkman, B1
Guetta, V1
Shechter, M1
Beinart, R1
Bienart, R1
Goldenberg, I1
Novikov, I1
Pres, H1
Savion, N1
Varon, D1
Hod, H2
Müller, I2
Besta, F1
Tsakiris, DA1
Schneider, C1
Patrono, C1
Coller, B1
FitzGerald, GA1
Roth, G1
Ezekowitz, M1
Meade, TW1
O'Connor, CM1
Vorchheimer, DA1
Guyatt, GH1
Zimarino, M3
Renda, G2
Maddestra, N1
De Caterina, R2
Schwimmbeck, PL1
Schulman, SP1
Schleinitz, MD1
Olkin, I1
Heidenreich, PA1
Danna, P1
Piccaluga, E1
Viecca, M1
von Mach, MA1
Eich, A1
Weilemann, LS1
Münzel, T2
Zaman, KA1
Yoho, JA1
Hayes, KM1
Leopold, JA1
Bavry, AA1
Kumbhani, DJ1
Helton, TJ1
Kunz, I1
Spada, S1
Sütsch, G1
Ruggieri, F1
Karvouni, E1
Korovesis, S1
Katritsis, DG1
Wyss, CA1
Roffi, M1
Biondi-Zoccai, GG2
Sangiorgi, GM2
Vittori, G1
Falchetti, E1
Margheri, M1
Barbagallo, R1
Tamburino, C2
Remigi, E1
Iakovou, I1
Agostoni, P1
Tsagalou, E1
Melzi, G1
Michev, I1
Airoldi, F1
Montorfano, M1
Carlino, M1
Wolak, A1
Amit, G1
Cafri, C1
Gilutz, H1
Ilia, R1
Zahger, D1
Phillips, DR1
Conley, PB1
Sinha, U1
Andre, P1
Wlazłowski, R1
Goch, A1
Goch, JH1
Leiva-Pons, JL1
Keltai, M1
Almsherqi, ZA1
McLachlan, CS1
Mossop, P1
Deng, Y1
Bierbach, B1
Horstick, G1
Berg, O1
Heimann, A1
Vahl, CF1
Kempski, O1
Darius, H1
Brügemann, J1
van Gelder, IC1
van der Meer, J1
Boztosun, B1
Gunes, Y1
Kirma, C1
Barutcu, I1
Hennan, JK1
Swillo, RE1
Morgan, GA1
Leik, CE1
Brooks, JM1
Shaw, GD1
Schaub, RG1
Crandall, DL1
Vlasuk, GP1
Vats, HS1
Hocking, WG1
Rezkalla, SH1
Templin, C1
Schaefer, A1
Stumme, B1
Drexler, H1
von Depka, M1
Olivier, AC1
Hollman, JL1
Fuchigami, S1
Oshima, S1
Noda, K1
Fukushima, H1
Yoshida, T1
Takushi, Y1
Ozben, B1
Ekmekci, A1
Bugra, Z1
Umman, S1
Meric, M1
Oo, TH1
Patel, TN1
Kreindel, M1
Lincoff, AM1
Vafai, JJ1
Aroesty, JM1
Granitskiĭ, NA1
Ishikawa, T1
Mutoh, M1
Fuda, Y1
Sakamoto, H1
Okada, H1
Higashitani, M1
Nakano, Y1
Yamaguchi, J1
Enta, K1
Satoh, T1
Imai, K1
Horie, T1
Mochizuki, S1
Plokker, HW1
Nesto, RW1
Gaku, N1
Kengo, T1
Aoki, J1
Yamamoto, H1
Higashikuni, Y1
Nakajima, H1
Chrissoheris, MP1
Mruthyunjayanna, V1
Donohue, TJ1
Yang, J1
Wang, N1
Xu, J1
Ling, F1
Zhou, L1
Ye, X1
Münzel, TF1
Post, F1
Sharifkazemi, MB1
Zamirian, M1
Aslani, A1
Matsumoto, D1
Paredes, OL1
Yokoyama, M1
Bochenek, A1
Wilczyński, M1
Pfisterer, M1
Brunner-La Rocca, HP1
Buser, PT1
Rickenbacher, P1
Hunziker, P1
Mueller, C1
Jeger, R1
Bader, F1
Osswald, S1
Kaiser, C1
Califf, RM1
Wiper, AJ1
Roberts, DH1
Antoniou, S1
Rothman, MT1
Chassot, PG2
Delabays, A2
Ravussin, P1
Spahn, DR2
Glowczynska, R1
Malek, LA1
Spiewak, M1
Filipiak, KJ1
Grabowski, M1
Kisiel, B1
Kochman, J1
Kostrzewa, G1
Ploski, R1
Opolski, G1
Hamdalla, H1
Eshaghian, S1
Kaul, S1
Amin, S1
Shah, PK2
Diamond, GA1
Okuno, T1
Nakamura, Y2
Sakakibara, M1
Miyazaki, A1
Shimizu, Y1
Seesing, TH1
Bal, ET1
den Heijer, P1
Grinius, V1
Navickas, R1
Unikas, R1
Bartorelli, AL1
Trabattoni, D1
Galassi, A1
Piovaccari, G2
Benassi, A2
Sangiorgio, P1
Chierchia, S1
Reimers, B3
Finn, AV1
Joner, M1
Nakazawa, G1
Kolodgie, F1
Newell, J1
John, MC1
Gold, HK1
Lee, JS1
Dunn, SP1
Marshall, HM1
Cohen, MG1
Schäfer, A1
Bonz, AW1
Bauersachs, J1
Karlsson, G1
Rehman, J1
Kalaria, V1
Breall, JA1
Fefer, P1
Tamura, A1
Watanabe, T1
Shinozaki, K1
Kotoku, M1
Yano, S1
Kadota, J1
Majdoub, MA1
Sauguet, A1
Tchetche, D1
Ducrocq, G2
Benamer, H1
Himbert, D1
Feldman, LJ1
Juliard, JM1
Digne, F1
Gérardin, B1
Pillière, R1
Estagnasié, P1
Dib, JC1
Terdjman, M1
Grinda, JM1
Dubois, C1
Baer, FM1
Tie, S1
Wong, CK1
Yap, J1
Wilkins, G1
Williams, M1
Kay, P1
Gladding, P1
Webster, M1
Marzocchi, A1
Saia, F1
Manari, A1
Aurier, E1
Cremonesi, A1
Varani, E1
Magnavacchi, P1
Guastaroba, P1
Grilli, R1
Maresta, A1
Kapp, M1
Göhring-Frischholz, K1
Daub, K1
Dösch, C1
Langer, H1
Herdeg, C1
Belli, G1
Rossi, M1
Presbitero, P1
Kupferwasser, LI1
Amorn, AM1
Kapoor, N1
Lee, MS1
Kar, S1
Cercek, B1
Dohad, S1
Mirocha, J1
Makkar, RR1
Parikh, SA1
Beckman, JA1
Sardella, G1
Bucciarelli-Ducci, C1
Mancone, M1
Fedele, F1
Tomaszuk-Kazberuk, A1
Sobkowicz, B1
Usowicz-Szaryńska, M1
Prokop, JB1
Knapp, M1
Sawicki, R1
Musiał, WJ1
Augoustides, JG1
Joyal, D1
Rudski, L1
Smith, K1
Ferguson, JJ3
Wilson, JM1
Diez, J1
Grube, E1
Dawkins, KD1
Banning, AP2
Zmudka, K1
Hauptman, K1
Marco, J1
Popma, JJ2
Buellesfeld, L1
Koglin, J1
Russell, ME1
Fitzgerald, DJ1
Maree, A1
Berger, K1
Hessel, F1
Kreuzer, J1
Smala, A1
Diener, HC1
Varvarovský, I1
Matejka, J1
Herman, A1
Conroy, M1
Black, SA1
Orford, N1
Kaya, MG1
Durakoglugil, E1
Yalcin, R1
Singh, S1
Arora, R1
Khraisat, A1
Handa, K1
Bahekar, A1
Trivedi, A1
Khosla, S1
Kirsch, M1
Vermes, E1
Boval, B1
Drouet, L1
Loisance, D1
Dupliakov, DV1
Endemann, S1
Gollapudi, RR1
Valencia, R1
Stinis, CT1
Levisay, JP1
Ernst, A1
Sawhney, NS1
Schatz, RA1
Teirstein, PS2
Ryding, AD1
Faurie, B1
Costerousse, O1
Beyar, R1
Nikolsky, E1
Bollati, M1
Gambino, A1
Lombardi, P1
Eslami, M1
Moayed, DA1
Pranno, N1
Noble, S1
Ibrahim, R1
Grégoire, JC1
Azzari, F1
Nozza, A1
Berry, C1
Doucet, S1
Labarthe, B1
Théroux, P1
Tardif, JC1
Piana, RN1
Caputo, RP1
Gordon, PC1
Lopez, JJ1
Ryan, TJ1
Kiernan, FJ1
Ho, KK2
Sharma, M1
Yeghiazarians, Y1
Sullebarger, JT1
Wymer, N1
Holloway, D1
Polack, B1
Bertrand, B1
Andrade, J1
Al Ali, A1
Saw, J1
Wong, GC1
King, SB1
Suzuka, H1
Fujiwara, H1
Tanaka, M1
Yoshifusa, H1
Shibata, Y1
Silvestri, M3
Siméoni, JB2
Villain, P2
Pietri, P2
Quatre, JM1
Bayet, G1
Rozenman, Y2
Lotan, C2
Mosseri, M2
Gotsman, MS2
Hall, P3
Nakamura, S3
Almagor, Y2
Maiello, L3
Martini, G4
Gaglione, A2
Goldberg, SL1
Tobis, JM2
White, BP1
Sullivan, AT1
Lumley, P1
Yao, SK2
Ober, JC2
Maffrand, JP2
Anderson, HV2
Buja, LM2
Willerson, JT3
Charmasson, C1
Bremondy, M1
Hasin, Y1
Lablanche, JM1
McFadden, EP1
Bedossa, M1
Leclercq, C1
Vahanian, A1
Bauters, C1
Bertrand, ME2
Pan, M1
Suárez de Lezo, J1
Velasco, F1
Romero, M1
Medina, A1
Segura, J1
Pavlovic, D1
Melian, F1
Gallardo, A1
Zayas, R1
Torres, A1
Moussa, I4
Akiyama, T1
Tiecco, F1
Di Maggio, M1
Chotinaiwattarakul, C1
Mahanonda, N1
Kangkagate, C1
Chaithiraphan, S1
Cho, SY1
Kim, KB1
Oh, BH1
Zubaid, M1
Penn, IM1
Buller, CE2
Moscovich, MD1
Ricci, DR1
Chauhan, A1
Hall, D1
Hobson, AG1
Sowinski, KM1
Moses, J1
Di Francesco, L1
Weber, AA1
Heublein, B1
Ozbek, C1
Pethig, K1
Elsner, M1
Peifer, A1
Drexler, M1
Wenzel, C1
Hebbeker, C1
Kasper, W1
Oemrawsingh, PV1
Udayachalerm, W1
van der Wall, EE1
Bruschke, AV1
Zidar, JP3
Buchwald, AB1
Alvarez, JM1
Harper, RW1
Peverill, RE1
Urban, P1
Rupprecht, HJ1
Kiemeneij, F1
Fontanelli, A1
Pieper, M1
Wesseling, T1
Sagnard, L1
Szto, GY1
Linnemeier, TJ2
Ball, MW1
Oetgen, M1
Roubin, G1
Wang, X1
Iyer, S1
Maida, R1
Kreps, E1
Topol, EJ2
McCullough, PA1
Marks, KR1
de Carvalho, HC1
Park, HK1
Zoldhelyi, P1
Jauhar, R1
Bergman, G1
Savino, S1
Deutsch, E2
Shaknovich, A1
Parikh, M1
Sanborn, TA1
Tcheng, JE1
Kong, DF1
Bennett, CL1
Davidson, CJ1
Raisch, DW1
Weinberg, PD1
Bennett, RH1
Feldman, MD1
Mishkel, GJ1
Aguirre, FV1
Ligon, RW1
Rocha-Singh, KJ1
Lucore, CL1
Ting, H1
Barsness, G1
Garratt, K1
Bellot, V1
Mathew, V1
Hammes, L1
Grill, D1
Klein, LW1
Calvin, JE1
Avran, A1
Fourcade, L1
Bory, M1
Müller, C1
Büttner, HJ1
Petersen, J1
Roskamm, H1
Miller, JL1
Prost, C1
Veyre, B1
Ollivier, L1
Daurat, MO1
Vial, T1
Augey, F1
Cohen, M1
O'Brien, M1
Parness, IA1
Neufeld, EJ1
Baker, AL1
Sundel, RP1
Newburger, JW1
Dillon, WC1
Eckert, GJ1
Dillon, JC1
Ritchie, ME1
Pascual Figal, DA1
Valdés Chávarri, M1
Ruipérez, JA1
Cortés, R1
López Pálop, R1
Picó Aracil, F1
García Alberola, A1
Kleiman, NS1
Grazeiadei, N1
Maresh, K1
Taylor, RJ1
Frederick, B1
Lance, ET1
Jordan, RE1
Mascelli, MA1
Rüdiger, S1
Wolf, B1
Pogatsa-Murray, G1
Van De Graaff, E1
Yip, HK1
Chang, HW1
Wu, CJ1
Chen, MC1
Hang, CL1
Fang, CY1
Hsieh, KY1
Baim, DS1
Carrozza, JP1
Chauhan, MS1
Rodriguez, O1
Kuntz, RE1
Kandzari, DE1
Behar, VS1
Sketch, MH1
Shimshak, T1
Broderick, T1
Young, J1
Runyon, JP1
Safian, RD1
Kern, M1
Taniuchi, M2
Kurz, HI1
Lasala, JM2
Kitai, T1
Nishikawa, M1
Tanigawa, T1
Okinaka, T1
Wada, H1
Shiku, H1
Ikeda, Y1
Ito, M1
Isaka, N1
Nakano, T1
Timurkaynak, T1
Goksen, I1
Cengel, A1
Dortlemez, O1
Lowe, HC1
Kumar, RK1
Chesterman, CN1
Fahmy, RG1
Khachigian, LM1
Cosmi, B1
Rubboli, A1
Castelvetri, C1
Milandri, M1
Batchelor, WB1
Meier, S1
Hasselblad, V1
Fry, ET2
Ross, AM1
Binanay, CA1
Ellis, SG1
Hasa, AA1
Schmaier, AH1
Warnock, M1
Normolle, D1
Driscoll, E1
Lucchesi, BR1
Werns, SW1
Bahit, MC1
Gobeil, F1
Juneau, C1
Plante, S1
Meier, SJ1
Batchelor, W1
Reed, MD1
Bell, D1
Hata, K1
Kitada, N1
Gomyo, T1
Hamanaka, M1
Koganei, A1
Kan, Z1
Kawaguchi, S1
Amemiya, T1
Tomoda, H1
Yokota, I1

Clinical Trials (105)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Comparative Study of the Antithrombotic Effects of Ticagrelor and Clopidogrel in Type 2 Diabetic Patients[NCT01823510]Phase 420 participants (Actual)Interventional2013-07-31Completed
Randomized, Multinational, Double-blind Study, Comparing a High Loading Dose Regimen of Clopidogrel Versus Standard Dose in Patients With Unstable Angina or Myocardial Infarction Managed With an Early Invasive Strategy.[NCT00335452]Phase 325,086 participants (Actual)Interventional2006-06-30Completed
Telephone Contacts to Improve Adherence to Dual Anti-Platelet Therapy Following Drug-Eluting Stent Implantation; A Randomized Controlled-Trial[NCT01134679]300 participants (Actual)Interventional2009-06-30Completed
A Randomised, Double-blind, Parallel Group, Phase 3, Efficacy and Safety Study of Ticagrelor Compared With Clopidogrel for Prevention of Vascular Events in Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS) [PLATO- a Study of PLATelet Inh[NCT00391872]Phase 318,624 participants (Actual)Interventional2006-10-31Completed
P2Y12 Inhibitors Utilization in Bifurcation and Chronic Total Occlusion PCI With Biologically Active Stents (P2BiTO) Registry[NCT01967615]4,500 participants (Actual)Observational2015-01-31Completed
The Use of BRILInta to Optimize ANTiplatelet Therapy (BRILIANT) Registry: The BRILIANT KOREA Registry[NCT02521038]2,000 participants (Anticipated)Observational [Patient Registry]2015-07-31Recruiting
Comparison of the Efficacy and Safety of New Platform Everolimus-eluting Coronary Stent System (Promus Element) With Zotarolimus-eluting Coronary Stent System (Endeavor Resolute) and Triple Anti-platelet Therapy With Double-dose Clopidogrel Anti-platelet [NCT01267734]Phase 43,750 participants (Anticipated)Interventional2010-06-30Recruiting
Study of the Efficacy and Safety of Cilostazol in the Prevention of Ischemic Vascular Events in Diabetic Patients With Symptomatic Peripheral Artery Disease.[NCT02983214]Phase 4826 participants (Actual)Interventional2016-11-30Completed
PROlonging Dual Antiplatelet Treatment In Patients With Coronary Artery Disease After Graded Stent-induced Intimal Hyperplasia studY[NCT00611286]Phase 41,700 participants (Anticipated)Interventional2006-12-31Completed
Short-term Outcomes of Elective High-risk PCI With Extracorporeal Membrane Oxygenation Support: a Single-centre Registry[NCT05387902]25 participants (Actual)Observational [Patient Registry]2022-02-03Completed
RESOLUTE International Registry: Evaluation of the Resolute Zotarolimus-Eluting Stent System in a 'Real-World' Patient Population[NCT00752128]2,349 participants (Actual)Observational2008-08-31Completed
Management of Antiplatelet Regimen During Surgical Procedures (MARS Registry)[NCT03981835]1,492 participants (Anticipated)Observational [Patient Registry]2019-08-01Recruiting
A Clinical Evaluation of the Medtronic Resolute Zotarolimus-Eluting Coronary Stent System in the Treatment of De Novo Lesions in Native Coronary Arteries With a Reference Vessel Diameter of 2.25 mm to 4.2mm[NCT00726453]1,516 participants (Actual)Interventional2008-07-31Completed
The Clinical Evaluation of the MDT-4107 Drug-Eluting Coronary Stent in De Novo Lesions in Native Coronary Arteries[NCT00927940]100 participants (Actual)Interventional2009-03-31Completed
RESOLUTE-III All-comers Trial: A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention[NCT00617084]Phase 42,292 participants (Actual)Interventional2008-04-30Completed
PROTECT Trial: Patient Related OuTcomes With Endeavor Versus Cypher Stenting Trial[NCT00476957]Phase 48,709 participants (Actual)Interventional2007-06-30Completed
Evaluation of the Occurence of Thrombotic and Bleeding Events After Coronary Angioplasty With Stent According to Aspirin and Clopidogrel Platelet Reactivity Assessed by a Point of Care Assay in the Cathlab (the Verifynow French Registry)[NCT00753753]1,001 participants (Actual)Observational2008-02-29Completed
EDUCATE: a Prospective, Multi-center Study Designed to Collect Real-world Safety and Clinical Outcomes in Subjects Receiving One or More Endeavor Zotarolimus-Eluting Stents and Either Clopidogrel and Aspirin or Prasugrel and Aspirin as Part of a Dual Anti[NCT01069003]Phase 42,272 participants (Actual)Interventional2010-04-30Completed
Platelet Function in Resuscitated Patients-2[NCT03445546]25 participants (Actual)Observational2016-05-01Completed
A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Native Coronary Artery Lesions[NCT00180310]Phase 3300 participants (Actual)Interventional2005-07-31Completed
SPIRIT V: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Coronary Artery Lesions[NCT00402272]Phase 42,700 participants (Actual)Interventional2006-11-30Completed
SPIRIT III: A Clinical Evaluation of the Investigational Device XIENCE V® Everolimus Eluting Coronary Stent System (EECSS) in the Treatment of Subjects With de Novo Native Coronary Artery Lesions[NCT00180479]Phase 31,002 participants (Actual)Interventional2005-06-30Completed
A Clinical Evaluation of the XIENCE Everolimus Eluting Coronary Stent System in the Treatment of Women With de Novo Coronary Artery Lesions[NCT00496938]Phase 41,600 participants (Actual)Interventional2007-07-31Completed
XIENCE V® Everolimus Eluting Coronary Stent System India Post-marketing Single-Arm Study[NCT00631228]1,000 participants (Actual)Observational2008-06-30Completed
XIENCE V® Everolimus Eluting Coronary Stent System (EECSS) USA Post-Approval Study[NCT00676520]8,053 participants (Actual)Observational2008-07-31Completed
SPIRIT IV Clinical Trial: Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Subjects With de Novo Native Coronary Artery Lesions[NCT00307047]Phase 33,687 participants (Actual)Interventional2006-08-31Completed
A Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention (CHAMPION PHOENIX)[NCT01156571]Phase 311,145 participants (Actual)Interventional2010-09-30Completed
VerifyNow to Optimise Platelet Inhibition in Coronary Acute Syndrome (VERONICA Trial)[NCT04654052]Phase 4634 participants (Anticipated)Interventional2021-07-02Recruiting
Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents[NCT00638794]8,575 participants (Actual)Observational2008-01-31Completed
Patterns of Non-Adherence to Dual Anti-Platelet Regimen In Stented Patients: An Observational Single-Arm Study (The PARIS Registry)[NCT00998127]5,031 participants (Actual)Observational2009-06-30Completed
Impact of IntraVascular UltraSound Guidance on Outcomes of Xience Prime Stents in Long Lesions (IVUS-XPL Study)[NCT01308281]1,079 participants (Actual)Interventional2010-10-31Completed
A Prospective, Multi-center, Randomized, Double-blind Trial to Assess the Effectiveness and Safety of 12 Versus 30 Months of Dual Antiplatelet Therapy in Subjects Undergoing Percutaneous Coronary Intervention With Either Drug-eluting Stent or Bare Metal S[NCT00977938]Phase 425,682 participants (Actual)Interventional2009-10-31Completed
A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention[NCT00097591]Phase 313,619 participants (Actual)Interventional2004-11-30Completed
Prospective Study of Bioresorbable Vascular Scaffold Treatment With Scoring Balloon Pre-dilatation in Patients With In-stent Restenosis[NCT03069066]Phase 4100 participants (Anticipated)Interventional2016-01-31Recruiting
RIBS V (Restenosis Intra-stent of Bare Metal Stents: Paclitaxel-eluting Balloon vs Everolimus-eluting Stent). A Prospective, Multicenter and Randomized Clinical Trial[NCT01239953]Phase 4190 participants (Actual)Interventional2010-01-31Active, not recruiting
RIBS IV (Restenosis Intra-stent of Drug-eluting Stents: Paclitaxel-eluting Balloon vs Everolimus-eluting Stent). A Prospective, Multicenter and Randomized Clinical Trial[NCT01239940]Phase 4310 participants (Anticipated)Interventional2010-01-31Recruiting
Prospective Study of Bioresorbable Vascular Scaffold Treatment in Patients With In-stent Restenosis[NCT02672878]Phase 4130 participants (Anticipated)Interventional2014-04-30Not yet recruiting
Observational Study of Treatment of Bioresorbable Vascular Scaffolds Restenosis[NCT03167424]100 participants (Anticipated)Observational [Patient Registry]2016-05-31Recruiting
Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel[NCT00398463]Phase 4263 participants (Actual)Interventional2006-05-31Completed
A Randomized, Multicenter, Double-Blind, Study to Evaluate the Efficacy of Tirofiban HCl Versus Placebo in the Setting of Standard Therapies Among Subjects Undergoing Percutaneous Coronary Intervention[NCT01245725]Phase 30 participants (Actual)InterventionalWithdrawn (stopped due to Study was not initiated, change in clinical development)
Customized Choice of P2Y12 Oral Receptor Blocker Based on Phenotype Assessment Via Point of Care Testing[NCT01477775]Phase 44,000 participants (Anticipated)Interventional2012-01-31Recruiting
Randomized, Prospective , Open Label, Phase 4 Trial of Efficacy and Safety of Adjunctive Cilostazol in Acute Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention With Drug-eluting Stent[NCT01261832]Phase 4951 participants (Anticipated)Interventional2011-07-31Active, not recruiting
Antiplatelet Resistance Research in Patients With Peripheral Arterial Revascularization[NCT03953547]88 participants (Actual)Observational2018-01-01Completed
Maintenance Of aNtiplatElet Therapy in Patients With Coronary Stenting Undergoing Surgery[NCT03445273]1,800 participants (Anticipated)Observational [Patient Registry]2018-11-21Not yet recruiting
ReAssessment of Anti-Platelet Therapy Using an InDividualized Strategy in Patients With ST-segment Elevation Myocardial Infarction[NCT01452139]Phase 2/Phase 3102 participants (Actual)Interventional2011-09-30Completed
Pharmacogenetics of Clopidogrel in Acute Coronary Syndromes[NCT03347435]889 participants (Actual)Interventional2013-06-30Terminated (stopped due to Ethics Committe decision)
Role of Innate and Adaptive Immunity After Acute Myocardial Infarction BATTLE-AMI Study (B And T Types of Lymphocytes Evaluation in Acute Myocardial Infarction)[NCT02428374]Phase 4300 participants (Anticipated)Interventional2015-05-31Recruiting
ReAssessment of Anti-Platelet Therapy Using an InDividualized Strategy Based on GENetic Evaluation (The RAPID GENE Study)[NCT01184300]Phase 2/Phase 3200 participants (Actual)Interventional2010-08-31Completed
The Role of Multiple Electrode Aggregometry in Detection of Clopidogrel Resistance in Diabetic Patients With Coronary Artery Disease and Prediction of Clinical Outcomes. A Comparative-method, Non Interventional, Single Center Study.[NCT01991093]280 participants (Actual)Observational2014-06-30Completed
Effect of Modifying Anti-platelet Treatment to Ticagrelor in Patients With Diabetes and Low Response to Clopidogrel[NCT01643031]Phase 4500 participants (Anticipated)Interventional2012-08-31Not yet recruiting
Efficacy and Safety of Anticoagulant on Early Treatment of Post-STEMI Left Ventricular Thrombus: an Open, Prospective, Randomized and Multi-centers Trial.[NCT03764241]Phase 3280 participants (Anticipated)Interventional2020-02-01Recruiting
Efficacy and Safety of Anticoagulant on Early Prevention of Post-STEMI Left Ventricular Thrombus: an Open, Prospective, Randomized and Multi-centers Trial.[NCT03786757]Phase 3200 participants (Anticipated)Interventional2019-04-01Not yet recruiting
REACTIC-TAVI Trial: Platelet REACtivity According to TICagrelor Dose After Transcatheter AorticValve Implantation. A Pilot Study.[NCT04331145]Phase 440 participants (Actual)Interventional2020-06-23Completed
Chinese People's Liberation Army General Hospital[NCT02798874]240 participants (Anticipated)Interventional2016-05-31Enrolling by invitation
Comparison of Ticagrelor and Clopidogrel on Reperfusion in Patients With AMI Undergoing PPCI Evaluated by SPECT[NCT02233790]Phase 4600 participants (Anticipated)Interventional2014-12-31Not yet recruiting
The MAgnitude of Platelet Inhibition and the Pharmacokinetics of a 600 mg Loading Dose of Clopidogrel, in Different Patient CATegories (Stable Angina Versus Acute-coronary Syndromes Versus ST-elevated Myocardial Infarction).[NCT01012544]Phase 4187 participants (Actual)Interventional2009-04-30Completed
Dual Arm Factorial Randomized Trial in Patients w/ST Segment Elevation AMI to Compare the Results of Using Anticoagulation With Either Unfractionated Heparin + Routine GP IIb/IIIa Inhibition or Bivalirudin + Bail-out GP IIb/IIIa Inhibition; and Primary An[NCT00433966]Phase 33,602 participants (Actual)Interventional2005-03-31Completed
The Laboratory AntiPlatelet Efficacy and Clinical Outcome Registry[NCT02264912]2,016 participants (Actual)Observational [Patient Registry]2008-07-31Completed
Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention[NCT02270242]Phase 49,006 participants (Actual)Interventional2015-07-31Completed
Ticagrelor in Comparison to Prasugrel for Inhibition of Platelet Reactivity, in Patients With Acute Coronary Syndrome (ACS) Presenting Resistance to the Usual Clopidogrel Dose After PCI[NCT01360437]Phase 344 participants (Actual)Interventional2011-05-31Completed
Double Randomization of a Monitoring Adjusted Antiplatelet Treatment Versus a Common Antiplatelet Treatment for DES Implantation, and a Interruption Versus Continuation of Double Antiplatelet Therapy, One Year After Stenting[NCT00827411]Phase 42,500 participants (Actual)Interventional2009-01-31Completed
Laboratory Implications of Non Obstructive Atherosclerotic Plaques Identified by Multiple Detector Coronary Angiotomography[NCT03632785]90 participants (Actual)Observational2017-03-27Completed
Randomized Comparison of Platelet Function Monitoring to Adjust Antiplatelet Therapy Versus a Common Antiplatelet Treatment for Intracranial Aneurysm Stent-assisted Coiling[NCT02224131]Phase 41,856 participants (Anticipated)Interventional2015-01-31Not yet recruiting
ASS-Nonresponse Following Cardiac Surgery as Assessed With Multiple Electrode Aggregometry[NCT01824147]400 participants (Actual)Observational2013-08-31Completed
A Randomized, Open-Label, Cross-Over, Study to Evaluate the Inhibitory Effect of Clopidogrel, EC Aspirin 81 mg and EC Omeprazole 40 mg All Dosed Concomitantly and PA32540 and Clopidogrel Dosed Separately on Platelet Aggregation in Healthy Volunteers[NCT01557335]Phase 130 participants (Actual)Interventional2010-11-30Completed
Revascularization With Paclitaxel-coated Balloon Angioplasty Versus Drug-eluting Stenting in Acute Myocardial Infarction - a Randomized Controlled Trial.[NCT02219802]120 participants (Anticipated)Interventional2014-08-31Not yet recruiting
SEA-SIDE: Sirolimus Versus Everolimus-eluting Stent Randomized Assessment in Bifurcated Lesions and Clinical SIgnificance of Residual siDE-branch Stenosis[NCT00697372]Phase 4150 participants (Actual)Interventional2007-09-30Completed
Prospective Randomized Study of the Paclitaxel-Coated Balloon Catheter in Bifurcated Coronary Lesions / BABILON Study (Paclitaxel-Coated Balloon in Bifurcated Lesions)[NCT01278186]Phase 4190 participants (Anticipated)Interventional2010-06-30Active, not recruiting
Prospective, Randomized, Single-Center Evaluation of the Cypher™ Sirolimus Eluting Coronary Stent System in the Treatment of Bifurcated Coronary Lesions[NCT00288535]Phase 4200 participants (Anticipated)Interventional2005-03-31Recruiting
Study of Lipid Core Plaque Shift at Sites of Native Coronary Artery Bifurcation[NCT00905671]Phase 420 participants (Actual)Interventional2009-06-30Completed
Z-SEA-SIDE: Sirolimus Versus Everolimus Versus Zotarolimus-eluting Stent Assessment in Bifurcated Lesions and Clinical SIgnificance of Residual siDE-branch Stenosis[NCT01200693]Phase 480 participants (Actual)Interventional2008-11-30Completed
Approaches to Chronic Occlusions With Sirolimus Stents-Cypher (ACROSS-Cypher) Total Occlusion Study of Coronary Arteries 4 Trial[NCT00378612]Phase 3200 participants (Actual)Interventional2005-06-30Completed
WilL LOWer Dose Aspirin be More Effective Following ACS? (WILLOW-ACS)[NCT02741817]Phase 420 participants (Actual)Interventional2016-06-26Completed
Prospective Pilot Study- Does Mean Platelet Volume Change With Clopidogrel in Patients With Stable Angina Undergoing Percutaneous Coronary Intervention?[NCT02550301]100 participants (Anticipated)Observational2015-09-30Not yet recruiting
Biological Efficacy of Clopidogrel 600 mg Loading Dose Followed by 75 mg Maintenance Dose After Implantation of Drug-eluting Stents in Patients With Diabetes Mellitus or Metabolic Syndrome (SPACE)[NCT00298428]159 participants (Actual)Interventional2006-05-31Completed
Chewing Clopidogrel in Addition to Regular Oral Clopidogrel Treatment to Improve Platelets Aggregation in Patient With NON ST ELEVATION MI[NCT00889044]Phase 330 participants (Anticipated)Interventional2009-04-30Recruiting
Randomized, Double-Blind, Active-Controlled, Multicenter Trial of Abciximab And Bivalirudin in Patients With Non-ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Interventions (ISAR-REACT-4)[NCT00373451]Phase 41,721 participants (Actual)Interventional2006-07-31Completed
The Effect of Ticagrelor on Acute Coronary Syndrome Patients With Clopidogrel Resistance Undergoing Percutaneous Coronary Intervention[NCT01812330]Phase 3180 participants (Anticipated)Interventional2013-01-31Recruiting
A Pilot Study of The Effects of a Single High Dose Bolus Tirofiban in Diabetic Patients Undergoing Elective Percutaneous Coronary Intervention[NCT00407771]Phase 444 participants (Anticipated)Interventional2007-11-30Not yet recruiting
"Evaluation of Antiplatelet Effects and Safety of Intraoperative Administration of Ticagrelor Versus Clopidogrel in Patients Undergoing One-stop Hybrid Coronary Revascularization"[NCT02513004]Phase 460 participants (Anticipated)Interventional2015-06-30Recruiting
Spot Drug-Eluting vs Full Cover Stenting for Long Coronary Stenoses: a Randomized Clinical Study[NCT00738556]179 participants (Actual)Interventional2003-01-31Completed
Activity of Platelets After Inhibition and Cardiovascular Events: Drug Eluting Stent Implantation in Patients With Acute Coronary Syndrome: Optical Coherence Tomography Study[NCT01239654]Phase 360 participants (Actual)Interventional2010-09-30Completed
A Prospective Optical Coherence Tomography Study on Completeness of Strut Coverage and Vessel Wall Response at 3-6 and 9 Months Following Paclitaxel Eluting Stent Implantation in Multivessel Coronary Artery Disease[NCT00704145]Phase 430 participants (Anticipated)Interventional2007-11-30Completed
In-Vivo Vascular Response of Sirolimus-,Paclitaxel- and Zotarolimus-Eluting Stents in Long Lesions Requiring Overlapping. A Prospective, Randomized, Controlled Study Using Optical Coherence Tomography[NCT00693030]Phase 477 participants (Anticipated)Interventional2006-08-31Recruiting
The Optical Coherence Tomography Drug Eluting Stent Investigation(OCTDESI)[NCT00776204]60 participants (Actual)Interventional2008-05-31Completed
Effect of TCFA on Neointimal Coverage After EXCEL Biodegradable Polymer-coated Sirolimus-eluting Stents Implantation at 9 Months Follow-up: Evaluated by Optical Coherence Tomography and Fractional Flow Reserve[NCT02384837]33 participants (Actual)Observational2014-12-31Completed
Prospective, Randomized, Controlled Arm Study Comparing the Coverage of the Zotarolimus-eluting Stent vs Bare Metal Stent Implanted in ST- Elevation Myocardial Infarction (STEMI).[NCT00704561]44 participants (Actual)Interventional2008-04-30Completed
A Randomized Optical Coherence Tomography Study Comparing Resolute Integrity to Biomatrix Drug-eluting Stent on the Degree of Early Stent Healing and Late Lumen Loss.The OCT-ORION Study[NCT01742507]Phase 460 participants (Actual)Interventional2012-04-30Completed
Qvanteq Bioactive Coronary Stent System First in Man (FIM) Clinical Investigation[NCT02176265]31 participants (Actual)Interventional2014-09-30Completed
Phase 4 Study of Randomized Comparison Among Oral Rapamycin Plus Bare Metal Stents Versus Drug Eluting Stents in de Novo Coronary Lesions.[NCT00552669]Phase 4200 participants (Actual)Interventional2006-01-31Completed
A Multicenter, Open-labeled, Randomized Controlled Trial Comparing Three 2nd Generation Drug-Eluting Stents in Real-World Practice[NCT01397175]1,960 participants (Actual)Interventional2013-01-16Terminated (stopped due to Slow enrollment)
Vessel Injury in Relation With Strut Thickness Assessed by OCT (VISTA): A Comparison of Vascular Injury Induced by a Polymer Free Sirolimus and Probucol Eluting Stent and a Biodegradable-polymer Biolimus-eluting Stent[NCT03026465]Phase 450 participants (Actual)Interventional2017-02-16Completed
Frequency Domain Imaging to Determine Stent Strut Coverage and Duration of Anti-Platelet Treatment After Endeavor Stent Placement[NCT01219894]0 participants (Actual)Observational2010-11-30Withdrawn (stopped due to Number of patients to meet individual IDE requirements was not obtained.)
Optical Frequency Domain Imaging (OFDI) Determined Stent Strut Coverage and Plaque Morphology After RESOLUTE Stent Placement in Non-Insulin Dependent Diabetics Presenting With Acute Coronary Syndrome (ACS)[NCT01794949]8 participants (Actual)Interventional2013-09-30Completed
Optimization of Antiplatelet Therapy With Clopidogrel on the Basis of the Extent of Platelet Inhibition in Patients With Acute Coronary Syndromes on Dual Antiplatelet Therapy Undergoing PCI With Stent Implantation[NCT00774475]Phase 3442 participants (Anticipated)Interventional2008-11-30Not yet recruiting
A Single-center, Randomized, Open-label, Controlled, Dose-escalating, Parallel-group Study to Assess the Anti-platelet Effect of Berberine in Patients Receiving Aspirin and Clopidogrel After Percutaneous Coronary Intervention[NCT03378934]Phase 464 participants (Anticipated)Interventional2018-09-26Recruiting
PercutaNEOus Coronary Intervention Followed by Monotherapy INstead of Dual Antiplatelet Therapy in the SETting of Acute Coronary Syndromes: The NEO-MINDSET Trial A Drug Reduction Study for Patients With Acute Coronary Syndrome in the Unified Health System[NCT04360720]Phase 33,400 participants (Anticipated)Interventional2020-10-15Recruiting
French Registry to Evaluate the Safety and Efficacy of the Diamondback 360TM Orbital Atherectomy System in the Preparation of Calcified Coronary Lesions Before Implantation of a Coronary Endoprothesis[NCT05417022]300 participants (Anticipated)Observational [Patient Registry]2022-06-15Recruiting
Rotational Atherectomy Prior to Taxus Stent Treatment for Complex Native Coronary Artery Disease. A Multicenter, Prospective, Randomized Controlled Trial.[NCT00380809]Phase 4240 participants (Actual)Interventional2006-08-31Completed
Early and Long-Term Outcome of Elective Stenting of the Infarct-Related Artery in Patients With Viability in the Infarct-Area Early After Acute Myocardial Infarction. The VIAMI-Trial.[NCT00149591]300 participants Interventional2001-04-30Active, not recruiting
A Multicenter, Randomized Trial Evaluating 30-day and 6-month Clinical Outcomes With Three Different Treatment Strategies (Coronary Angioplasty + Abciximab, Intracoronary Stent + Abciximab, and Intracoronary Stent + Placebo) in Patients Undergoing Percuta[NCT00271401]Phase 32,399 participants (Actual)Interventional1996-07-31Completed
Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of the Glycoprotein IIb/IIIa Inhibition With Abciximab in Patients With ACS Undergoing Coronary Stenting After Pretreatment With a High Loading Dose of Clopidogrel (ISAR-REACT-2)[NCT00133003]Phase 42,022 participants (Actual)Interventional2003-03-31Completed
Value of Abciximab in Patients With AMI Undergoing PCI After High Dose Clopidogrel Pretreatment (BRAVE 3)[NCT00133250]Phase 4800 participants (Actual)Interventional2003-06-30Completed
A Double-Blind, Randomized Comparison Between Two Different Clopidogrel Maintenance Doses After Percutaneous Coronary Intervention (ISAR-CHOICE-2)[NCT00140465]Phase 460 participants (Actual)Interventional2004-10-31Completed
Gastrointestinal Ulceration in Patients on Dual Antiplatelet Therapy After Percutaneous Coronary Intervention[NCT00413309]30 participants (Anticipated)Interventional2006-04-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

P2Y12 Reaction Unit (PRU)

Platelet reactivity by measuring P2Y12 Reaction Unit using Accumetrics VerifyNow (NCT01823510)
Timeframe: up to 7 days

,
Interventionpercentage of baseline PRU (Mean)
2 hour post-loading dose6 hour post-loading dose5-7 days of maintenance dosing
Clopidogrel + Aspirin77.866.862.7
Ticagrelor + Aspirin14.88.214.5

Platelet Reactivity

Platelet reactivity by Multiplate Analyzer (NCT01823510)
Timeframe: up to 7 days

,
Interventionpercentage of baseline Unit (Mean)
2 hour post-loading dose6 hour post-loading dose5-7 days of maintenance dosing
Clopidogrel + Aspirin54.543.645.5
Ticagrelor + Aspirin20.520.624.2

Platelet Reactivity Index (PRI)

Platelet reactivity index by Vasodilator-Stimulated Phosphoprotein phosphorylation (VASP) assay. (NCT01823510)
Timeframe: up to 7 days

,
Interventionpercentage of baseline PRI (Mean)
2 hour post-loading dose6 hour post-loading dose5-7 days of maintenance dosing
Clopidogrel + Aspirin85.882.568.4
Ticagrelor + Aspirin21.817.817.2

Thrombus Formation

Thrombus formation in Badimon Perfusion Chamber high-shear) (ex vivo model of thrombosis). (NCT01823510)
Timeframe: up to 7 days

,
Interventionpercentage of baseline size (Mean)
2 hour post loading dose6 hours post loading dose5-7 days of maintenance dose
Clopidogrel + Aspirin84.479.882.6
Ticagrelor + Aspirin66.959.968.9

First Occurrence of CV Death / MI / Stroke - Interaction Clopidogrel Treatment Regimen and ASA Dose Level

(NCT00335452)
Timeframe: 30 days

Interventionparticipants (Number)
Clopidogrel 300/75/75 mg + ASA Low Dose267
Clopidogrel 300/75/75 mg + ASA High Dose290
Clopidogrel 600/150/75 mg + ASA Low Dose282
Clopidogrel 600/150/75 mg + ASA High Dose240

First Occurrence of CV Death / MI / Stroke - ASA Dose Comparison

(NCT00335452)
Timeframe: 30 days

,
Interventionparticipants (Number)
CV death/MI/Stroke- CV death- MI (fatal or not)- Stroke (fatal or not)
Clopidogrel + ASA High Dose52721125165
Clopidogrel + ASA Low Dose54623126055

First Occurrence of CV Death / MI / Stroke - Clopidogrel Treatment Regimen Comparison

"The primary endpoint is the first occurrence of any of the following events:~Cardiovascular death (any death with a clear cardiovascular or unknown cause),~Myocardial Infarction (diagnosis of new Myocardial Infarction (MI) - nonfatal or fatal)~Stroke (presence of a new focal neurologic deficit thought to be vascular in origin, with signs or symptoms lasting more than 24 hours - nonfatal or fatal)~reported between the randomization and Day 30 (inclusive), and validated by the blinded Event Adjudication Committee (EAC)." (NCT00335452)
Timeframe: 30 days

,
Interventionparticipants (Number)
CV death/MI/Stroke- CV death- MI (fatal or not)- Stroke (fatal or not)
Clopidogrel 300/75/75 mg + ASA55722227461
Clopidogrel 600/150/75 mg + ASA52222623759

First Occurrence of CV Death / MI / Stroke - Clopidogrel Treatment Regimen Comparison in PCI Subgroup

(NCT00335452)
Timeframe: 30 days

,
Interventionparticipants (Number)
CV death/MI/Stroke- CV death- MI (fatal or not)- Stroke (fatal or not)
Clopidogrel 300/75/75 mg + ASA39213222535
Clopidogrel 600/150/75 mg + ASA33013017228

Occurrence of Major Bleeding - ASA Dose Level Comparison

(NCT00335452)
Timeframe: 30 days

,
Interventionparticipants (Number)
Major bleeding- Severe bleeding- Major but not severe bleeding
Clopidogrel + ASA High Dose28221673
Clopidogrel + ASA Low Dose28521574

Occurrence of Major Bleeding - Clopidogrel Dose Regimen Comparison

Major bleeding is defined as any severe bleeding (associated with any of the following: death, leading to a drop in hemoglobin ≥ 5 g/dl, significant hypotension with the need for inotropic agents, symptomatic intracranial hemorrhage, requirement for surgery or for a transfusion ≥ 4 units of red blood cells or equivalent whole blood) and other major bleeding (significantly disabling bleeding, or intraocular bleeding leading to significant loss of vision or bleeding requiring transfusion of 2-3 units of red blood cells or equivalent whole blood) after validation by the independent EAC. (NCT00335452)
Timeframe: 30 days

,
Interventionparticipants (Number)
Major bleeding- Severe bleeding- Major but not severe bleeding
Clopidogrel 300/75/75 mg + ASA25519565
Clopidogrel 600/150/75 mg + ASA31323683

Occurrence of Stent Thrombosis - Clopidogrel Treatment Regimen Comparison

This includes definite stent thrombosis (confirmed by angiography or evidence of recent thrombus determined at autopsy or by examination of tissue retrieved following thrombectomy) and probable stent thrombosis (unexplained death having occurred after intracoronary stenting or, MI related to acute ischemia in the territory of the implanted stent without angiographic confirmation and in the absence of any obvious cause) after validation by the EAC. (NCT00335452)
Timeframe: 30 days

,
Interventionparticipants (Number)
Stent trombosis- Definite- Probable
Clopidogrel 300/75/75 mg + ASA20011189
Clopidogrel 600/150/75 mg + ASA1355877

Participants With Any Event From the Composite of All-cause Mortality, MI, and Stroke

Participants with death from any cause, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal of consent or date of scheduled withdrawal from therapy. ITT analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months

InterventionParticipants (Number)
TICAGRELOR901
CLOPIDOGREL1065

Participants With Any Event From the Composite of Death From Vascular Causes, MI (Including Silent), Stroke, Recurrent Ischemia, Transient Ischemic Attack (TIA) and Other Arterial Thrombotic Events.

Participants with death from vascular causes, MI, stroke, recurrent ischemia, or other thrombotic events. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT analysis of whole population. Events were adjudicated. (NCT00391872)
Timeframe: Randomization up to 12 months

InterventionParticipants (Number)
TICAGRELOR1290
CLOPIDOGREL1456

Participants With Any Event From the Composite of Death From Vascular Causes, MI, and Stroke for the Subgroup of Patients With Intent for Invasive Management at Randomization

Participants with death from vascular causes, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT analysis of intent for invasive management population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months

InterventionParticipants (Number)
TICAGRELOR569
CLOPIDOGREL668

Participants With Any Event From the Composite of Death From Vascular Causes, Myocardial Infarction (MI), and Stroke

Participants with death from vascular causes, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. Intention To Treat (ITT) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months

InterventionParticipants (Number)
TICAGRELOR864
CLOPIDOGREL1014

Participants With Any Major Bleeding Event

Participants with major (fatal/life-threatening or other) bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months

InterventionParticipants (Number)
TICAGRELOR961
CLOPIDOGREL929

Participants With Coronary Artery Bypass Graft (CABG) Major Bleeding

Participants with a major CABG-related bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. All CABG surgeries were submitted for adjudication by an endpoint committee as potential bleeds. (NCT00391872)
Timeframe: First dosing up to 12 months

InterventionParticipants (Number)
TICAGRELOR619
CLOPIDOGREL654

Participants With Coronary Artery Bypass Graft (CABG) Major Fatal/Life-threatening Bleeding

Number of participants with a major fatal/life-threatening CABG-related bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. All CABG surgeries were submitted for adjudication by an endpoint committee as potential bleeds. (NCT00391872)
Timeframe: First dosing up to 12 months

InterventionParticipants (Number)
TICAGRELOR329
CLOPIDOGREL341

Participants With Death From Any Cause

Participants with death from any cause. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months

InterventionParticipants (Number)
TICAGRELOR399
CLOPIDOGREL506

Participants With Death From Vascular Causes

Participants with death from vascular causes. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months

InterventionParticipants (Number)
TICAGRELOR353
CLOPIDOGREL442

Participants With Major or Minor Bleeding

Participants with major (fatal/life-threatening or other) or minor bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months

InterventionParticipants (Number)
TICAGRELOR1339
CLOPIDOGREL1215

Participants With MI Event

Participants with MI event. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months

InterventionParticipants (Number)
TICAGRELOR504
CLOPIDOGREL593

Participants With Non-CABG (Coronary Artery Bypass Graft) Related Major Bleeding

Participants with non CABG related major (fatal/life-threatening or other) bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months

InterventionParticipants (Number)
TICAGRELOR362
CLOPIDOGREL306

Participants With Non-procedural Major Bleeding

Participants with non-procedural major bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months

InterventionParticipants (Number)
TICAGRELOR235
CLOPIDOGREL180

Participants With Stroke

Participants with stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months

InterventionParticipants (Number)
TICAGRELOR125
CLOPIDOGREL106

Participants With Ventricular Pauses of Greater Than or Equal to 3 Seconds in Patients Monitored by Holter 24 Hour ECG Recorders for 1 Week at 1 Month Following Randomization

Number of participants who were observed to have at least 1 ventricular pause of at least 3 seconds. Population is all patients who were observed over 2 week-long periods. Pauses were flagged algorithmically and confirmed by TIMI cardiologists. (NCT00391872)
Timeframe: 1-week period following randomization

InterventionParticipants (Number)
TICAGRELOR21
CLOPIDOGREL16

Participants With Ventricular Pauses of Greater Than or Equal to 3 Seconds in Patients Monitored by Holter 24-hour ECG Recorders for 1 Week Following Randomization

Number of participants who were observed to have at least 1 ventricular pause of at least 3 seconds. Population is all patients who were observed over 2 week-long periods. Pauses were flagged algorithmically and confirmed by Thrombolysis in Myocardial Infarction (TIMI) group cardiologists. (NCT00391872)
Timeframe: 1-week period following randomization

InterventionParticipants (Number)
TICAGRELOR84
CLOPIDOGREL51

Composite Endpoint of Cardiac Death and Myocardial Infarction (Not Clearly Attributable to a Non-target Vessel)

(NCT00752128)
Timeframe: 12 Months

Interventionpercentage of participants (Number)
Cardiac Death or Target Vessel MI4.2

Overall Stent Thrombosis, Defined as Definite and Probable Stent Thrombosis, According to the Academic Research Consortium (ARC) Definition

(NCT00752128)
Timeframe: 12 Months

Interventionpercentage of participants (Number)
Overall Stent Thrombosis (Definite and Probable-ARC)0.9

Death

(NCT00726453)
Timeframe: 12 months

Interventionpercentage of participants (Number)
Primary Enrollment Group1.3

Major Adverse Cardiac Event (MACE)

Major Adverse Cardiac Event (MACE) composite endpoint and each individual component (death, Target Vessel MI (Q wave and non-Q wave), emergent coronary bypass surgery (CABG), or clinically-driven repeat Target Lesion Revascularization (TLR) by percutaneous or surgical methods). (NCT00726453)
Timeframe: 12 months

Interventionpercentage of participants (Number)
Primary Enrollment Group5.5

Stent Thrombosis (ST)

Stent Thrombosis (ST) (as determined by historic and ARC definitions). (NCT00726453)
Timeframe: 12 months

Interventionpercentage of participants (Number)
Primary Enrollment Group0.1

Target Lesion Failure (TLF)

Target Lesion Failure (TLF) at 12 months post-procedure, defined as Cardiac Death, Target Vessel Myocardial Infarction (TVMI) (Q wave and non-Q wave) or clinically-driven Target Lesion Revascularization (TLR) by percutaneous or surgical methods. (NCT00726453)
Timeframe: 12 Months

Interventionpercentage of participants (Number)
Primary Enrollment Group4.7

Target Vessel Failure (TVF)

Target Vessel Failure (TVF) composite endpoint and each individual component (Cardiac Death, Target Vessel MI, or clinically-driven Target Vessel Revascularization (TVR) by percutaneous or surgical methods). (NCT00726453)
Timeframe: 12 months

Interventionpercentage of participants (Number)
Primary Enrollment Group6.3

Target Vessel MI

Target Vessel MI (as determined by extended historical and ARC definitions). (NCT00726453)
Timeframe: 12 months

Interventionpercentage of eligible participants (Number)
Primary Enrollment Group1.4

In-stent Late Lumen Loss (LLL)

The difference between the post-procedure immediate minimal lumen diameter (MLD) and follow up angigraphy MLD (NCT00927940)
Timeframe: Post procedure, 8 Months

Interventionmm (Mean)
Zotarolimus Eluting Stent0.13

Percent of Patient With Target Lesion Failure(Major Secondary Endpoint)

Major Secondary Endpoint Target lesion fature (TLF) is defined as cardiac death, target vessel myocardial infarction(Q wave and non-Q wave), or clinically-driven target lesion revascularization (TLR) by percutaneous or surgical methods. (NCT00927940)
Timeframe: 12 months

Interventionpercentage of participants with TLF (Number)
Zotarolims Eluting Stent4.0

In-Stent Percent Diameter Stenosis

In Stent Percent Diameter Stenosis at thirteen months. In Stent Percent Diameter Stenosis: measured percent of diameter stenosis at the region of the stent (calculated as 100x(RVD-MLD)/RVD using the mean values from 2 orthogonal views by QCA. RVD (Reference Vessel Diameter): average of normal segments within 10mm proximal and distal to target lesion from 2 orthogonal views using QCA. MLD (Minimal Lumen Diameter): average of 2 orthogonal views of the narrowest point wihtin the area of assessment. MLD measured during QCA by the angiographic core laboratory. (NCT00617084)
Timeframe: 13 Months

InterventionPercentage diameter stenosis (Mean)
1. Resolute - 12-13 Months21.65
2. XIENCE V - 12-13 Months19.76

Target Lesion Failure

Percentage of participants that had either Cardiac Death, Myocardial Infarction (not clearly attributable to a non-target vessel)or Target Lesion Revascularization (TLR, clinically indicated) after one year. MI: Q MI if new pathological Q waves and chest pain, non Q MI if CK elevated more than two times normal, troponin elevated more than normal, according to ARC definitions. TLR, clinically indicated if associated with ischemic symptoms and angiographic min lumen diameter bigger than fifty percent by QCA or without symptoms and min lumen diameter bigger than seventy percent. Measure average. (NCT00617084)
Timeframe: 12 months

Interventionpercentage of participants (Number)
1. Resolute - 12-13 Months8.2
2. XIENCE V - 12-13 Months8.3

To Compare Overall Definite or Probable Stent Thrombosis Rate of the Endeavor® Zotarolimus Eluting Coronary Stent System Versus the Cypher® Sirolimus-eluting Coronary Stent in a Patient Population Requiring Stent Implantation

Definite or probable stent thrombosis rate. (NCT00476957)
Timeframe: 3 years

Interventionparticipants (Number)
E-ZES61
C-SES75

Composites of (Cardiac) Death and (Large) Non-fatal Myocardial Infarctions

Total death and large non-fatal myocardial infarctions Total death and non-fatal myocardial infarctions Cardiac death and large non-fatal MI Cardiac death and non-fatal myocardial infarctions (NCT00476957)
Timeframe: 3 years

,
Interventionparticipants (Number)
Total death and large non-fatal myocardial infarctTotal death and non-fatal myocardial infarctionsCardiac death and large non-fatal MICardiac death and non-fatal MITarget lesion revascularizationStrokeBleeding events
C-SES25536017428215672184
E-ZES22533115726524977201

Incidence of Major Bleeding (GUSTO Classification, Severe and Moderate Bleeding Combined) for Randomized Subjects

(NCT01069003)
Timeframe: Placebo and Thienopyridine 12 - 30 months; Surveillance Arm (0 - 24 months)

InterventionPercentage of participants (Number)
Placebo Arm1.8
Thienopyridine Therapy2.0
Surveillance Arm4.8

Percentage of Participants of Incidence of ARC Definite or Probable Stent Thrombosis (ST) for Randomized Subjects

"All definite and probable Stent Thrombosis (ST) are adjudicated by an independent committee according to the definition based on Academic Research Consortium (ARC)~Definite is defined as angiographic or pathologic confirmation of partial or total thrombotic occlusion within the peri-stent region and at least 1 of the following: Acute ischemic symptoms, Ischemic ECG changes, Elevated cardiac biomarkers~Probable defined as any unexplained death within the first 30 days of procedure and any myocardial infarction, which is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause" (NCT01069003)
Timeframe: Placebo and Thienopyridine 12 - 30 months; Surveillance Arm (0 - 24 months)

Interventionpercentage of participants (Number)
Placebo Arm1.0
Thienopyridine Therapy0.5
Surveillance Arm2.4

Percentage of Participants With Composite of All Death, Target Vessel Myocardial Infarction (MI) and Stroke (Defined as MACCE) for Randomized Subjects

(NCT01069003)
Timeframe: Placebo and Thienopyridine 12 - 30 months; Surveillance Arm (0 - 24 months)

InterventionPercentage of participants (Number)
Placebo Arm4.3
Thienopyridine Therapy4.8
Surveillance Arm16.9

% Volume Obstruction (% VO)

Defined as stent intimal hyperplasia and calculated as 100*(Stent Volume - Lumen Volume)/Stent Volume by IVUS. (NCT00180479)
Timeframe: at 240 days

Interventionpercent of volume obstruction (Mean)
XIENCE V® EECSS6.91
TAXUS® EXPRESS2™ ECSS11.21

Acute Success: Clinical Device

Successful delivery and deployment of 1st implanted study stent/s @ the intended target lesion and successful withdrawal of the stent delivery system with final residual stenosis < 50%. (NCT00180479)
Timeframe: In-hospital

Interventionpercentage of participants (Number)
XIENCE V® EECSS98.3
TAXUS® EXPRESS2™ ECSS98.7

Acute Success: Clinical Procedure

Successful delivery and deployment of study stent/s @ the intended target lesion and successful withdrawal of the stent delivery system with final residual stenosis < 50%. (NCT00180479)
Timeframe: In-hospital

Interventionpercentage of participants (Number)
XIENCE V® EECSS98.5
TAXUS® EXPRESS2™ ECSS97.3

Distal Late Loss

Distal MLD post-procedure minus distal MLD at follow-up (distal defined as within 5 mm of healthy tissue distal to stent placement) (NCT00180479)
Timeframe: 240 days

Interventionmillimeters (Mean)
XIENCE V® EECSS0.09
TAXUS® EXPRESS2™ ECSS0.10

In-segment % Angiographic Binary Restenosis (% ABR) Rate

Percent of subjects with a follow-up in-segment percent diameter stenosis of ≥ 50% per QCA (NCT00180479)
Timeframe: 240 days

Interventionpercentage of participants (Number)
XIENCE V® EECSS4.7
TAXUS® EXPRESS2™ ECSS8.9

In-segment % Diameter Stenosis (% DS)

Within the margins of the stent, 5 mm proximal and 5 mm distal to the stent, the value calculated as 100 * (1 - in-segment MLD/RVD) using the mean values from two orthogonal views (when possible) by QCA. (NCT00180479)
Timeframe: 240 days

Interventionpercent of in-segment diameter stenosis (Mean)
XIENCE V® EECSS18.77
TAXUS® EXPRESS2™ ECSS22.82

In-stent % Angiographic Binary Restenosis (% ABR) Rate

Percent of subjects with a follow-up in-stent percent diameter stenosis of ≥ 50% per quantitative coronary angiography (QCA) (NCT00180479)
Timeframe: at 240 days

Interventionpercentage of participants (Number)
XIENCE V® EECSS2.3
TAXUS® EXPRESS2™ ECSS5.7

In-stent % Diameter Stenosis (% DS)

In-stent: Within the margins of the stent, the value calculated as 100 * (1 - in-stent MLD/RVD) using the mean values from two orthogonal views (when possible) by QCA. (NCT00180479)
Timeframe: at 240 days

Interventionpercent diameter stenosis (Mean)
XIENCE V® EECSS5.92
TAXUS® EXPRESS2™ ECSS10.30

In-stent Late Loss

In-stent MLD post-procedure minus in-stent MLD at follow-up (in-stent defined as within the margins of the stent) (NCT00180479)
Timeframe: at 240 days

Interventionmillimeters (Mean)
XIENCE V® EECSS0.16
TAXUS® EXPRESS2™ ECSS0.30

Ischemia Driven Major Adverse Cardiac Event (MACE)

"The composite endpoint comprised of:~Cardiac death~Myocardial infarction (MI, classified as Q-wave and non-Q wave)~Ischemia-driven target lesion revascularization (TLR) by CABG or PCI" (NCT00180479)
Timeframe: 1 year

Interventionpercentage of participants (Number)
XIENCE V® EECSS6.0
TAXUS® EXPRESS2™ ECSS10.3

Ischemia Driven Major Adverse Cardiac Event (MACE)

"The composite endpoint comprised of:~Cardiac death~Myocardial infarction (MI, classified as Q-wave and non-Q wave)~Ischemia-driven target lesion revascularization (TLR) by CABG or PCI" (NCT00180479)
Timeframe: 180 days

Interventionpercentage of participants (Number)
XIENCE V® EECSS2.9
TAXUS® EXPRESS2™ ECSS5.2

Ischemia Driven Major Adverse Cardiac Event (MACE)

"The composite endpoint comprised of:~Cardiac death~Myocardial infarction (MI, classified as Q-wave and non-Q wave)~Ischemia-driven target lesion revascularization (TLR) by CABG or PCI" (NCT00180479)
Timeframe: 270 days

Interventionpercentage of participants (Number)
XIENCE V® EECSS5.0
TAXUS® EXPRESS2™ ECSS8.8

Ischemia Driven Major Adverse Cardiac Event (MACE)

"The composite endpoint comprised of:~Cardiac death~Myocardial infarction (MI, classified as Q-wave and non-Q wave)~Ischemia-driven target lesion revascularization (TLR) by CABG or PCI" (NCT00180479)
Timeframe: 3 year

Interventionpercentage of participants (Number)
XIENCE V® EECSS9.7
TAXUS® EXPRESS2™ ECSS16.4

Ischemia Driven Major Adverse Cardiac Event (MACE)

"The composite endpoint comprised of:~Cardiac death~Myocardial infarction (MI, classified as Q-wave and non-Q wave)~Ischemia-driven target lesion revascularization (TLR) by CABG or PCI" (NCT00180479)
Timeframe: 30 days

Interventionpercentage of participants (Number)
XIENCE V® EECSS1.3
TAXUS® EXPRESS2™ ECSS3.0

Ischemia Driven Major Adverse Cardiac Event (MACE)

"The composite endpoint comprised of:~Cardiac death~Myocardial infarction (MI, classified as Q-wave and non-Q wave)~Ischemia-driven target lesion revascularization (TLR) by CABG or PCI" (NCT00180479)
Timeframe: 4 year

Interventionpercentage of participants (Number)
XIENCE V® EECSS12.8
TAXUS® EXPRESS2™ ECSS18.5

Ischemia Driven Major Adverse Cardiac Event (MACE)

"The composite endpoint comprised of:~Cardiac death~Myocardial infarction (MI, classified as Q-wave and non-Q wave)~Ischemia-driven target lesion revascularization (TLR) by CABG or PCI" (NCT00180479)
Timeframe: 5 years

Interventionpercentage of participants (Number)
XIENCE V® EECSS14.4
TAXUS® EXPRESS2™ ECSS22.0

Ischemia Driven Major Adverse Cardiac Event(MACE)

"The composite endpoint comprised of:~Cardiac death~Myocardial infarction (MI, classified as Q-wave and non-Q wave)~Ischemia-driven target lesion revascularization (TLR) by CABG or PCI" (NCT00180479)
Timeframe: 2 years

Interventionpercentage of participants (Number)
XIENCE V® EECSS7.7
TAXUS® EXPRESS2™ ECSS13.8

Ischemia Driven Target Lesion Revascularization (ID-TLR)

"Revascularization @ target lesion associated w/ any of following:~(+) functional ischemia study Ischemic symptoms & angiographic diameter stenosis ≥50% by core lab quantitative coronary angiography (QCA) Revascularization of a target lesion w/ angiographic diameter stenosis ≥70% by core laboratory QCA without angina or (+) functional study" (NCT00180479)
Timeframe: 1 years

Interventionpercentage of participants (Number)
XIENCE V® EECSS3.4
TAXUS® EXPRESS2™ ECSS5.6

Ischemia Driven Target Lesion Revascularization (ID-TLR)

"Revascularization @ target lesion associated w/ any of following:~(+) functional ischemia study Ischemic symptoms & angiographic diameter stenosis ≥50% by core lab quantitative coronary angiography (QCA) Revascularization of a target lesion w/ angiographic diameter stenosis ≥70% by core laboratory QCA without angina or (+) functional study" (NCT00180479)
Timeframe: 180 days

Interventionpercentage of participants (Number)
XIENCE V® EECSS1.5
TAXUS® EXPRESS2™ ECSS2.1

Ischemia Driven Target Lesion Revascularization (ID-TLR)

"Revascularization @ target lesion associated w/ any of following:~(+) functional ischemia study Ischemic symptoms & angiographic diameter stenosis ≥50% by core lab quantitative coronary angiography (QCA) Revascularization of a target lesion w/ angiographic diameter stenosis ≥70% by core laboratory QCA without angina or (+) functional study" (NCT00180479)
Timeframe: 2 years

Interventionpercentage of participants (Number)
XIENCE V® EECSS5.7
TAXUS® EXPRESS2™ ECSS9.2

Ischemia Driven Target Lesion Revascularization (ID-TLR)

"Revascularization @ target lesion associated w/ any of following:~(+) functional ischemia study Ischemic symptoms & angiographic diameter stenosis ≥50% by core lab quantitative coronary angiography (QCA) Revascularization of a target lesion w/ angiographic diameter stenosis ≥70% by core laboratory QCA without angina or (+) functional study" (NCT00180479)
Timeframe: 270 days

Interventionpercentage of participants (Number)
XIENCE V® EECSS2.7
TAXUS® EXPRESS2™ ECSS5.0

Ischemia Driven Target Lesion Revascularization (ID-TLR)

"Revascularization @ target lesion associated w/ any of following:~(+) functional ischemia study Ischemic symptoms & angiographic diameter stenosis ≥50% by core lab quantitative coronary angiography (QCA) Revascularization of a target lesion w/ angiographic diameter stenosis ≥70% by core laboratory QCA without angina or (+) functional study" (NCT00180479)
Timeframe: 3 year

Interventionpercentage of participants (Number)
XIENCE V® EECSS5.7
TAXUS® EXPRESS2™ ECSS9.2

Ischemia Driven Target Lesion Revascularization (ID-TLR)

"Revascularization @ target lesion associated w/ any of following:~(+) functional ischemia study Ischemic symptoms & angiographic diameter stenosis ≥50% by core lab quantitative coronary angiography (QCA) Revascularization of a target lesion w/ angiographic diameter stenosis ≥70% by core laboratory QCA without angina or (+) functional study" (NCT00180479)
Timeframe: 30 days

Interventionpercentage of participants (Number)
XIENCE V® EECSS0.4
TAXUS® EXPRESS2™ ECSS0.3

Ischemia Driven Target Lesion Revascularization (ID-TLR)

"Revascularization @ target lesion associated w/ any of following:~(+) functional ischemia study Ischemic symptoms & angiographic diameter stenosis ≥50% by core lab quantitative coronary angiography (QCA) Revascularization of a target lesion w/ angiographic diameter stenosis ≥70% by core laboratory QCA without angina or (+) functional study" (NCT00180479)
Timeframe: 4 year

Interventionpercentage of participants (Number)
XIENCE V® EECSS8.0
TAXUS® EXPRESS2™ ECSS10.6

Ischemia Driven Target Lesion Revascularization (ID-TLR)

"Revascularization @ target lesion associated w/ any of following:~(+) functional ischemia study Ischemic symptoms & angiographic diameter stenosis ≥50% by core lab quantitative coronary angiography (QCA) Revascularization of a target lesion w/ angiographic diameter stenosis ≥70% by core laboratory QCA without angina or (+) functional study" (NCT00180479)
Timeframe: 5 years

Interventionpercentage of participants (Number)
XIENCE V® EECSS8.9
TAXUS® EXPRESS2™ ECSS12.9

Ischemia Driven Target Vessel Revascularization (ID-TVR)

"Revascularization at the target vessel associated with any of the following~Positive functional ischemia study~Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA~Revascularization of a target vessel with angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study~Derived from Non-Hierarchical Subject Counts of Adverse Events" (NCT00180479)
Timeframe: 1 year

Interventionpercentage of participants (Number)
XIENCE V® EECSS3.1
TAXUS® EXPRESS2™ ECSS4.7

Ischemia Driven Target Vessel Revascularization (ID-TVR)

"Revascularization at the target vessel associated with any of the following~Positive functional ischemia study~Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA~Revascularization of a target vessel with angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study~Derived from Non-Hierarchical Subject Counts of Adverse Events" (NCT00180479)
Timeframe: 180 days

Interventionpercentage of participants (Number)
XIENCE V® EECSS1.2
TAXUS® EXPRESS2™ ECSS1.8

Ischemia Driven Target Vessel Revascularization (ID-TVR)

"Revascularization at the target vessel associated with any of the following~Positive functional ischemia study~Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA~Revascularization of a target vessel with angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study~Derived from Non-Hierarchical Subject Counts of Adverse Events" (NCT00180479)
Timeframe: 2 years

Interventionpercentage of participants (Number)
XIENCE V® EECSS4.9
TAXUS® EXPRESS2™ ECSS6.6

Ischemia Driven Target Vessel Revascularization (ID-TVR)

"Revascularization at the target vessel associated with any of the following~Positive functional ischemia study~Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA~Revascularization of a target vessel with angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study~Derived from Non-Hierarchical Subject Counts of Adverse Events" (NCT00180479)
Timeframe: 270 days

Interventionpercentage of participants (Number)
XIENCE V® EECSS2.9
TAXUS® EXPRESS2™ ECSS4.1

Ischemia Driven Target Vessel Revascularization (ID-TVR)

"Revascularization at the target vessel associated with any of the following~Positive functional ischemia study~Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA~Revascularization of a target vessel with angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study~Derived from Non-Hierarchical Subject Counts of Adverse Events" (NCT00180479)
Timeframe: 3 years

Interventionpercentage of participants (Number)
XIENCE V® EECSS6.7
TAXUS® EXPRESS2™ ECSS8.9

Ischemia Driven Target Vessel Revascularization (ID-TVR)

"Revascularization at the target vessel associated with any of the following~Positive functional ischemia study~Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA~Revascularization of a target vessel with angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study~Derived from Non-Hierarchical Subject Counts of Adverse Events" (NCT00180479)
Timeframe: 30 days

Interventionpercentage of participants (Number)
XIENCE V® EECSS0.3
TAXUS® EXPRESS2™ ECSS0.9

Ischemia Driven Target Vessel Revascularization (ID-TVR)

"Revascularization at the target vessel associated with any of the following~Positive functional ischemia study~Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA~Revascularization of a target vessel with angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study~Derived from Non-Hierarchical Subject Counts of Adverse Events" (NCT00180479)
Timeframe: 4 years

Interventionpercentage of participants (Number)
XIENCE V® EECSS7.8
TAXUS® EXPRESS2™ ECSS9.6

Ischemia Driven Target Vessel Revascularization (ID-TVR)

"Revascularization at the target vessel associated with any of the following~Positive functional ischemia study~Ischemic symptoms and angiographic diameter stenosis ≥ 50% by core laboratory QCA~Revascularization of a target vessel with angiographic diameter stenosis ≥ 70% by core laboratory QCA without angina or positive functional study~Derived from Non-Hierarchical Subject Counts of Adverse Events" (NCT00180479)
Timeframe: 5 years

Interventionpercentage of participants (Number)
XIENCE V® EECSS8.8
TAXUS® EXPRESS2™ ECSS11.9

Major Secondary Endpoint: Ischemia Driven Target Vessel Failure (ID-TVF)

"The composite endpoint comprised of:~Cardiac death (death in which a cardiac cause cannot be excluded)~Myocardial infarction (MI, classified as Q-wave and non-Q wave)~Ischemia-driven target lesion revascularization (TLR) by CABG or PCI~Ischemia-driven target vessel revascularization (TVR) by CABG or PCI" (NCT00180479)
Timeframe: 270 days

Interventionpercentage of participants (Number)
XIENCE V® EECSS7.2
TAXUS® EXPRESS2™ ECSS9.0

Persisting Incomplete Stent Apposition, Late-acquired Incomplete Stent Apposition, Aneurysm, Thrombosis, and Persisting Dissection

"Incomplete Apposition (Persisting & Late acquired): Failure to completely appose vessel wall w/ ≥1 strut separated from vessel wall w/ blood behind strut per ultrasound. Aneurysm: Abnormal vessel expansion ≥ 1.5 of reference vessel diameter. Thrombus: Protocol & ARC definition.~Persisting dissection @ follow-up, present post-procedure." (NCT00180479)
Timeframe: at 240 days

Interventionpercentage of participants (Number)
XIENCE V® EECSS24.4
TAXUS® EXPRESS2™ ECSS14.0

Primary Endpoint: In-segment Late Loss (LL)

In-segment minimal lumen diameter (MLD) post-procedure minus (-) in segment MLD at 240 day follow-up and 5 mm proximal and 5mm distal to the stent equals Late Loss. MLD defined: The average of two orthogonal views (when possible) of the narrowest point within the area of assessment. (NCT00180479)
Timeframe: 240 days

Interventionmillimeters (Mean)
XIENCE V® EECSS0.14
TAXUS® EXPRESS2™ ECSS0.28

Proximal Late Loss

Proximal Minimum Lumen Diameter (MLD) post-procedure minus proximal MLD at follow-up (proximal defined as within 5 mm of healthy tissue proximal to stent placement) (NCT00180479)
Timeframe: at 240 days

Interventionmillimeters (Mean)
XIENCE V® EECSS0.12
TAXUS® EXPRESS2™ ECSS0.20

Target Vessel Failure (TVF)

"The composite endpoint comprised of:~Cardiac death (death in which a cardiac cause cannot be excluded)~Myocardial infarction (MI, classified as Q-wave and non-Q wave)~Ischemia-driven target lesion revascularization (TLR) by CABG or PCI~Ischemia-driven target vessel revascularization (TVR) by CABG or PCI" (NCT00180479)
Timeframe: 1 year

Interventionpercentage of participants (Number)
XIENCE V® EECSS8.6
TAXUS® EXPRESS2™ ECSS11.6

Target Vessel Failure (TVF)

"The composite endpoint comprised of:~Cardiac death (death in which a cardiac cause cannot be excluded)~Myocardial infarction (MI, classified as Q-wave and non-Q wave)~Ischemia-driven target lesion revascularization (TLR) by CABG or PCI~Ischemia-driven target vessel revascularization (TVR) by CABG or PCI" (NCT00180479)
Timeframe: 180 days

Interventionpercentage of participants (Number)
XIENCE V® EECSS4.1
TAXUS® EXPRESS2™ ECSS5.5

Target Vessel Failure (TVF)

"The composite endpoint comprised of:~Cardiac death (death in which a cardiac cause cannot be excluded)~Myocardial infarction (MI, classified as Q-wave and non-Q wave)~Ischemia-driven target lesion revascularization (TLR) by CABG or PCI~Ischemia-driven target vessel revascularization (TVR) by CABG or PCI" (NCT00180479)
Timeframe: 2 year

Interventionpercentage of participants (Number)
XIENCE V® EECSS11.3
TAXUS® EXPRESS2™ ECSS16.4

Target Vessel Failure (TVF)

"The composite endpoint comprised of:~Cardiac death (death in which a cardiac cause cannot be excluded)~Myocardial infarction (MI, classified as Q-wave and non-Q wave)~Ischemia-driven target lesion revascularization (TLR) by CABG or PCI~Ischemia-driven target vessel revascularization (TVR) by CABG or PCI" (NCT00180479)
Timeframe: 3 year

Interventionpercentage of participants (Number)
XIENCE V® EECSS14.3
TAXUS® EXPRESS2™ ECSS20.0

Target Vessel Failure (TVF)

"The composite endpoint comprised of:~Cardiac death (death in which a cardiac cause cannot be excluded)~Myocardial infarction (MI, classified as Q-wave and non-Q wave)~Ischemia-driven target lesion revascularization (TLR) by CABG or PCI~Ischemia-driven target vessel revascularization (TVR) by CABG or PCI" (NCT00180479)
Timeframe: 30 days

Interventionpercentage of participants (Number)
XIENCE V® EECSS1.6
TAXUS® EXPRESS2™ ECSS3.3

Target Vessel Failure (TVF)

"The composite endpoint comprised of:~Cardiac death (death in which a cardiac cause cannot be excluded)~Myocardial infarction (MI, classified as Q-wave and non-Q wave)~Ischemia-driven target lesion revascularization (TLR) by CABG or PCI~Ischemia-driven target vessel revascularization (TVR) by CABG or PCI" (NCT00180479)
Timeframe: 4 year

Interventionpercentage of participants (Number)
XIENCE V® EECSS18.5
TAXUS® EXPRESS2™ ECSS22.5

Target Vessel Failure (TVF)

"The composite endpoint comprised of:~Cardiac death (death in which a cardiac cause cannot be excluded)~Myocardial infarction (MI, classified as Q-wave and non-Q wave)~Ischemia-driven target lesion revascularization (TLR) by CABG or PCI~Ischemia-driven target vessel revascularization (TVR) by CABG or PCI" (NCT00180479)
Timeframe: 5 years

Interventionpercentage of participants (Number)
XIENCE V® EECSS20.3
TAXUS® EXPRESS2™ ECSS26.6

Any MI (Q-wave and Non Q-wave)

MI= Academic Research Consortium (ARC) defined (NCT00676520)
Timeframe: at 1 year

Interventionpercentage of participants (Number)
Subjects Receiving the XIENCE V EECSS6.3

Any MI (Q-wave and Non Q-wave)

MI= Academic Research Consortium (ARC) defined (NCT00676520)
Timeframe: at 180 days

Interventionpercentage of participants (Number)
Subjects Receiving the XIENCE V EECSS4.7

Any MI (Q-wave and Non Q-wave)

MI= Academic Research Consortium (ARC) defined (NCT00676520)
Timeframe: at 30 days

Interventionpercentage of participants (Number)
Subjects Receiving the XIENCE V EECSS3.3

Clinical Device Success

(NCT00676520)
Timeframe: acute: post index procedure until hospital discharge

Interventionpercentage of lesions (Number)
Subjects Receiving the XIENCE V EECSS99.8

Composite Rate of All Death and Any MI (Q-wave and Non Q-wave)

MI= Academic Research Consortium (ARC) defined (NCT00676520)
Timeframe: at 1 year

Interventionpercentage of participants (Number)
Subjects Receiving the XIENCE V EECSS8.3

Composite Rate of All Death and Any MI (Q-wave and Non Q-wave)

MI= Academic Research Consortium (ARC) defined (NCT00676520)
Timeframe: at 180 days

Interventionpercentage of participants (Number)
Subjects Receiving the XIENCE V EECSS5.8

Composite Rate of All Death and Any MI (Q-wave and Non Q-wave)

MI= Academic Research Consortium (ARC) defined (NCT00676520)
Timeframe: at 30 days

Interventionpercentage of participants (Number)
Subjects Receiving the XIENCE V EECSS3.6

Composite Rate of All Death, Any MI (Q-wave and Non Q-wave) and Any Repeat Revascularization (Percutaneous Coronary Intervention [PCI] and Coronary Artery Bypass Graft [CABG])

MI= Academic Research Consortium (ARC) defined (NCT00676520)
Timeframe: at 1 year

Interventionpercentage of participants (Number)
Subjects Receiving the XIENCE V EECSS14.9

Composite Rate of All Death, Any MI (Q-wave and Non Q-wave) and Any Repeat Revascularization (Percutaneous Coronary Intervention [PCI] and Coronary Artery Bypass Graft [CABG])

MI= Academic Research Consortium (ARC) defined (NCT00676520)
Timeframe: at 180 days

Interventionpercentage of participants (Number)
Subjects Receiving the XIENCE V EECSS9.4

Composite Rate of All Death, Any MI (Q-wave and Non Q-wave) and Any Repeat Revascularization (Percutaneous Coronary Intervention [PCI] and Coronary Artery Bypass Graft [CABG])

MI= Academic Research Consortium (ARC) defined (NCT00676520)
Timeframe: at 30 days

Interventionpercentage of participants (Number)
Subjects Receiving the XIENCE V EECSS4.3

Composite Rate of Cardiac Death and Any MI (Q-wave and Non Q-wave)

MI= Academic Research Consortium (ARC) defined (NCT00676520)
Timeframe: at 180 days

Interventionpercentage of participants (Number)
Subjects Receiving the XIENCE V EECSS5.4

Composite Rate of Cardiac Death and Any MI (Q-wave and Non Q-wave)

MI= Academic Research Consortium (ARC) defined (NCT00676520)
Timeframe: at 30 days

Interventionpercentage of participants (Number)
Subjects Receiving the XIENCE V EECSS3.6

Composite Rate of Cardiac Death and Any Myocardial Infarction (MI)

MI= ARC (Academic Research Constortium) defined (NCT00676520)
Timeframe: 1 year

Interventionpercentage of participants (Number)
Subjects Receiving the XIENCE V EECSS7.2

Composite Rate of Cardiac Death and MI (Q-wave and Non Q-wave) Attributed to the Target Vessel, and Clinically-indicated Target Lesion Revascularization (CI-TLR) (PCI and CABG) (This Composite Endpoint is Also Denoted as TLF)

MI= Academic Research Consortium (ARC) defined (NCT00676520)
Timeframe: at 1 year

Interventionpercentage of participants (Number)
Subjects Receiving the XIENCE V EECSS9.4

Composite Rate of Cardiac Death and MI (Q-wave and Non Q-wave) Attributed to the Target Vessel, and Clinically-indicated Target Lesion Revascularization (CI-TLR) (PCI and CABG) (This Composite Endpoint is Also Denoted as TLF)

MI= Academic Research Consortium (ARC) defined (NCT00676520)
Timeframe: at 180 days

Interventionpercentage of participants (Number)
Subjects Receiving the XIENCE V EECSS6.2

Composite Rate of Cardiac Death and MI (Q-wave and Non Q-wave) Attributed to the Target Vessel, and Clinically-indicated Target Lesion Revascularization (CI-TLR) (PCI and CABG) (This Composite Endpoint is Also Denoted as TLF)

MI= Academic Research Consortium (ARC) defined (NCT00676520)
Timeframe: at 30 days

Interventionpercentage of participants (Number)
Subjects Receiving the XIENCE V EECSS3.5

Composite Rate of Cardiac Death, Any MI (Q-wave and Non Q-wave) Attributed to the Target Vessel, and Target Lesion Revascularization (TLR) (PCI and CABG)

MI= Academic Research Consortium (ARC) defined (NCT00676520)
Timeframe: at 1 year

Interventionpercentage of participants (Number)
Subjects Receiving the XIENCE V EECSS9.6

Composite Rate of Cardiac Death, Any MI (Q-wave and Non Q-wave) Attributed to the Target Vessel, and Target Lesion Revascularization (TLR) (PCI and CABG)

MI= Academic Research Consortium (ARC) defined (NCT00676520)
Timeframe: at 180 days

Interventionpercentage of participants (Number)
Subjects Receiving the XIENCE V EECSS6.3

Composite Rate of Cardiac Death, Any MI (Q-wave and Non Q-wave) Attributed to the Target Vessel, and Target Lesion Revascularization (TLR) (PCI and CABG)

MI= Academic Research Consortium (ARC) defined (NCT00676520)
Timeframe: at 30 days

Interventionpercentage of participants (Number)
Subjects Receiving the XIENCE V EECSS3.5

Death (Cardiac Death, Vascular Death, and Non-cardiovascular Death)

(NCT00676520)
Timeframe: at 1 year

Interventionpercentage of participants (Number)
Subjects Receiving the XIENCE V EECSS2.6

Death (Cardiac Death, Vascular Death, and Non-cardiovascular Death)

(NCT00676520)
Timeframe: at 180 days

Interventionpercentage of participants (Number)
Subjects Receiving the XIENCE V EECSS1.4

Death (Cardiac Death, Vascular Death, and Non-cardiovascular Death)

(NCT00676520)
Timeframe: at 30 days

Interventionpercentage of participants (Number)
Subjects Receiving the XIENCE V EECSS0.4

Dual Antiplatelet Medication Usage

"Patient is included if medications (both aspirin and thienopyridine) were taken for at least 1 day during the visit window. The visit window for 14-day visit is 7-21 days, 30-day visit is 23-37 days, 180-day visit is 166-194 days, 1-year visit is 323-407 days, and 2-year visit is 688-772 days.~Adjunctive antiplatelet therapy includes: Aspirin & Thienopyridines (Clopidogrel/Ticlopidine/Prasugrel).~Compliance refers to subjects following prescribed instructions for taking these medications. Therapy interruptions refer to any intervals during which the subject stops taking one or all of the prescribed medications." (NCT00676520)
Timeframe: at 1 year

Interventionpercentage of participants (Number)
Subjects Receiving the XIENCE V EECSS79.9

Dual Antiplatelet Medication Usage

"Patient is included if medications (both aspirin and thienopyridine) were taken for at least 1 day during the visit window. The visit window for 14-day visit is 7-21 days, 30-day visit is 23-37 days, 180-day visit is 166-194 days, 1-year visit is 323-407 days, and 2-year visit is 688-772 days.~Adjunctive antiplatelet therapy includes: Aspirin & Thienopyridines (Clopidogrel/Ticlopidine/Prasugrel).~Compliance refers to subjects following prescribed instructions for taking these medications. Therapy interruptions refer to any intervals during which the subject stops taking one or all of the prescribed medications." (NCT00676520)
Timeframe: at 14 days

Interventionpercentage of participants (Number)
Subjects Receiving the XIENCE V EECSS89.4

Dual Antiplatelet Medication Usage

"Patient is included if medications (both aspirin and thienopyridine) were taken for at least 1 day during the visit window. The visit window for 14-day visit is 7-21 days, 30-day visit is 23-37 days, 180-day visit is 166-194 days, 1-year visit is 323-407 days, and 2-year visit is 688-772 days.~Adjunctive antiplatelet therapy includes: Aspirin & Thienopyridines (Clopidogrel/Ticlopidine/Prasugrel).~Compliance refers to subjects following prescribed instructions for taking these medications. Therapy interruptions refer to any intervals during which the subject stops taking one or all of the prescribed medications." (NCT00676520)
Timeframe: at 180 days

Interventionpercentage of participants (Number)
Subjects Receiving the XIENCE V EECSS86.4

Dual Antiplatelet Medication Usage

"Patient is included if medications (both aspirin and thienopyridine) were taken for at least 1 day during the visit window. The visit window for 14-day visit is 7-21 days, 30-day visit is 23-37 days, 180-day visit is 166-194 days, 1-year visit is 323-407 days, and 2-year visit is 688-772 days.~Adjunctive antiplatelet therapy includes: Aspirin & Thienopyridines (Clopidogrel/Ticlopidine/Prasugrel).~Compliance refers to subjects following prescribed instructions for taking these medications. Therapy interruptions refer to any intervals during which the subject stops taking one or all of the prescribed medications." (NCT00676520)
Timeframe: at 30 days

Interventionpercentage of participants (Number)
Subjects Receiving the XIENCE V EECSS89.2

Dual Antiplatelet Therapy Non-compliance Through 1 Year

Defined as patients who had at least 1 day without using either aspirin or thienopyridine from 1 to 407 days post index procedure. (NCT00676520)
Timeframe: 1 year

Interventionpercentage of participants (Number)
Subjects Receiving the XIENCE V EECSS18.0

Major Bleeding Complications

by TIMI flow (NCT00676520)
Timeframe: at 1 year

Interventionpercentage of participants (Number)
Subjects Receiving the XIENCE V EECSS2.8

Major Bleeding Complications

by TIMI flow (NCT00676520)
Timeframe: at 14 days

Interventionpercentage of participants (Number)
Subjects Receiving the XIENCE V EECSS0.6

Major Bleeding Complications

by TIMI flow (NCT00676520)
Timeframe: at 180 days

Interventionpercentage of participants (Number)
Subjects Receiving the XIENCE V EECSS1.8

Major Bleeding Complications

by TIMI flow (NCT00676520)
Timeframe: at 30 days

Interventionpercentage of participants (Number)
Subjects Receiving the XIENCE V EECSS0.7

Patient Health Status, Physical Limitations Assessed Using the SAQ (Seattle Angina Questionaire)

"SAQ: 19-item, 5-6-point Likert, questionnaire measuring 5 dimensions of coronary artery disease:~Anginal Stability: whether a patient's symptoms are changing over time. Anginal Frequency: how often a patient is having symptoms now Physical Limitation: how much a patient's condition is hampering his ability to do what he wants to do.~Treatment Satisfaction: how well a patient understands her care and what she thinks of it.~Disease Perception: the overall impact of a patient's condition on a patient's interpersonal relationships and state of mind.~Each dimension is assigns each response an ordinal value, beginning with 1 for the response at the lowest level of functioning, and summing across items within each of the 5 scales. Scale scores then transformed to 0-100 range by subtracting the lowest possible scale score, dividing by the range of the scale and multiplying by 100." (NCT00676520)
Timeframe: at 1 year

Interventionunits on the SAQ scale (Mean)
Subjects Receiving the XIENCE V EECSS76.0

Patient Health Status, Physical Limitations Assessed Using the SAQ (Seattle Angina Questionaire)

"SAQ: 19-item, 5-6-point Likert, questionnaire measuring 5 dimensions of coronary artery disease:~Anginal Stability: whether a patient's symptoms are changing over time. Anginal Frequency: how often a patient is having symptoms now Physical Limitation: how much a patient's condition is hampering his ability to do what he wants to do.~Treatment Satisfaction: how well a patient understands her care and what she thinks of it.~Disease Perception: the overall impact of a patient's condition on a patient's interpersonal relationships and state of mind.~Each dimension is assigns each response an ordinal value, beginning with 1 for the response at the lowest level of functioning, and summing across items within each of the 5 scales. Scale scores then transformed to 0-100 range by subtracting the lowest possible scale score, dividing by the range of the scale and multiplying by 100." (NCT00676520)
Timeframe: at 180 days

Interventionunits on the SAQ scale (Mean)
Subjects Receiving the XIENCE V EECSS75.8

Patient Health Status, Physical Limitations Assessed Using the SAQ (Seattle Angina Questionaire)

"SAQ: 19-item, 5-6-point Likert, questionnaire measuring 5 dimensions of coronary artery disease:~Anginal Stability: whether a patient's symptoms are changing over time. Anginal Frequency: how often a patient is having symptoms now Physical Limitation: how much a patient's condition is hampering his ability to do what he wants to do.~Treatment Satisfaction: how well a patient understands her care and what she thinks of it.~Disease Perception: the overall impact of a patient's condition on a patient's interpersonal relationships and state of mind.~Each dimension is assigns each response an ordinal value, beginning with 1 for the response at the lowest level of functioning, and summing across items within each of the 5 scales. Scale scores then transformed to 0-100 range by subtracting the lowest possible scale score, dividing by the range of the scale and multiplying by 100." (NCT00676520)
Timeframe: at baseline

Interventionunits on the SAQ scale (Mean)
Subjects Receiving the XIENCE V EECSS70.0

Procedural Success

(NCT00676520)
Timeframe: acute: post index procedure until hospital discharge

Interventionpercentage of participants (Number)
Subjects Receiving the XIENCE V EECSS97.3

Revascularization (Target Lesion, Target Vessel [TVR], and Non-target Vessel) (PCI and CABG)

(NCT00676520)
Timeframe: at 1 year

Interventionpercentage of participants (Number)
Subjects Receiving the XIENCE V EECSS9.2

Revascularization (Target Lesion, Target Vessel [TVR], and Non-target Vessel) (PCI and CABG)

(NCT00676520)
Timeframe: at 180 days

Interventionpercentage of participants (Number)
Subjects Receiving the XIENCE V EECSS5.0

Revascularization (Target Lesion, Target Vessel [TVR], and Non-target Vessel) (PCI and CABG)

(NCT00676520)
Timeframe: at 30 days

Interventionpercentage of participants (Number)
Subjects Receiving the XIENCE V EECSS1.1

SAQ (Seattle Angina Questionaire)

"SAQ: 19-item, 5-6-point Likert, questionnaire measuring 5 dimensions of coronary artery disease:~Anginal Stability: whether a patient's symptoms are changing over time. Anginal Frequency: how often a patient is having symptoms now Physical Limitation: how much a patient's condition is hampering his ability to do what he wants to do.~Treatment Satisfaction: how well a patient understands her care and what she thinks of it.~Disease Perception: the overall impact of a patient's condition on a patient's interpersonal relationships and state of mind.~Each dimension is assigns each response an ordinal value, beginning with 1 for the response at the lowest level of functioning, and summing across items within each of the 5 scales. Scale scores then transformed to 0-100 range by subtracting the lowest possible scale score, dividing by the range of the scale and multiplying by 100." (NCT00676520)
Timeframe: 1 year

Interventionunits on the SAQ scale (Mean)
Physical Limitations76.0
Angina Stability54.3
Angina Frequency90.7
Treatment Satisfaction92.2
Perception of Disease/Quality of Life78.0

SAQ (Seattle Angina Questionaire)

"SAQ: 19-item, 5-6-point Likert, questionnaire measuring 5 dimensions of coronary artery disease:~Anginal Stability: whether a patient's symptoms are changing over time. Anginal Frequency: how often a patient is having symptoms now Physical Limitation: how much a patient's condition is hampering his ability to do what he wants to do.~Treatment Satisfaction: how well a patient understands her care and what she thinks of it.~Disease Perception: the overall impact of a patient's condition on a patient's interpersonal relationships and state of mind.~Each dimension is assigns each response an ordinal value, beginning with 1 for the response at the lowest level of functioning, and summing across items within each of the 5 scales. Scale scores then transformed to 0-100 range by subtracting the lowest possible scale score, dividing by the range of the scale and multiplying by 100." (NCT00676520)
Timeframe: 180 days

Interventionunits on the SAQ scale (Mean)
Physical Limitations75.8
Angina Stability57.3
Angina Frequency90.1
Treatment Satisfaction91.4
Perception of Disease/Quality of Life76.8

SAQ (Seattle Angina Questionaire)

"SAQ: 19-item, 5-6-point Likert, questionnaire measuring 5 dimensions of coronary artery disease:~Anginal Stability: whether a patient's symptoms are changing over time. Anginal Frequency: how often a patient is having symptoms now Physical Limitation: how much a patient's condition is hampering his ability to do what he wants to do.~Treatment Satisfaction: how well a patient understands her care and what she thinks of it.~Disease Perception: the overall impact of a patient's condition on a patient's interpersonal relationships and state of mind.~Each dimension is assigns each response an ordinal value, beginning with 1 for the response at the lowest level of functioning, and summing across items within each of the 5 scales. Scale scores then transformed to 0-100 range by subtracting the lowest possible scale score, dividing by the range of the scale and multiplying by 100." (NCT00676520)
Timeframe: at baseline

Interventionunits on the SAQ scale (Mean)
Physical Limitations70.0
Angina Stability42.0
Angina Frequency73.1
Treatment Satisfaction98.1
Perception of Disease/Quality of Life55.3

Stent Thrombosis (Definite and Probable) Rate as Defined by ARC (Academic Research Constortium).

"ARC Defines Stent Thrombosis in the following way:~Definite Stent Thrombosis: Angiographic or pathologic confirmation of partial or total thrombotic occlusion within the peri-stent region AND at least ONE of the following, additional criteria:~Acute ischemic symptoms Ischemic ECG changes Elevated cardiac biomarkers~Probable Stent Thrombosis: Any unexplained death within 30 days of stent implantation or any myocardial infarction, which is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause~Possible Stent Thrombosis Any unexplained death beyond 30 days~For further information on ARC definitions, please refer to the following website: http://circ.ahajournals.org/content/115/17/2344.full#sec-1" (NCT00676520)
Timeframe: up to 1 year

Interventionpercentage of participants (Number)
Subjects Receiving the XIENCE V EECSS0.81

Acute Success (Clinical Device)

Successful delivery and deployment of the first implanted study stent (in overlapping stent setting a successful delivery and deployment of the first and second study stents) at the intended target lesion and successful withdrawal of the stent delivery system with attainment of final residual stenosis of less than 50% of the target lesion by QCA (by visual estimation if QCA unavailable). Bailout subjects will be included as device success only if the above criteria for clinical device are met. (NCT00307047)
Timeframe: Acute: At time of index procedure

InterventionPercent of success (Number)
XIENCE V®92.0
TAXUS™ EXPRESS 2™90.7

Acute Success (Clinical Procedure)

Successful delivery and deployment of the study stent or stents at the intended target lesion and successful withdrawal of the stent delivery system with attainment of final residual stenosis of less than 50% of the target lesion by QCA (by visual estimation if QCA unavailable) and/or using any adjunctive device without the occurrence of major adverse cardiac event (MACE) during the hospital stay with a maximum of first seven days following the index procedure. In multiple lesion setting all lesions must meet clinical procedure success. (NCT00307047)
Timeframe: Acute: At time of index procedure

InterventionPercentage of success (Number)
XIENCE V®98.6
TAXUS™ EXPRESS 2™98.1

All Cause Mortality

(NCT00307047)
Timeframe: 1 year

InterventionPercentage of participants (Number)
XIENCE V®1.0
TAXUS™ EXPRESS 2™1.3

All Cause Mortality

(NCT00307047)
Timeframe: 180 days

InterventionPercentage of participants (Number)
XIENCE V®0.5
TAXUS™ EXPRESS 2™0.6

All Cause Mortality

(NCT00307047)
Timeframe: 2 years

InterventionPercentage of participants (Number)
XIENCE V®2.1
TAXUS™ EXPRESS 2™2.7

All Cause Mortality

(NCT00307047)
Timeframe: 270 days

InterventionPercentage of participants (Number)
XIENCE V®0.7
TAXUS™ EXPRESS 2™0.9

All Cause Mortality

(NCT00307047)
Timeframe: 3 years

InterventionPercentage of participants (Number)
XIENCE V®3.4
TAXUS™ EXPRESS 2™5.2

All Cause Mortality

(NCT00307047)
Timeframe: 30 days

InterventionPercentage of participants (Number)
XIENCE V®0.0
TAXUS™ EXPRESS 2™0.2

All MI

(NCT00307047)
Timeframe: 1 year

InterventionPercentage of participants (Number)
XIENCE V®1.9
TAXUS™ EXPRESS 2™3.1

All MI

(NCT00307047)
Timeframe: 180 days

InterventionPercentage of participants (Number)
XIENCE V®1.6
TAXUS™ EXPRESS 2™2.9

All MI

(NCT00307047)
Timeframe: 2 years

InterventionPercentage of participants (Number)
XIENCE V®2.6
TAXUS™ EXPRESS 2™3.9

All MI

(NCT00307047)
Timeframe: 270 days

InterventionPercentage of participants (Number)
XIENCE V®1.8
TAXUS™ EXPRESS 2™3.0

All MI

(NCT00307047)
Timeframe: 3 years

InterventionPercentage of participants (Number)
XIENCE V®3.1
TAXUS™ EXPRESS 2™4.7

All Myocardial Infarction (MI)

(NCT00307047)
Timeframe: 30 days

InterventionPercentage of participants (Number)
XIENCE V®1.5
TAXUS™ EXPRESS 2™2.1

Cardiac Death or Target Vessel MI Rate

(NCT00307047)
Timeframe: 1 year

InterventionPercentage of participants (Number)
XIENCE V®2.2
TAXUS™ EXPRESS 2™3.2

Cardiac Death or Target Vessel MI Rate

(NCT00307047)
Timeframe: 180 days

InterventionPercentage of participants (Number)
XIENCE V®1.8
TAXUS™ EXPRESS 2™2.8

Cardiac Death or Target Vessel MI Rate

(NCT00307047)
Timeframe: 2 years

InterventionPercentage of participants (Number)
XIENCE V®3.2
TAXUS™ EXPRESS 2™4.3

Cardiac Death or Target Vessel MI Rate

(NCT00307047)
Timeframe: 270 days

InterventionPercentage of participants (Number)
XIENCE V®2.1
TAXUS™ EXPRESS 2™3.0

Cardiac Death or Target Vessel MI Rate

(NCT00307047)
Timeframe: 3 years

InterventionPercentage of participants (Number)
XIENCE V®4.1
TAXUS™ EXPRESS 2™5.5

Cardiac Death or Target Vessel MI Rate

(NCT00307047)
Timeframe: 30 days

InterventionPercentage of participants (Number)
XIENCE V®1.5
TAXUS™ EXPRESS 2™2.1

Composite Endpoint of All Deaths, All MI, All Revascularizations (DMR)

(NCT00307047)
Timeframe: 1 year

InterventionPercentage of participants (Number)
XIENCE V®9.0
TAXUS™ EXPRESS 2™10.5

Composite Endpoint of All Deaths, All MI, All Revascularizations (DMR)

(NCT00307047)
Timeframe: 180 days

InterventionPercentage of participants (Number)
XIENCE V®5.5
TAXUS™ EXPRESS 2™7.5

Composite Endpoint of All Deaths, All MI, All Revascularizations (DMR)

(NCT00307047)
Timeframe: 2 years

InterventionPercentage of participants (Number)
XIENCE V®15.5
TAXUS™ EXPRESS 2™16.2

Composite Endpoint of All Deaths, All MI, All Revascularizations (DMR)

(NCT00307047)
Timeframe: 270 days

InterventionPercentage of participants (Number)
XIENCE V®7.2
TAXUS™ EXPRESS 2™9.3

Composite Endpoint of All Deaths, All MI, All Revascularizations (DMR)

(NCT00307047)
Timeframe: 3 years

InterventionPercentage of participants (Number)
XIENCE V®21.4
TAXUS™ EXPRESS 2™22.5

Composite Endpoint of All Deaths, All MI, All Revascularizations (DMR)

(NCT00307047)
Timeframe: 30 days

InterventionPercentage of participants (Number)
XIENCE V®2.4
TAXUS™ EXPRESS 2™3.6

Definite + Probable Stent Thrombosis Rate Based on Academic Research Consortium (ARC) Definition

"ARC: Academic Research Consortium-defines ST as a cumulative value at the different time points and with the different seperate time points. Time 0 is defined as the time point after the guiding catheter has been removed. Acute*: 0-24 hours post implantation Subacute*: >24 hours-30 days post Late†: 30 days-1 year post Very late stent thrombosis†: >1 year post~* Acute/subacute can also be replaced by early ST. Early ST (0-30 days) is currently used in the community.~† Including primary as well as secondary late ST; secondary late ST is after a target segment revascularization." (NCT00307047)
Timeframe: 0-30 days

InterventionPercentage of participants (Number)
XIENCE V®0.16
TAXUS™ EXPRESS 2™0.74

Definite + Probable Stent Thrombosis Rate Based on ARC Definition

"ARC: Academic Research Consortium-defines ST as a cumulative value at the different time points and with the different seperate time points. Time 0 is defined as the time point after the guiding catheter has been removed. Acute*: 0-24 hours post implantation Subacute*: >24 hours-30 days post Late†: 30 days-1 year post Very late stent thrombosis†: >1 year post~* Acute/subacute can also be replaced by early ST. Early ST (0-30 days) is currently used in the community.~† Including primary as well as secondary late ST; secondary late ST is after a target segment revascularization." (NCT00307047)
Timeframe: 0 -393 days

InterventionPercentage of participants (Number)
XIENCE V®0.29
TAXUS™ EXPRESS 2™1.10

Definite + Probable Stent Thrombosis Rate Based on ARC Definition

"ARC: Academic Research Consortium-defines ST as a cumulative value at the different time points and with the different seperate time points. Time 0 is defined as the time point after the guiding catheter has been removed. Acute*: 0-24 hours post implantation Subacute*: >24 hours-30 days post Late†: 30 days-1 year post Very late stent thrombosis†: >1 year post~* Acute/subacute can also be replaced by early ST. Early ST (0-30 days) is currently used in the community.~† Including primary as well as secondary late ST; secondary late ST is after a target segment revascularization." (NCT00307047)
Timeframe: 0-1123 days

InterventionPercentage of participants (Number)
XIENCE V®0.62
TAXUS™ EXPRESS 2™1.73

Definite + Probable Stent Thrombosis Rate Based on ARC Definition

"ARC: Academic Research Consortium-defines ST as a cumulative value at the different time points and with the different seperate time points. Time 0 is defined as the time point after the guiding catheter has been removed. Acute*: 0-24 hours post implantation Subacute*: >24 hours-30 days post Late†: 30 days-1 year post Very late stent thrombosis†: >1 year post~* Acute/subacute can also be replaced by early ST. Early ST (0-30 days) is currently used in the community.~† Including primary as well as secondary late ST; secondary late ST is after a target segment revascularization." (NCT00307047)
Timeframe: 0-758 days

InterventionPercentage of participants (Number)
XIENCE V®0.48
TAXUS™ EXPRESS 2™1.32

Definite + Probable Stent Thrombosis Rate Based on ARC Definition

"ARC: Academic Research Consortium-defines ST as a cumulative value at the different time points and with the different seperate time points. Time 0 is defined as the time point after the guiding catheter has been removed. Acute*: 0-24 hours post implantation Subacute*: >24 hours-30 days post Late†: 30 days-1 year post Very late stent thrombosis†: >1 year post~* Acute/subacute can also be replaced by early ST. Early ST (0-30 days) is currently used in the community.~† Including primary as well as secondary late ST; secondary late ST is after a target segment revascularization." (NCT00307047)
Timeframe: 31-393 days

InterventionPercentage of participants (Number)
XIENCE V®0.13
TAXUS™ EXPRESS 2™0.42

Ischemia Driven Major Adverse Cardiac Events (MACE)

Patients determined to have had a MACE event, defined as one of the following events: Cardiac death, myocardial infarction, and TLR (NCT00307047)
Timeframe: 1 years

InterventionPercentage of participants (Number)
XIENCE V®4.2
TAXUS™ EXPRESS 2™6.9

Ischemia Driven Major Adverse Cardiac Events (MACE)

Patients determined to have had a MACE event, defined as one of the following events: Cardiac death, myocardial infarction, and TLR (NCT00307047)
Timeframe: 180 days

InterventionPercentage of participants (Number)
XIENCE V®2.6
TAXUS™ EXPRESS 2™5.3

Ischemia Driven Major Adverse Cardiac Events (MACE)

Patients determined to have had a MACE event, defined as one of the following events: Cardiac death, myocardial infarction, and TLR (NCT00307047)
Timeframe: 2 years

InterventionPercentage of participants (Number)
XIENCE V®7.2
TAXUS™ EXPRESS 2™10.2

Ischemia Driven Major Adverse Cardiac Events (MACE)

Patients determined to have had a MACE event, defined as one of the following events: Cardiac death, myocardial infarction, and TLR (NCT00307047)
Timeframe: 270 days

InterventionPercentage of participants (Number)
XIENCE V®3.5
TAXUS™ EXPRESS 2™6.2

Ischemia Driven Major Adverse Cardiac Events (MACE)

Patients determined to have had a MACE event, defined as one of the following events: Cardiac death, myocardial infarction, and TLR (NCT00307047)
Timeframe: 3 years

InterventionPercentage of participants (Number)
XIENCE V®9.8
TAXUS™ EXPRESS 2™12.3

Ischemia Driven Major Adverse Cardiac Events (MACE)

Patients determined to have had a MACE event, defined as one of the following events: Cardiac death, myocardial infarction, and TLR (NCT00307047)
Timeframe: 30 days

InterventionPercentage of participants (Number)
XIENCE V®1.6
TAXUS™ EXPRESS 2™2.7

Ischemia Driven Target Lesion Failure (TLF)

Percentage of participants with the determination of TLF. TLF is the composite of cardiac death, target vessel myocardial infarction, and ischemic driven target lesion revascularization (TLR). (NCT00307047)
Timeframe: 1 year

InterventionPercentage of participants (Number)
XIENCE V®4.2
TAXUS™ EXPRESS 2™6.8

Ischemia Driven Target Lesion Failure (TLF)

Percentage of participants with the determination of TLF. TLF is the composite of cardiac death, target vessel myocardial infarction, and ischemic driven target lesion revascularization (TLR). (NCT00307047)
Timeframe: 180 days

InterventionPercentage of participants (Number)
XIENCE V®2.5
TAXUS™ EXPRESS 2™5.1

Ischemia Driven Target Lesion Failure (TLF)

Percentage of participants with the determination of TLF. TLF is the composite of cardiac death, target vessel myocardial infarction, and ischemic driven target lesion revascularization (TLR). (NCT00307047)
Timeframe: 2 years

InterventionPercentage of participants (Number)
XIENCE V®7.0
TAXUS™ EXPRESS 2™10.0

Ischemia Driven Target Lesion Failure (TLF)

Percentage of participants with the determination of TLF. TLF is the composite of cardiac death, target vessel myocardial infarction, and ischemic driven target lesion revascularization (TLR). (NCT00307047)
Timeframe: 270 days

InterventionPercentage of participants (Number)
XIENCE V®3.4
TAXUS™ EXPRESS 2™6.1

Ischemia Driven Target Lesion Failure (TLF)

Percentage of participants with the determination of TLF. TLF is the composite of cardiac death, target vessel myocardial infarction, and ischemic driven target lesion revascularization (TLR). (NCT00307047)
Timeframe: 3 years

InterventionPercentage of participants (Number)
XIENCE V®9.5
TAXUS™ EXPRESS 2™11.9

Ischemia Driven Target Lesion Failure (TLF)

Percentage of participants with the determination of TLF. TLF is the composite of cardiac death, target vessel myocardial infarction, and ischemic driven target lesion revascularization (TLR). (NCT00307047)
Timeframe: 30 days

InterventionPercentage of participants (Number)
XIENCE V®1.6
TAXUS™ EXPRESS 2™2.7

Ischemia Driven Target Lesion Revascularization (TLR)

"Revascularization of a target lesion associated with any of the following:~positive functional ischemia study~ischemic symptoms and angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)~angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study" (NCT00307047)
Timeframe: 1 year

Interventionpercentage of participants (Number)
XIENCE V®2.5
TAXUS™ EXPRESS 2™4.6

Ischemia Driven Target Lesion Revascularization (TLR)

"Revascularization of a target lesion associated with any of the following:~positive functional ischemia study~ischemic symptoms and angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)~angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study" (NCT00307047)
Timeframe: 180 days

Interventionpercentage of participants (Number)
XIENCE V®1.1
TAXUS™ EXPRESS 2™3.2

Ischemia Driven Target Lesion Revascularization (TLR)

"Revascularization of a target lesion associated with any of the following:~positive functional ischemia study~ischemic symptoms and angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)~angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study" (NCT00307047)
Timeframe: 2 years

Interventionpercentage of participants (Number)
XIENCE V®4.4
TAXUS™ EXPRESS 2™6.9

Ischemia Driven Target Lesion Revascularization (TLR)

"Revascularization of a target lesion associated with any of the following:~positive functional ischemia study~ischemic symptoms and angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)~angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study" (NCT00307047)
Timeframe: 270 days

Interventionpercentage of participants (Number)
XIENCE V®1.9
TAXUS™ EXPRESS 2™4.1

Ischemia Driven Target Lesion Revascularization (TLR)

"Revascularization of a target lesion associated with any of the following:~positive functional ischemia study~ischemic symptoms and angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)~angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study" (NCT00307047)
Timeframe: 3 years

Interventionpercentage of participants (Number)
XIENCE V®6.3
TAXUS™ EXPRESS 2™7.9

Ischemia Driven Target Lesion Revascularization (TLR)

"Revascularization of a target lesion associated with any of the following:~positive functional ischemia study~ischemic symptoms and angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)~angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study" (NCT00307047)
Timeframe: 30 days

Interventionpercentage of participants (Number)
XIENCE V®0.4
TAXUS™ EXPRESS 2™1.1

Ischemia Driven Target Vessel Failure (TVF)

Defined as the composite endpoint comprised of cardiac death (CD), myocardial infarction (MI), TLR, and TVR (NCT00307047)
Timeframe: 1 year

Interventionpercentage of participants (Number)
XIENCE V®5.6
TAXUS™ EXPRESS 2™7.9

Ischemia Driven Target Vessel Failure (TVF)

Defined as the composite endpoint comprised of cardiac death (CD), myocardial infarction (MI), TLR, and TVR (NCT00307047)
Timeframe: 180 days

Interventionpercentage of participants (Number)
XIENCE V®3.4
TAXUS™ EXPRESS 2™6.2

Ischemia Driven Target Vessel Failure (TVF)

Defined as the composite endpoint comprised of cardiac death (CD), myocardial infarction (MI), TLR, and TVR (NCT00307047)
Timeframe: 2 years

Interventionpercentage of participants (Number)
XIENCE V®9.6
TAXUS™ EXPRESS 2™11.8

Ischemia Driven Target Vessel Failure (TVF)

Defined as the composite endpoint comprised of cardiac death (CD), myocardial infarction (MI), TLR, and TVR (NCT00307047)
Timeframe: 270 days

Interventionpercentage of participants (Number)
XIENCE V®4.6
TAXUS™ EXPRESS 2™7.2

Ischemia Driven Target Vessel Failure (TVF)

Defined as the composite endpoint comprised of cardiac death (CD), myocardial infarction (MI), TLR, and TVR (NCT00307047)
Timeframe: 3 years

Interventionpercentage of participants (Number)
XIENCE V®13.3
TAXUS™ EXPRESS 2™14.5

Ischemia Driven Target Vessel Failure (TVF)

Defined as the composite endpoint comprised of cardiac death (CD), myocardial infarction (MI), TLR, and TVR (NCT00307047)
Timeframe: 30 days

Interventionpercentage of participants (Number)
XIENCE V®1.9
TAXUS™ EXPRESS 2™3.1

Ischemia Driven Target Vessel Revascularization (TVR)

"Revascularization of a lesion within the target vessel associated with any of the following:~positive functional ischemia study~ischemic symptoms and an angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)~angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study" (NCT00307047)
Timeframe: 1 year

Interventionpercentage of participants (Number)
XIENCE V®3.9
TAXUS™ EXPRESS 2™5.9

Ischemia Driven Target Vessel Revascularization (TVR)

"Revascularization of a lesion within the target vessel associated with any of the following:~positive functional ischemia study~ischemic symptoms and an angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)~angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study" (NCT00307047)
Timeframe: 180 days

Interventionpercentage of participants (Number)
XIENCE V®1.9
TAXUS™ EXPRESS 2™4.3

Ischemia Driven Target Vessel Revascularization (TVR)

"Revascularization of a lesion within the target vessel associated with any of the following:~positive functional ischemia study~ischemic symptoms and an angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)~angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study" (NCT00307047)
Timeframe: 2 years

Interventionpercentage of participants (Number)
XIENCE V®7.0
TAXUS™ EXPRESS 2™8.9

Ischemia Driven Target Vessel Revascularization (TVR)

"Revascularization of a lesion within the target vessel associated with any of the following:~positive functional ischemia study~ischemic symptoms and an angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)~angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study" (NCT00307047)
Timeframe: 270 days

Interventionpercentage of participants (Number)
XIENCE V®3.0
TAXUS™ EXPRESS 2™5.3

Ischemia Driven Target Vessel Revascularization (TVR)

"Revascularization of a lesion within the target vessel associated with any of the following:~positive functional ischemia study~ischemic symptoms and an angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)~angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study" (NCT00307047)
Timeframe: 3 years

Interventionpercentage of participants (Number)
XIENCE V®10.1
TAXUS™ EXPRESS 2™10.6

Ischemia Driven Target Vessel Revascularization (TVR)

"Revascularization of a lesion within the target vessel associated with any of the following:~positive functional ischemia study~ischemic symptoms and an angiographic minimal lumen diameter stenosis ≥ 50% by core laboratory quantitative coronary angiography (QCA)~angiographic diameter stenosis ≥ 70% by core laboratory QCA without either ischemic symptoms or a positive functional study" (NCT00307047)
Timeframe: 30 days

Interventionpercentage of participants (Number)
XIENCE V®0.7
TAXUS™ EXPRESS 2™1.6

Protocol Defined Stent Thrombosis Rate

"ST will be categorized as acute (≤ 1day), subacute (>1 day to ≤ 30 days) and late (>30 days) and will be defined as any of the following:~Clinical presentation of acute coronary syndrome with angiographic evidence of ST~In the absence of angiography, any unexplained death, or acute MI (S-T segment elevation or new Q-wave)* in the distribution of the target lesion within 30 days *(Non-specific S-T/T changes, and cardiac enzyme elevations do not suffice) Any thromboses that occur less than 30 days after the index procedure will not be counted as restenosis." (NCT00307047)
Timeframe: 0-1123 days

InterventionPercentage of participants (Number)
XIENCE V®0.79
TAXUS™ EXPRESS 2™1.99

Protocol Defined Stent Thrombosis Rate

"ST will be categorized as acute (≤ 1day), subacute (>1 day to ≤ 30 days) and late (>30 days) and will be defined as any of the following:~Clinical presentation of acute coronary syndrome with angiographic evidence of ST~In the absence of angiography, any unexplained death, or acute MI (S-T segment elevation or new Q-wave)* in the distribution of the target lesion within 30 days *(Non-specific S-T/T changes, and cardiac enzyme elevations do not suffice) Any thromboses that occur less than 30 days after the index procedure will not be counted as restenosis." (NCT00307047)
Timeframe: 0-30 days

InterventionPercentage of participants (Number)
XIENCE V®0.12
TAXUS™ EXPRESS 2™0.57

Protocol Defined Stent Thrombosis Rate

"ST will be categorized as acute (≤ 1day), subacute (>1 day to ≤ 30 days) and late (>30 days) and will be defined as any of the following:~Clinical presentation of acute coronary syndrome with angiographic evidence of ST~In the absence of angiography, any unexplained death, or acute MI (S-T segment elevation or new Q-wave)* in the distribution of the target lesion within 30 days *(Non-specific S-T/T changes, and cardiac enzyme elevations do not suffice) Any thromboses that occur less than 30 days after the index procedure will not be counted as restenosis." (NCT00307047)
Timeframe: 0-393 days

InterventionPercentage of participants (Number)
XIENCE V®0.17
TAXUS™ EXPRESS 2™0.85

Protocol Defined Stent Thrombosis Rate

"ST will be categorized as acute (≤ 1day), subacute (>1 day to ≤ 30 days) and late (>30 days) and will be defined as any of the following:~Clinical presentation of acute coronary syndrome with angiographic evidence of ST~In the absence of angiography, any unexplained death, or acute MI (S-T segment elevation or new Q-wave)* in the distribution of the target lesion within 30 days *(Non-specific S-T/T changes, and cardiac enzyme elevations do not suffice) Any thromboses that occur less than 30 days after the index procedure will not be counted as restenosis." (NCT00307047)
Timeframe: 0-758 days

InterventionPercentage of participants (Number)
XIENCE V®0.52
TAXUS™ EXPRESS 2™1.23

Protocol Defined Stent Thrombosis Rate

"ST will be categorized as acute (≤ 1day), subacute (>1 day to ≤ 30 days) and late (>30 days) and will be defined as any of the following:~Clinical presentation of acute coronary syndrome with angiographic evidence of ST~In the absence of angiography, any unexplained death, or acute MI (S-T segment elevation or new Q-wave)* in the distribution of the target lesion within 30 days *(Non-specific S-T/T changes, and cardiac enzyme elevations do not suffice) Any thromboses that occur less than 30 days after the index procedure will not be counted as restenosis." (NCT00307047)
Timeframe: 31-393 days

InterventionPercentage of participants (Number)
XIENCE V®0.04
TAXUS™ EXPRESS 2™0.34

The Composite Incidence of All-cause Mortality, Myocardial Infarction (MI), Ischemia-driven Revascularization (IDR) and Stent Thrombosis (ST)

Clinical Events Committee (CEC)-adjudicated results (modified intent-to-treat [mITT] population) (NCT01156571)
Timeframe: 48 hours after randomization

Interventionparticipants (Number)
Cangrelor Treatment Arm257
Clopidogrel Treatment Arm322

Incidence of Major/Minor Non-coronary Artery Bypass Graft (CABG)-Related Hemorrhage by Clinical Relevant Criteria - GUSTO Severe/Life-threatening, Moderate and Mild

GUSTO = Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries trial (NCT01156571)
Timeframe: 48 hours after randomization

,
Interventionparticipants (Number)
GUSTO severe/life threateningGUSTO moderateGUSTO severe or moderateTIMI majorTIMI minorTIMI major or minorAny blood transfusion
Cangrelor Treatment Arm92231591425
Clopidogrel Treatment Arm6131953816

Individual Incidence of Stent Thrombosis (ST), Death, Myocardial Infarction (MI) and Ischemia-driven Revascularization (IDR)

CEC-adjudicated results (mITT population) (NCT01156571)
Timeframe: 48 hours after randomization

,
Interventionparticipants (Number)
Stent ThrombosisDeathMI (myocardial infarction)IDR (ischemia-driven revascularization)
Cangrelor Treatment Arm461820728
Clopidogrel Treatment Arm741825538

Definite or Probable Stent Thrombosis (ST) - Propensity Matched DES vs. BMS

Secondary powered endpoint (NCT00977938)
Timeframe: 33 months (0-33 months post-index procedure)

Interventionpercentage of patients (Number)
Propensity-matched DES1.70
Propensity-matched BMS2.61

Definite or Probable Stent Thrombosis (ST) - Randomized BMS ITT

ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)

Interventionpercentage of patients (KM estimate) (Number)
BMS 30-month DAPT0.50
BMS 12-month DAPT1.11

Definite or Probable Stent Thrombosis (ST) - Randomized BMS ITT

ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)

Interventionpercentage of patients (KM estimate) (Number)
BMS 30-month DAPT0.50
BMS 12-month DAPT1.11

Definite or Probable Stent Thrombosis (ST) - Randomized DES ITT

ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)

Interventionpercentage of patients (KM estimate) (Number)
DES 30-month DAPT0.69
DES 12-month DAPT1.45

Definite or Probable Stent Thrombosis (ST) - Randomized DES ITT

The coprimary efficacy endpoints were the cumulative incidence of MACCE and the cumulative incidence of definite or probable ST within randomized DES ITT patients between 12 and 30 months post procedure. ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)

Interventionpercentage of patients (KM estimate) (Number)
DES 30-month DAPT0.40
DES 12-month DAPT1.35

GUSTO Severe or Moderate Bleeding - Randomized BMS ITT

Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)

Interventionpercentage of patients (Number)
BMS 30-month DAPT2.03
BMS 12-month DAPT0.90

GUSTO Severe or Moderate Bleeding - Randomized BMS ITT

Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)

Interventionpercentage of patients (Number)
BMS 30-month DAPT2.09
BMS 12-month DAPT1.05

GUSTO Severe or Moderate Bleeding - Randomized DES ITT

Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)

Interventionpercentage of patients (Number)
DES 30-month DAPT2.74
DES 12-month DAPT1.88

GUSTO Severe or Moderate Bleeding - Randomized DES ITT

The primary safety endpoint was moderate or severe bleeding within randomized DES ITT patients between 12 and 30 months post procedure. Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)

Interventionpercentage of patients (Number)
DES 30-month DAPT2.53
DES 12-month DAPT1.57

MACCE (Death, Myocardial Infarction or Stroke) - Propensity Matched DES vs. BMS

Secondary powered endpoint (NCT00977938)
Timeframe: 33 months (0-33 months post-index procedure)

Interventionpercentage of patients (Number)
Propensity-matched DES11.37
Propensity-matched BMS13.24

MACCE (Death, Myocardial Infarction or Stroke) - Randomized BMS ITT

(NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)

Interventionpercentage of patients (KM estimate) (Number)
BMS 30-month DAPT4.04
BMS 12-month DAPT4.69

MACCE (Death, Myocardial Infarction or Stroke) - Randomized BMS ITT

(NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)

Interventionpercentage of patients (KM estimate) (Number)
BMS 30-month DAPT4.68
BMS 12-month DAPT5.48

MACCE (Death, Myocardial Infarction or Stroke) - Randomized DES ITT

(NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)

Interventionpercentage of patients (KM estimate) (Number)
DES 30-month DAPT5.62
DES 12-month DAPT6.49

MACCE (Death, Myocardial Infarction or Stroke) - Randomized DES ITT

The coprimary efficacy endpoints were the cumulative incidence of MACCE and the cumulative incidence of ARC definite or probable stent thrombosis within randomized DES ITT patients between 12 and 30 months post procedure. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)

Interventionpercentage of patients (KM estimate) (Number)
DES 30-month DAPT4.34
DES 12-month DAPT5.92

Number of Subjects Reaching the Composite Endpoint of All-Cause Death, Nonfatal Myocardial Infarction (MI), or Nonfatal Stroke

The endpoint in this measure is a combination of all-cause death, nonfatal MI, or nonfatal stroke. Results are reported for the All ACS population. (NCT00097591)
Timeframe: Randomization up to 15 months

InterventionParticipants (Number)
Prasugrel692
Clopidogrel822

Number of Subjects Reaching the Composite Endpoint of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), Nonfatal Stroke, or Rehospitalization for Cardiac Ischemic Events

The endpoint in this measure is a combination of CV death, nonfatal MI, nonfatal stroke, or rehospitalization for cardiac ischemic events. Results are reported for the All ACS population. (NCT00097591)
Timeframe: Randomization up to 15 months

InterventionParticipants (Number)
Prasugrel797
Clopidogrel938

Number of Subjects Reaching the Composite Endpoint of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), or Nonfatal Stroke

The endpoint in this measure is a combination of CV death, nonfatal MI, or nonfatal stroke. Results are reported for the All ACS population for the 30 and 90 day periods. (NCT00097591)
Timeframe: Randomization to 30 days; randomization to 90 days

,
InterventionParticipants (Number)
All ACS (Through 30 days)All ACS (Through 90 days)
Clopidogrel502573
Prasugrel389462

Number of Subjects Reaching the Composite Endpoint of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), or Nonfatal Stroke

The endpoint in this measure is a combination of CV death, nonfatal MI, or nonfatal stroke. The data is presented by the study population, which is represented as follows: 1) subjects who presented with unstable angina and non-ST-segment elevation myocardial infarction (UA/NSTEMI), 2) subjects who presented with ST segment elevation myocardial infarction (STEMI), and 3) all subjects with acute coronary syndromes (ACS) (i.e. all subjects with UA/NSTEMI or STEMI). (NCT00097591)
Timeframe: Randomization up to 15 months

,
InterventionParticipants (Number)
UA/NSTEMI (n=5044, n=5030)STEMI (n=1769, n=1765)All ACS (n=6813, n=6795)
Clopidogrel565216781
Prasugrel469174643

Number of Subjects Reaching the Composite Endpoint of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), or Urgent Target Vessel Revascularization (UTVR)

The endpoint in this measure is a combination of CV death, nonfatal MI, or UTVR. Results are reported for the All ACS subject population for the 30 and 90 day periods. (NCT00097591)
Timeframe: Randomization to 30 days; randomization to 90 days

,
InterventionParticipants (Number)
All ACS (Through 30 days)All ACS (Through 90 days)
Clopidogrel504588
Prasugrel399472

Number of Treated Subjects With Non-Coronary Artery Bypass Graft (CABG) Related Thrombolysis In Myocardial Infarction (TIMI) Study Group Major and Minor Bleeding Events

TIMI classification for major and minor bleeding in the subset of subjects who did not undergo a coronary artery bypass operation (CABG) were defined as follows: Major bleeding: any intracranial hemorrhage (ICH) OR any clinically overt bleeding (including bleeding evident on imaging studies) associated with a fall in hemoglobin (Hgb) of ≥5 grams/deciliter (gm/dL)from baseline. Minor Bleeding: any clinically overt bleeding associated with a fall in Hgb of ≥3 gm/dL but <5 gm/dL from baseline. Major bleeding events were further examined as events that were deemed life threatening and/or fatal. (NCT00097591)
Timeframe: First dose of study drug up to 15 months (while at risk)

,
InterventionParticipants (Number)
TIMI Major or Minor BleedingTIMI Major BleedingTIMI Major Bleeding - Life-threatening (LT)LT - FatalLT - Symptomatic intracranial hemorrage (ICH)LT - Requiring inotropesLT - Requiring surgical interventionLT - Requiring transfusion (>=4 units)TIMI Minor Bleeding
Clopidogrel2311115651781930125
Prasugrel303146852119211945164

Pharmacology Arm - Major Adverse Cardiovascular Events

Number of participants with major adverse cardiovascular events (death, reinfarction, target-vessel revascularization for ischemia, and stroke) (NCT00433966)
Timeframe: 3 years

InterventionParticipants (Count of Participants)
Pharmacology Arm - Bivalirudin379
Pharmacology Arm - Unfractionated Heparin377

Pharmacology Arm - Major Adverse Cardiovascular Events

Number of participants with major adverse cardiovascular events (death, reinfarction, target-vessel revascularization for ischemia, and stroke) (NCT00433966)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Pharmacology Arm - Bivalirudin98
Pharmacology Arm - Unfractionated Heparin99

Pharmacology Arm - Major Adverse Ischemic Cardiac Events and Major Bleeding Events

Number of participants with major adverse cardiovascular events (death, reinfarction, target-vessel revascularization for ischemia, and stroke) and major bleeding (bleeding adjudicated as not related to coronary artery bypass grafting). (NCT00433966)
Timeframe: 30 Days

InterventionParticipants (Count of Participants)
Pharmacology Arm - Bivalirudin166
Pharmacology Arm - Unfractionated Heparin218

Pharmacology Arm - Non-Coronary Artery Bypass Grafting-Related Major Bleeding

Number of participants with major bleeding (bleeding adjudicated as not related to coronary artery bypass grafting) (NCT00433966)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Pharmacology Arm - Bivalirudin89
Pharmacology Arm - Unfractionated Heparin149

Stent Arm - Death, Reinfarction, Stroke, or Stent Thrombosis

Number of Participants With Death, Reinfarction, Stroke, or Stent Thrombosis (NCT00433966)
Timeframe: 1 year

InterventionParticipants (Count of Participants)
Stent Arm - Paclitaxel-Eluting Stent181
Stent Arm - Bare Metal Stent59

Stent Arm - Ischemic Target Lesion Revascularization

Number of Participants With Ischemic Target Lesion Revascularization (NCT00433966)
Timeframe: 1 year

InterventionParticipants (Count of Participants)
Stent Arm - Paclitaxel-Eluting Stent98
Stent Arm - Bare Metal Stent54

Stent Arm - Segment Binary Angiographic Restenosis

Number of Participants With Segment Binary Angiographic Restenosis (13-month Angiographic Subset). (NCT00433966)
Timeframe: 13 months

InterventionParticipants (Count of Participants)
Stent Arm - Paclitaxel-Eluting Stent102
Stent Arm - Bare Metal Stent76

Number of Participants With BARC Type 2, 3, or 5

Number of participants with first occurrence of clinically relevant bleeding episode, defined as Bleeding Academic Research Consortium (BARC) Types 2, 3 or 5 bleeding. BARC bleeding types range from 0 (no bleeding) to 5 (fatal bleeding). (NCT02270242)
Timeframe: 12 months after randomization

InterventionParticipants (Count of Participants)
Placebo + Ticagrelor141
Aspirin + Ticagrelor250

Number of Participants With Ischemic Episode

Number of participants with first occurrence of confirmed all-cause death, non-fatal myocardial infarction or stroke. (NCT02270242)
Timeframe: 12 months after randomization

InterventionParticipants (Count of Participants)
Placebo + Ticagrelor135
Aspirin + Ticagrelor137

Differences in Costs Between Two Revascularization Strategies for de Novo Coronary Lesions.

Overall costs expressed in US dollars at 18 months of follow up between Oral Sirolimus Plus BMS vs DES implantation in denovo coronary lesions. (NCT00552669)
Timeframe: Follow up will be conducted by the coordinating Center at 18 months of follow up

InterventionUS dollars (Mean)
Oral Sirolimus + Bare Metal Stent5483
Drug Eluting Stents7658.2

Target Vessel Revascularization (TVR)

Efficacy end point was TVR as revasacularization of the treated vessel. (NCT00552669)
Timeframe: 18 months

Interventionvessels (Number)
Oral Sirolimus + Bare Metal Stent14
Drug Eluting Stents15

Major Adverse Cardiovascular Events (MACCE)

Death from any cause, myocardial infarction and stroke. Safety was analyzed as MACCE (major adverse cardiovascular events) including death, MI and stroke. (NCT00552669)
Timeframe: 18 Months

,
Interventionparticipants (Number)
MACCEDeathAcute Myocardial InfarctionStroke
Drug Eluting Stents15791
Oral Sirolimus + Bare Metal Stent9360

Percent Stent Coverage

Assessment of vascular healing 6 months after Resolute Integrity placement in non-diabetic patients and patients with non-insulin dependent diabetes presenting with acute coronary syndrome (ACS) using optical frequency domain imaging (OFDI). Vascular healing will be measured by percent covered stents as determined by OFDI. A higher percentage of stent coverage indicates increased endothelial regrowth, which is an essential component for the maintenance of long-term luminal patency. (NCT01794949)
Timeframe: 6 months

,
InterventionParticipants (Count of Participants)
85% up to 90% stent coverage90% up to 95% stent coverage95% or greater percent stent coverage
NIDDM Patients Receiving the Resolute Stent010
Non-diabetic Patients Receiving the Resolute Stent131

Reviews

85 reviews available for ticlopidine and Coronary Thrombosis

ArticleYear
Individualized dual antiplatelet therapy based on platelet function testing in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials.
    BMC cardiovascular disorders, 2017, 06-15, Volume: 17, Issue:1

    Topics: Acute Coronary Syndrome; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Thrombosis;

2017
Risk of Early Adverse Events After Clopidogrel Discontinuation in Patients Undergoing Short-Term Dual Antiplatelet Therapy: An Individual Participant Data Analysis.
    JACC. Cardiovascular interventions, 2017, 08-28, Volume: 10, Issue:16

    Topics: Aged; Aspirin; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; Drug Administration Schedule;

2017
Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: a meta-analysis based on 23,035 subjects.
    Archives of cardiovascular diseases, 2013, Volume: 106, Issue:10

    Topics: Aryl Hydrocarbon Hydroxylases; Chi-Square Distribution; Clopidogrel; Coronary Thrombosis; Cytochrome

2013
Long-term clinical efficacy and safety of adding cilostazol to dual antiplatelet therapy for patients undergoing PCI: a meta-analysis of randomized trials with adjusted indirect comparisons.
    Current medical research and opinion, 2014, Volume: 30, Issue:1

    Topics: Aspirin; Cilostazol; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Hemorrhage; Humans

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death,

2014
New antiplatelet agents in the treatment of acute coronary syndromes.
    Archives of cardiovascular diseases, 2014, Volume: 107, Issue:3

    Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Clinical Trials as Topic; Clopidogrel;

2014
How to improve the concept of individualised antiplatelet therapy with P2Y12 receptor inhibitors--is an algorithm the answer?
    Thrombosis and haemostasis, 2015, Volume: 113, Issue:1

    Topics: Algorithms; Animals; Blood Platelets; Clopidogrel; Coronary Thrombosis; Decision Support Techniques;

2015
Ticagrelor: a safe and effective approach for overcoming clopidogrel resistance in patients with stent thrombosis?
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2016, Volume: 27, Issue:2

    Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Co

2016
Optimal P2Y12 Inhibitor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Network Meta-Analysis.
    JACC. Cardiovascular interventions, 2016, 05-23, Volume: 9, Issue:10

    Topics: Adenosine; Antithrombins; Bayes Theorem; Blood Platelets; Clinical Trials as Topic; Clopidogrel; Cor

2016
Antiplatelet treatment of cardiovascular disease: a translational research perspective.
    Polskie Archiwum Medycyny Wewnetrznej, 2008, Volume: 118, Issue:5

    Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Resistance; Humans; Platele

2008
Coronary artery stents: II. Perioperative considerations and management.
    Anesthesia and analgesia, 2008, Volume: 107, Issue:2

    Topics: Anesthesia, Conduction; Angioplasty, Balloon, Coronary; Aspirin; Blood Loss, Surgical; Clopidogrel;

2008
Impact of pretreatment with clopidogrel on initial patency and outcome in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a systematic review.
    Circulation, 2008, Oct-28, Volume: 118, Issue:18

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Coronary Thrombosis; Electro

2008
Emergence of the concept of platelet reactivity monitoring of response to thienopyridines.
    Heart (British Cardiac Society), 2009, Volume: 95, Issue:15

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Drug Resistance; Humans; Platelet

2009
[Resistance to desaggregants: causes, clinical implication, methods of diagnosis and correction].
    Terapevticheskii arkhiv, 2008, Volume: 80, Issue:12

    Topics: Aspirin; Clopidogrel; Coronary Thrombosis; Dose-Response Relationship, Drug; Drug Resistance; Drug T

2008
Diabetes mellitus: a prothrombotic state implications for outcomes after coronary revascularization.
    Vascular health and risk management, 2009, Volume: 5, Issue:1

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Angiography; C

2009
Improving outcomes in patients undergoing percutaneous coronary intervention: role of prasugrel.
    Vascular health and risk management, 2009, Volume: 5, Issue:1

    Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Thrombosis; Dia

2009
[Clopidogrel resistance].
    Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology, 2009, Volume: 9, Issue:3

    Topics: Aspirin; Clopidogrel; Coronary Thrombosis; Drug Resistance; Drug Therapy, Combination; Humans; Plate

2009
Coronary stent thrombosis in patients with chronic renal insufficiency.
    Angiology, 2010, Volume: 61, Issue:3

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Huma

2010
Combined mechanical and pharmacological approach to a thrombus-containing lesion.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2010, May-01, Volume: 75, Issue:6

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Coronary Angiography; Corona

2010
[Discontinuation of treatment with platelet aggregation inhibitors in surgical patients with cardiac stents].
    Ugeskrift for laeger, 2010, Mar-15, Volume: 172, Issue:11

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Loss, Surgical; Clopidogrel; Coronary Thrombosis; Dru

2010
New antithrombotic agents--insights from clinical trials.
    Nature reviews. Cardiology, 2010, Volume: 7, Issue:9

    Topics: Adenosine; Anticoagulants; Aspirin; Clopidogrel; Coronary Thrombosis; Coumarins; Fibrinolytic Agents

2010
Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis.
    Journal of the American College of Cardiology, 2010, Jul-06, Volume: 56, Issue:2

    Topics: Alleles; Clopidogrel; Coronary Thrombosis; Cytochrome P-450 Enzyme System; Humans; Myocardial Ischem

2010
Prevention of the renarrowing of coronary arteries using drug-eluting stents in the perioperative period: an update.
    Vascular health and risk management, 2010, Oct-05, Volume: 6

    Topics: Aspirin; Blood Loss, Surgical; Clopidogrel; Coronary Thrombosis; Coronary Vessels; Drug-Eluting Sten

2010
Prasugrel for the treatment of coronary thrombosis: a review of pharmacological properties, indications for use and future development.
    Expert opinion on investigational drugs, 2011, Volume: 20, Issue:1

    Topics: Animals; Clopidogrel; Coronary Thrombosis; Humans; Piperazines; Platelet Aggregation Inhibitors; Pra

2011
Platelet function testing in clinical diagnostics.
    Hamostaseologie, 2011, May-02, Volume: 31, Issue:2

    Topics: Aspirin; Clopidogrel; Coronary Thrombosis; Hemorrhage; Humans; Intracranial Embolism; Intracranial T

2011
[New approaches and indications for the analysis of platelet function in cardiology].
    Hamostaseologie, 2011, May-02, Volume: 31, Issue:2

    Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Coronary Thrombos

2011
Proton pump inhibitors, genetic polymorphisms and response to clopidogrel therapy.
    Thrombosis and haemostasis, 2011, Volume: 105, Issue:6

    Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Blood Vessel Prosthesis Implantation; Clopid

2011
Platelet-mediated thrombosis and drug-eluting stents.
    Circulation. Cardiovascular interventions, 2011, Dec-01, Volume: 4, Issue:6

    Topics: Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Equipment Design; Humans; Piperazines; Platel

2011
Switching antiplatelet regimens: alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI: a review of the literature and practical considerations for the interventional cardiologist.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2013, Volume: 81, Issue:2

    Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Interactions; Dr

2013
Pharmacogenetics of clopidogrel.
    Current pharmaceutical design, 2012, Volume: 18, Issue:33

    Topics: Aryl Hydrocarbon Hydroxylases; Biotransformation; Blood Platelets; Clopidogrel; Coronary Thrombosis;

2012
Tailoring antiplatelet therapy: a step toward individualized therapy to improve clinical outcome?
    Current pharmaceutical design, 2012, Volume: 18, Issue:33

    Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Blood Platelets; Clopidogrel; Coronary Thrombosis; Drug

2012
Clinical impact of genetically determined platelet reactivity.
    Journal of cardiovascular translational research, 2013, Volume: 6, Issue:3

    Topics: Animals; Aryl Hydrocarbon Hydroxylases; Biotransformation; Blood Platelets; Clopidogrel; Coronary Th

2013
The discovery of a new class of synaptic transmitters in smooth muscle 50 years ago and amelioration of coronary artery thrombosis.
    Acta physiologica (Oxford, England), 2013, Volume: 207, Issue:2

    Topics: Adenosine; Animals; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; History, 20th Century

2013
Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
    Thrombosis and haemostasis, 2013, Volume: 109, Issue:1

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Thrombosis; Female; Humans; Intracra

2013
Preventing thrombosis: update of first-line therapy in the management of non-ST segment elevation acute coronary syndromes.
    The Canadian journal of cardiology, 2002, Volume: 18, Issue:11

    Topics: Acute Disease; Algorithms; Clopidogrel; Coronary Disease; Coronary Thrombosis; Enoxaparin; Fibrinoly

2002
Short- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention.
    Journal of the American College of Cardiology, 2003, Feb-19, Volume: 41, Issue:4 Suppl S

    Topics: Acute Disease; Administration, Oral; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clop

2003
[Stent thrombosis in patients with myocardial infarction].
    Kardiologiia, 2003, Volume: 43, Issue:2

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Coronary Thrombosis; Fibrinolytic Age

2003
[Treatment of ischemic heart disease with the platelet aggregation inhibitor clopidogrel].
    Ugeskrift for laeger, 2004, Apr-26, Volume: 166, Issue:18

    Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Therapy, Combination; Humans; Myoc

2004
Combined antithrombotic therapy for acute coronary syndrome.
    Seminars in vascular medicine, 2003, Volume: 3, Issue:2

    Topics: Administration, Oral; Angina, Unstable; Anticoagulants; Aspirin; Clopidogrel; Coronary Thrombosis; D

2003
Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
    Chest, 2004, Volume: 126, Issue:3 Suppl

    Topics: Antithrombins; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary Artery D

2004
Cilostazol, clopidogrel or ticlopidine to prevent sub-acute stent thrombosis: a meta-analysis of randomized trials.
    American heart journal, 2004, Volume: 148, Issue:6

    Topics: Anticoagulants; Aspirin; Cilostazol; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Hu

2004
What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention?: a meta-analysis.
    Journal of the American College of Cardiology, 2005, Mar-15, Volume: 45, Issue:6

    Topics: Aged; Angioplasty, Balloon, Coronary; Antineoplastic Agents, Phytogenic; Aspirin; Blood Vessel Prost

2005
Platelet inhibition in percutaneous coronary interventions.
    Herz, 2005, Volume: 30, Issue:3

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Thrombosis; Humans; Platelet Aggregat

2005
Therapeutic approaches in arterial thrombosis.
    Journal of thrombosis and haemostasis : JTH, 2005, Volume: 3, Issue:8

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Atherosclerosis; Blood Pl

2005
[Place of ticlopidine in antiplatelet treatment].
    Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2005, Volume: 19, Issue:110

    Topics: Animals; Cardiovascular Diseases; Coronary Thrombosis; Humans; Platelet Aggregation Inhibitors; Ticl

2005
[Cardiological (pharmaco)therapy and dental practice].
    Nederlands tijdschrift voor tandheelkunde, 2006, Volume: 113, Issue:2

    Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Thrombosis; Defibrillators, Implantable; Hea

2006
Multiple coronary thrombosis and stent implantation to the subtotally occluded right renal artery in a patient with essential thrombocytosis: a case report with review.
    Journal of thrombosis and thrombolysis, 2006, Volume: 22, Issue:1

    Topics: Angina, Unstable; Angioplasty; Clopidogrel; Coronary Thrombosis; Female; Humans; Hypertension; Middl

2006
Drug insight: Clopidogrel nonresponsiveness.
    Nature clinical practice. Cardiovascular medicine, 2006, Volume: 3, Issue:7

    Topics: Clopidogrel; Coronary Thrombosis; Drug Resistance; Humans; Platelet Aggregation; Platelet Aggregatio

2006
[Pathogenesis and therapy of the acute coronary syndrome: differentiated advantage of glycoprotein IIb/IIIa receptor antagonists for high-risk patients].
    Deutsche medizinische Wochenschrift (1946), 2006, Nov-24, Volume: 131, Issue:47 Suppl 7

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Coronary Thrombosis; Diabetes Complic

2006
[Antiplatelet agents--problem for cardiac surgeon].
    Kardiologia polska, 2006, Volume: 64, Issue:11

    Topics: Anticoagulants; Aspirin; Coronary Thrombosis; Dipyridamole; Fibrinolytic Agents; Humans; Myocardial

2006
Platelet P2 receptors: old and new targets for antithrombotic drugs.
    Expert review of cardiovascular therapy, 2007, Volume: 5, Issue:1

    Topics: Adenosine; Adenosine Monophosphate; Angina, Unstable; Animals; Blood Platelets; Clopidogrel; Coronar

2007
[Antiplatelet drugs and intraoperative hemorrhage].
    Revue medicale suisse, 2006, Nov-22, Volume: 2, Issue:88

    Topics: Algorithms; Aspirin; Blood Loss, Surgical; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combinati

2006
Oral antiplatelet therapy for percutaneous coronary revascularization.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2007, Apr-01, Volume: 69, Issue:5

    Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therap

2007
Role of clopidogrel in managing atherothrombotic cardiovascular disease.
    Annals of internal medicine, 2007, Mar-20, Volume: 146, Issue:6

    Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Administration Schedule; Dr

2007
[Stents in interventional cardiology].
    Medicina (Kaunas, Lithuania), 2007, Volume: 43, Issue:3

    Topics: Aged; Angioplasty, Balloon, Coronary; Anti-Bacterial Agents; Anti-Inflammatory Agents; Aspirin; Clop

2007
Clopidogrel resistance--the cardiologist's perspective.
    Platelets, 2007, Volume: 18, Issue:3

    Topics: Blood Platelets; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Resistance; Humans; Platel

2007
[Very late intrastent thrombosis--at 27 months!].
    Archives des maladies du coeur et des vaisseaux, 2007, Volume: 100, Issue:3

    Topics: Aspirin; Clopidogrel; Coronary Thrombosis; Fatal Outcome; Flurbiprofen; Follow-Up Studies; Hernia, I

2007
[Dual platelet aggregation inhibition in coronary artery stent implantation--what is evidence-based?].
    Deutsche medizinische Wochenschrift (1946), 2007, Jun-08, Volume: 132, Issue:23

    Topics: Aspirin; Clopidogrel; Coronary Thrombosis; Coronary Vessels; Drug Therapy, Combination; Evidence-Bas

2007
Contemporary use of clopidogrel in patients with coronary artery disease.
    Current cardiology reports, 2007, Volume: 9, Issue:4

    Topics: Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Coro

2007
Perioperative use of anti-platelet drugs.
    Best practice & research. Clinical anaesthesiology, 2007, Volume: 21, Issue:2

    Topics: Aspirin; Clopidogrel; Coronary Thrombosis; Elective Surgical Procedures; Hemorrhage; Humans; Periope

2007
[Management coronary syndrome in the acute phase].
    Annales de cardiologie et d'angeiologie, 2007, Volume: 56 Suppl 1

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Clopidog

2007
Antithrombotic therapy and the transition to the catheterization laboratory in UA/NSTEMI.
    Minerva cardioangiologica, 2007, Volume: 55, Issue:5

    Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Th

2007
Aspirin and clopidogrel resistance.
    Hematology. American Society of Hematology. Education Program, 2007

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Clopidogrel; Coronary Thrombosis;

2007
[Late coronary stent thrombosis and clopidogrel].
    Vnitrni lekarstvi, 2007, Volume: 53, Issue:10

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Humans; Plate

2007
Increased incidence of in-stent thrombosis related to cocaine use: case series and review of literature.
    Journal of cardiovascular pharmacology and therapeutics, 2007, Volume: 12, Issue:4

    Topics: Adult; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Cocaine; Cocaine-Related Disorders; Cor

2007
[Clopidogrel and statins or once more on the danger of direct transfer of results of experimental studies in clinical practice].
    Kardiologiia, 2008, Volume: 48, Issue:2

    Topics: Atorvastatin; Clopidogrel; Coronary Thrombosis; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans;

2008
[Antiplatelet therapy during coronary endoprosthesis placement].
    Archives des maladies du coeur et des vaisseaux, 1996, Volume: 89, Issue:11 Suppl

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Disease; Coronary Thrombosis; Drug Therapy, Combin

1996
Ticlopidine and aspirin therapy following implantation of coronary artery stents.
    The Annals of pharmacotherapy, 1997, Volume: 31, Issue:6

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Coronary Disease; Coronary Thromb

1997
[Pharmacology of ticlopidine and clopidogrel in comparison with acetylsalicylic acid].
    Der Internist, 1997, Volume: 38, Issue:11

    Topics: Aspirin; Cerebrovascular Disorders; Clopidogrel; Coronary Thrombosis; Death, Sudden, Cardiac; Humans

1997
Beyond aspirin.
    Harvard heart letter : from Harvard Medical School, 1998, Volume: 8, Issue:10

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Thrombosis; Humans; Myocardial Infarc

1998
Clopidogrel with aspirin is the optimal antiplatelet regimen for intracoronary stenting.
    Journal of thrombosis and thrombolysis, 1999, Volume: 7, Issue:3

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Co

1999
Aspirin and ticlopidine after routine coronary stenting: the gold standard as of 1999.
    Journal of thrombosis and thrombolysis, 1999, Volume: 7, Issue:3

    Topics: Anemia, Aplastic; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Clopidogrel; Co

1999
Future directions in thrombolysis.
    Clinical cardiology, 1999, Volume: 22, Issue:8 Suppl

    Topics: Clopidogrel; Coronary Disease; Coronary Thrombosis; Cyclooxygenase 2; Enzyme Inhibitors; Fibrinolyti

1999
Thrombotic thrombocytopenic purpura associated with ticlopidine in the setting of coronary artery stents and stroke prevention.
    Archives of internal medicine, 1999, Nov-22, Volume: 159, Issue:21

    Topics: Coronary Thrombosis; Humans; Platelet Aggregation Inhibitors; Purpura, Thrombotic Thrombocytopenic;

1999
Use of clopidrogel in coronary stenting: what was the question?
    Journal of the American College of Cardiology, 1999, Volume: 34, Issue:7

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Humans; Plat

1999
[Acute complications of coronary angioplasty: prevention and management].
    Archives des maladies du coeur et des vaisseaux, 1999, Volume: 92, Issue:11 Suppl

    Topics: Angioplasty, Balloon, Coronary; Coronary Artery Bypass; Coronary Disease; Coronary Thrombosis; Human

1999
Treatment of unstable angina: the role of platelet inhibitors and anticoagulants.
    The Journal of invasive cardiology, 1999, Volume: 11, Issue:3

    Topics: Abciximab; Angina, Unstable; Antibodies, Monoclonal; Anticoagulants; Clopidogrel; Coronary Thrombosi

1999
Antiplatelet agents in cardiology: the choice of therapy.
    The Annals of thoracic surgery, 2000, Volume: 70, Issue:2 Suppl

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Humans;

2000
The thienopyridines in coronary artery disease.
    Current cardiology reports, 1999, Volume: 1, Issue:3

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Humans;

1999
Antiplatelet medications and their indications in preventing and treating coronary thrombosis.
    Annals of medicine, 2000, Volume: 32, Issue:8

    Topics: Aspirin; Clopidogrel; Coronary Thrombosis; Humans; Platelet Aggregation Inhibitors; Platelet Glycopr

2000
Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials.
    Circulation, 2001, Apr-17, Volume: 103, Issue:15

    Topics: Aspirin; Blood Vessel Prosthesis Implantation; Causality; Coronary Disease; Coronary Thrombosis; End

2001
Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials.
    Circulation, 2001, Apr-17, Volume: 103, Issue:15

    Topics: Aspirin; Blood Vessel Prosthesis Implantation; Causality; Coronary Disease; Coronary Thrombosis; End

2001
Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials.
    Circulation, 2001, Apr-17, Volume: 103, Issue:15

    Topics: Aspirin; Blood Vessel Prosthesis Implantation; Causality; Coronary Disease; Coronary Thrombosis; End

2001
Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials.
    Circulation, 2001, Apr-17, Volume: 103, Issue:15

    Topics: Aspirin; Blood Vessel Prosthesis Implantation; Causality; Coronary Disease; Coronary Thrombosis; End

2001
Ticlopidine versus oral anticoagulation for coronary stenting.
    The Cochrane database of systematic reviews, 2001, Issue:4

    Topics: Administration, Oral; Anticoagulants; Aspirin; Coronary Thrombosis; Drug Therapy, Combination; Fibri

2001
Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting.
    Journal of the American College of Cardiology, 2002, Jan-02, Volume: 39, Issue:1

    Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Therapy, Combination; Humans; Odds

2002
Persistence of the prothrombotic state after acute coronary syndromes: implications for treatment.
    American heart journal, 2002, Volume: 143, Issue:2

    Topics: Angina, Unstable; Aspirin; Clopidogrel; Coronary Thrombosis; Heparin, Low-Molecular-Weight; Humans;

2002
Clinical pharmacology of bivalirudin.
    Pharmacotherapy, 2002, Volume: 22, Issue:6 Pt 2

    Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Antithrombins; Clinical Trials as

2002

Trials

92 trials available for ticlopidine and Coronary Thrombosis

ArticleYear
Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study.
    JACC. Cardiovascular interventions, 2017, 05-08, Volume: 10, Issue:9

    Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Double-Blind Method; Drug

2017
6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin: Final Results of the ITALIC Trial (Is There a Life for DES After Discontinuation of Clopidogrel).
    JACC. Cardiovascular interventions, 2017, 06-26, Volume: 10, Issue:12

    Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Administration Schedu

2017
Validation of the DAPT score in patients randomized to 6 or 12 months clopidogrel after predominantly second-generation drug-eluting stents.
    Thrombosis and haemostasis, 2017, 10-05, Volume: 117, Issue:10

    Topics: Aged; Aspirin; Clinical Decision-Making; Clopidogrel; Coronary Disease; Coronary Thrombosis; Decisio

2017
Antithrombotic potency of ticagrelor versus clopidogrel in type-2 diabetic patients with cardiovascular disease.
    Thrombosis and haemostasis, 2017, 10-05, Volume: 117, Issue:10

    Topics: Adenosine; Aged; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Coronary Thrombosis; Cross-O

2017
Double-Dose Versus Standard-Dose Clopidogrel According to Smoking Status Among Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention.
    Journal of the American Heart Association, 2017, Nov-03, Volume: 6, Issue:11

    Topics: Acute Coronary Syndrome; Aged; Chi-Square Distribution; Clopidogrel; Coronary Thrombosis; Female; He

2017
Telephone contact to improve adherence to dual antiplatelet therapy after drug-eluting stent implantation.
    Heart (British Cardiac Society), 2013, Volume: 99, Issue:8

    Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Counseling; Drug Prescriptions; Drug Therapy, Combi

2013
Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes).
    JACC. Cardiovascular interventions, 2013, Volume: 6, Issue:7

    Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aged; Clopidogrel; Coronary Angiography; C

2013
Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial.
    Circulation, 2013, Sep-03, Volume: 128, Issue:10

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Thrombosis; Double-Blind Method; Fem

2013
Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial.
    Circulation, 2013, Sep-03, Volume: 128, Issue:10

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Thrombosis; Double-Blind Method; Fem

2013
Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial.
    Circulation, 2013, Sep-03, Volume: 128, Issue:10

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Thrombosis; Double-Blind Method; Fem

2013
Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial.
    Circulation, 2013, Sep-03, Volume: 128, Issue:10

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Thrombosis; Double-Blind Method; Fem

2013
Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial.
    Circulation, 2013, Sep-03, Volume: 128, Issue:10

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Thrombosis; Double-Blind Method; Fem

2013
Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial.
    Circulation, 2013, Sep-03, Volume: 128, Issue:10

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Thrombosis; Double-Blind Method; Fem

2013
Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial.
    Circulation, 2013, Sep-03, Volume: 128, Issue:10

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Thrombosis; Double-Blind Method; Fem

2013
Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial.
    Circulation, 2013, Sep-03, Volume: 128, Issue:10

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Thrombosis; Double-Blind Method; Fem

2013
Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial.
    Circulation, 2013, Sep-03, Volume: 128, Issue:10

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Thrombosis; Double-Blind Method; Fem

2013
Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-plate
    JACC. Cardiovascular interventions, 2013, Volume: 6, Issue:9

    Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy,

2013
Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment
    JACC. Cardiovascular interventions, 2014, Volume: 7, Issue:1

    Topics: Aged, 80 and over; Chi-Square Distribution; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; D

2014
Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment
    JACC. Cardiovascular interventions, 2014, Volume: 7, Issue:1

    Topics: Aged, 80 and over; Chi-Square Distribution; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; D

2014
Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment
    JACC. Cardiovascular interventions, 2014, Volume: 7, Issue:1

    Topics: Aged, 80 and over; Chi-Square Distribution; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; D

2014
Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment
    JACC. Cardiovascular interventions, 2014, Volume: 7, Issue:1

    Topics: Aged, 80 and over; Chi-Square Distribution; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; D

2014
Clinical implications and correlates of Q waves in patients with ST-elevation myocardial infarction treated with fibrinolysis: observations from the CLARITY-TIMI 28 trial.
    Clinical cardiology, 2014, Volume: 37, Issue:3

    Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Circulation; Coronary Thrombosis; Creatin

2014
Coronary artery bypass grafting-related bleeding complications in real-life acute coronary syndrome patients treated with clopidogrel or ticagrelor.
    European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 2014, Volume: 46, Issue:4

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Artery Bypass; Coronary Thrombosis;

2014
Modifying effect of dual antiplatelet therapy on incidence of stent thrombosis according to implanted drug-eluting stent type.
    European heart journal, 2014, Aug-01, Volume: 35, Issue:29

    Topics: Aspirin; Blood Vessel Prosthesis; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; Drug-Elutin

2014
High clopidogrel dose in patients with chronic kidney disease having clopidogrel resistance after percutaneous coronary intervention.
    Angiology, 2015, Volume: 66, Issue:4

    Topics: Aged; China; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Administration Schedule

2015
Platelet reactivity and cardiovascular events after percutaneous coronary intervention in patients with stable coronary artery disease: the Stent Thrombosis In Belgium (STIB) trial.
    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2014, Volume: 10, Issue:2

    Topics: Aged; Angina, Stable; Aspirin; Belgium; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coron

2014
Tradeoff between bleeding and stent thrombosis in different dual antiplatelet therapy regimes: Importance of case fatality rates and effective treatment durations.
    American heart journal, 2014, Volume: 168, Issue:5

    Topics: Aged; Angina Pectoris; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Drug-El

2014
Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]).
    JACC. Cardiovascular interventions, 2015, Volume: 8, Issue:3

    Topics: Adenosine Monophosphate; Aged; Anticoagulants; Chi-Square Distribution; Clopidogrel; Coronary Artery

2015
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
    Circulation. Cardiovascular interventions, 2015, Volume: 8, Issue:5

    Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus;

2015
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
    Circulation. Cardiovascular interventions, 2015, Volume: 8, Issue:5

    Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus;

2015
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
    Circulation. Cardiovascular interventions, 2015, Volume: 8, Issue:5

    Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus;

2015
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
    Circulation. Cardiovascular interventions, 2015, Volume: 8, Issue:5

    Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus;

2015
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
    Circulation. Cardiovascular interventions, 2015, Volume: 8, Issue:5

    Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus;

2015
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
    Circulation. Cardiovascular interventions, 2015, Volume: 8, Issue:5

    Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus;

2015
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
    Circulation. Cardiovascular interventions, 2015, Volume: 8, Issue:5

    Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus;

2015
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
    Circulation. Cardiovascular interventions, 2015, Volume: 8, Issue:5

    Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus;

2015
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
    Circulation. Cardiovascular interventions, 2015, Volume: 8, Issue:5

    Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus;

2015
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
    Circulation. Cardiovascular interventions, 2015, Volume: 8, Issue:5

    Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus;

2015
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
    Circulation. Cardiovascular interventions, 2015, Volume: 8, Issue:5

    Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus;

2015
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
    Circulation. Cardiovascular interventions, 2015, Volume: 8, Issue:5

    Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus;

2015
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
    Circulation. Cardiovascular interventions, 2015, Volume: 8, Issue:5

    Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus;

2015
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
    Circulation. Cardiovascular interventions, 2015, Volume: 8, Issue:5

    Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus;

2015
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
    Circulation. Cardiovascular interventions, 2015, Volume: 8, Issue:5

    Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus;

2015
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
    Circulation. Cardiovascular interventions, 2015, Volume: 8, Issue:5

    Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus;

2015
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
    Circulation. Cardiovascular interventions, 2015, Volume: 8, Issue:5

    Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus;

2015
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
    Circulation. Cardiovascular interventions, 2015, Volume: 8, Issue:5

    Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus;

2015
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
    Circulation. Cardiovascular interventions, 2015, Volume: 8, Issue:5

    Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus;

2015
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
    Circulation. Cardiovascular interventions, 2015, Volume: 8, Issue:5

    Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus;

2015
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
    Circulation. Cardiovascular interventions, 2015, Volume: 8, Issue:5

    Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus;

2015
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
    Circulation. Cardiovascular interventions, 2015, Volume: 8, Issue:5

    Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus;

2015
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
    Circulation. Cardiovascular interventions, 2015, Volume: 8, Issue:5

    Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus;

2015
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
    Circulation. Cardiovascular interventions, 2015, Volume: 8, Issue:5

    Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus;

2015
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
    Circulation. Cardiovascular interventions, 2015, Volume: 8, Issue:5

    Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus;

2015
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
    Circulation. Cardiovascular interventions, 2015, Volume: 8, Issue:5

    Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus;

2015
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
    Circulation. Cardiovascular interventions, 2015, Volume: 8, Issue:5

    Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus;

2015
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
    Circulation. Cardiovascular interventions, 2015, Volume: 8, Issue:5

    Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus;

2015
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
    Circulation. Cardiovascular interventions, 2015, Volume: 8, Issue:5

    Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus;

2015
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
    Circulation. Cardiovascular interventions, 2015, Volume: 8, Issue:5

    Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus;

2015
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
    Circulation. Cardiovascular interventions, 2015, Volume: 8, Issue:5

    Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus;

2015
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
    Circulation. Cardiovascular interventions, 2015, Volume: 8, Issue:5

    Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus;

2015
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
    Circulation. Cardiovascular interventions, 2015, Volume: 8, Issue:5

    Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus;

2015
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
    Circulation. Cardiovascular interventions, 2015, Volume: 8, Issue:5

    Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus;

2015
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
    Circulation. Cardiovascular interventions, 2015, Volume: 8, Issue:5

    Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus;

2015
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
    Circulation. Cardiovascular interventions, 2015, Volume: 8, Issue:5

    Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus;

2015
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
    Circulation. Cardiovascular interventions, 2015, Volume: 8, Issue:5

    Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus;

2015
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
    Circulation. Cardiovascular interventions, 2015, Volume: 8, Issue:5

    Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus;

2015
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
    Circulation. Cardiovascular interventions, 2015, Volume: 8, Issue:5

    Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus;

2015
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
    Circulation. Cardiovascular interventions, 2015, Volume: 8, Issue:5

    Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus;

2015
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
    Circulation. Cardiovascular interventions, 2015, Volume: 8, Issue:5

    Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus;

2015
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
    Circulation. Cardiovascular interventions, 2015, Volume: 8, Issue:5

    Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus;

2015
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
    Circulation. Cardiovascular interventions, 2015, Volume: 8, Issue:5

    Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus;

2015
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
    Circulation. Cardiovascular interventions, 2015, Volume: 8, Issue:5

    Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus;

2015
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
    Circulation. Cardiovascular interventions, 2015, Volume: 8, Issue:5

    Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus;

2015
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
    Circulation. Cardiovascular interventions, 2015, Volume: 8, Issue:5

    Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus;

2015
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
    Circulation. Cardiovascular interventions, 2015, Volume: 8, Issue:5

    Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus;

2015
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
    Circulation. Cardiovascular interventions, 2015, Volume: 8, Issue:5

    Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus;

2015
Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
    Circulation. Cardiovascular interventions, 2015, Volume: 8, Issue:5

    Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Combinations; Drug-Eluting Stents; Everolimus;

2015
Prasugrel in Clopidogrel Nonresponders Undergoing Percutaneous Coronary Intervention: The RECLOSE-3 Study (REsponsiveness to CLOpidogrel and StEnt Thrombosis).
    JACC. Cardiovascular interventions, 2015, Volume: 8, Issue:12

    Topics: Aged; Aged, 80 and over; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thr

2015
The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX.
    European heart journal, 2016, Apr-07, Volume: 37, Issue:14

    Topics: Adenosine Monophosphate; Aged; Clopidogrel; Coronary Thrombosis; Double-Blind Method; Female; Femora

2016
Assessment of Ticagrelor Versus Clopidogrel Treatment in Patients With ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
    Journal of cardiovascular pharmacology, 2016, Volume: 68, Issue:2

    Topics: Adenosine; Aged; Chi-Square Distribution; China; Clopidogrel; Coronary Thrombosis; Drug Therapy, Com

2016
Role of stent type and of duration of dual antiplatelet therapy in patients with chronic kidney disease undergoing percutaneous coronary interventions. Is bare metal stent implantation still a justifiable choice? A post-hoc analysis of the all comer PRODI
    International journal of cardiology, 2016, Jun-01, Volume: 212

    Topics: Aged; Aged, 80 and over; Aspirin; Clinical Decision-Making; Clopidogrel; Coronary Thrombosis; Drug T

2016
6-Month Versus 12-Month Dual-Antiplatelet Therapy Following Long Everolimus-Eluting Stent Implantation: The IVUS-XPL Randomized Clinical Trial.
    JACC. Cardiovascular interventions, 2016, 07-25, Volume: 9, Issue:14

    Topics: Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Thrombosis; Drug Administration Schedule; Drug

2016
Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial.
    Circulation. Cardiovascular interventions, 2016, Volume: 9, Issue:6

    Topics: Adenosine Monophosphate; Aged; Brazil; Chi-Square Distribution; Clopidogrel; Coronary Thrombosis; Do

2016
Impact of Sex on 2-Year Clinical Outcomes in Patients Treated With 6-Month or 24-Month Dual-Antiplatelet Therapy Duration: A Pre-Specified Analysis From the PRODIGY Trial.
    JACC. Cardiovascular interventions, 2016, 09-12, Volume: 9, Issue:17

    Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; C

2016
Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial.
    JACC. Cardiovascular interventions, 2016, 09-26, Volume: 9, Issue:18

    Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Aged; Angina, Stable; Chi-Square Distribution; Clo

2016
Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy).
    Circulation, 2017, May-02, Volume: 135, Issue:18

    Topics: Acute Coronary Syndrome; Aged; Angina, Stable; Aspirin; Clopidogrel; Coronary Thrombosis; Double-Bli

2017
Effect of 150-mg vs 300-mg loading doses of clopidogrel on platelet function in Japanese patients undergoing coronary stent placement.
    Circulation journal : official journal of the Japanese Circulation Society, 2008, Volume: 72, Issue:8

    Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Asian People; Clopidogrel; Coronary Art

2008
Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial I
    Circulation, 2008, Oct-14, Volume: 118, Issue:16

    Topics: Administration, Oral; Aged; Clopidogrel; Coronary Thrombosis; Diabetes Mellitus, Type 1; Diabetes Me

2008
Tirofiban optimizes platelet inhibition for immediate percutaneous coronary intervention in high-risk acute coronary syndromes.
    Thrombosis and haemostasis, 2008, Volume: 100, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease

2008
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
    Journal of the American College of Cardiology, 2008, Nov-11, Volume: 52, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis;

2008
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
    Journal of the American College of Cardiology, 2008, Nov-11, Volume: 52, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis;

2008
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
    Journal of the American College of Cardiology, 2008, Nov-11, Volume: 52, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis;

2008
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
    Journal of the American College of Cardiology, 2008, Nov-11, Volume: 52, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis;

2008
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
    Journal of the American College of Cardiology, 2008, Nov-11, Volume: 52, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis;

2008
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
    Journal of the American College of Cardiology, 2008, Nov-11, Volume: 52, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis;

2008
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
    Journal of the American College of Cardiology, 2008, Nov-11, Volume: 52, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis;

2008
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
    Journal of the American College of Cardiology, 2008, Nov-11, Volume: 52, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis;

2008
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
    Journal of the American College of Cardiology, 2008, Nov-11, Volume: 52, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis;

2008
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
    Journal of the American College of Cardiology, 2008, Nov-11, Volume: 52, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis;

2008
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
    Journal of the American College of Cardiology, 2008, Nov-11, Volume: 52, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis;

2008
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
    Journal of the American College of Cardiology, 2008, Nov-11, Volume: 52, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis;

2008
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
    Journal of the American College of Cardiology, 2008, Nov-11, Volume: 52, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis;

2008
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
    Journal of the American College of Cardiology, 2008, Nov-11, Volume: 52, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis;

2008
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
    Journal of the American College of Cardiology, 2008, Nov-11, Volume: 52, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis;

2008
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
    Journal of the American College of Cardiology, 2008, Nov-11, Volume: 52, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis;

2008
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
    Journal of the American College of Cardiology, 2008, Nov-11, Volume: 52, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis;

2008
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
    Journal of the American College of Cardiology, 2008, Nov-11, Volume: 52, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis;

2008
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
    Journal of the American College of Cardiology, 2008, Nov-11, Volume: 52, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis;

2008
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
    Journal of the American College of Cardiology, 2008, Nov-11, Volume: 52, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis;

2008
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
    Journal of the American College of Cardiology, 2008, Nov-11, Volume: 52, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis;

2008
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
    Journal of the American College of Cardiology, 2008, Nov-11, Volume: 52, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis;

2008
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
    Journal of the American College of Cardiology, 2008, Nov-11, Volume: 52, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis;

2008
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
    Journal of the American College of Cardiology, 2008, Nov-11, Volume: 52, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis;

2008
Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study.
    Journal of the American College of Cardiology, 2008, Nov-11, Volume: 52, Issue:20

    Topics: Aged; Angioplasty, Balloon, Coronary; Antibiotics, Antineoplastic; Clopidogrel; Coronary Restenosis;

2008
Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis.
    The American journal of cardiology, 2009, Jan-01, Volume: 103, Issue:1

    Topics: Acute Disease; Aged; Angina Pectoris; Blood Platelets; Clopidogrel; Coronary Angiography; Coronary T

2009
Temporal relation between Clopidogrel cessation and stent thrombosis after drug-eluting stent implantation.
    The American journal of cardiology, 2009, Mar-15, Volume: 103, Issue:6

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Female;

2009
Rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: The Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of 6 Months Dual
    American heart journal, 2009, Volume: 157, Issue:4

    Topics: Clopidogrel; Coronary Angiography; Coronary Restenosis; Coronary Thrombosis; Dose-Response Relations

2009
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho
    Circulation, 2009, Jun-30, Volume: 119, Issue:25

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Thera

2009
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho
    Circulation, 2009, Jun-30, Volume: 119, Issue:25

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Thera

2009
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho
    Circulation, 2009, Jun-30, Volume: 119, Issue:25

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Thera

2009
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho
    Circulation, 2009, Jun-30, Volume: 119, Issue:25

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Thera

2009
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho
    Circulation, 2009, Jun-30, Volume: 119, Issue:25

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Thera

2009
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho
    Circulation, 2009, Jun-30, Volume: 119, Issue:25

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Thera

2009
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho
    Circulation, 2009, Jun-30, Volume: 119, Issue:25

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Thera

2009
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho
    Circulation, 2009, Jun-30, Volume: 119, Issue:25

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Thera

2009
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Sho
    Circulation, 2009, Jun-30, Volume: 119, Issue:25

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Thera

2009
Marked reduction of early stent thrombosis with pre-hospital initiation of high-dose Tirofiban in ST-segment elevation myocardial infarction.
    Journal of thrombosis and haemostasis : JTH, 2009, Volume: 7, Issue:10

    Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Thrombosis; Dis

2009
Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction.
    The American journal of cardiology, 2009, Nov-15, Volume: 104, Issue:10

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Angiography; C

2009
Clopidogrel affects leukocyte dependent platelet aggregation by P2Y12 expressing leukocytes.
    Basic research in cardiology, 2010, Volume: 105, Issue:3

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thromb

2010
Urgent surgery in patients with a recently implanted coronary drug-eluting stent: a phase II study of 'bridging' antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel.
    British journal of anaesthesia, 2010, Volume: 104, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Blood Loss, Surgical; Clopidogrel; C

2010
High maintenance dosage of clopidogrel is associated with a reduced risk of stent thrombosis in clopidogrel-resistant patients.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2010, Volume: 10, Issue:1

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Dose-Resp

2010
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
    Circulation, 2010, Nov-23, Volume: 122, Issue:21

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro

2010
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
    Circulation, 2010, Nov-23, Volume: 122, Issue:21

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro

2010
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
    Circulation, 2010, Nov-23, Volume: 122, Issue:21

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro

2010
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
    Circulation, 2010, Nov-23, Volume: 122, Issue:21

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro

2010
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
    Circulation, 2010, Nov-23, Volume: 122, Issue:21

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro

2010
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
    Circulation, 2010, Nov-23, Volume: 122, Issue:21

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro

2010
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
    Circulation, 2010, Nov-23, Volume: 122, Issue:21

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro

2010
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
    Circulation, 2010, Nov-23, Volume: 122, Issue:21

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro

2010
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
    Circulation, 2010, Nov-23, Volume: 122, Issue:21

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro

2010
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
    Circulation, 2010, Nov-23, Volume: 122, Issue:21

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro

2010
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
    Circulation, 2010, Nov-23, Volume: 122, Issue:21

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro

2010
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
    Circulation, 2010, Nov-23, Volume: 122, Issue:21

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro

2010
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
    Circulation, 2010, Nov-23, Volume: 122, Issue:21

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro

2010
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
    Circulation, 2010, Nov-23, Volume: 122, Issue:21

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro

2010
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
    Circulation, 2010, Nov-23, Volume: 122, Issue:21

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro

2010
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
    Circulation, 2010, Nov-23, Volume: 122, Issue:21

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro

2010
A case-control study on platelet reactivity in patients with coronary stent thrombosis.
    Journal of thrombosis and haemostasis : JTH, 2011, Volume: 9, Issue:5

    Topics: Aged; Aspirin; Blood Platelets; Case-Control Studies; Clopidogrel; Coronary Thrombosis; Female; Flow

2011
Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction.
    Circulation, 2011, Apr-26, Volume: 123, Issue:16

    Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Antithrombins; Clopidogrel; Coronary Restenosi

2011
Residual platelet reactivity after clopidogrel loading in patients with ST-elevation myocardial infarction undergoing an unexpectedly delayed primary percutaneous coronary intervention. - Impact on intracoronary thrombus burden and myocardial perfusion-.
    Circulation journal : official journal of the Japanese Circulation Society, 2011, Volume: 75, Issue:9

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Circulation; Co

2011
Relationship between clopidogrel-induced platelet P2Y12 inhibition and stent thrombosis or myocardial infarction after percutaneous coronary intervention-a case-control study.
    American heart journal, 2011, Volume: 162, Issue:2

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Co

2011
A novel regimen of alternate day clopidogrel would provide a cost-effective strategy to prevent very late stent thrombosis.
    Medical hypotheses, 2012, Volume: 78, Issue:1

    Topics: Aspirin; Clopidogrel; Cohort Studies; Coronary Thrombosis; Drug-Eluting Stents; Equipment Safety; Hu

2012
The effect of pre-hospital glycoprotein IIb-IIIa inhibitors on angiographic outcome in STEMI patients who are candidates for primary PCI.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2012, May-01, Volume: 79, Issue:6

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Circulati

2012
Effects of pantoprazole on dual antiplatelet therapy in stable angina pectoris patients after percutaneous coronary intervention.
    Pharmacological reports : PR, 2012, Volume: 64, Issue:2

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Angina, Stable; Angioplasty, Balloon, Coronary; Aspirin; Cl

2012
Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.
    Journal of the American College of Cardiology, 2012, Jul-17, Volume: 60, Issue:3

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro

2012
Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.
    Journal of the American College of Cardiology, 2012, Jul-17, Volume: 60, Issue:3

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro

2012
Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.
    Journal of the American College of Cardiology, 2012, Jul-17, Volume: 60, Issue:3

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro

2012
Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.
    Journal of the American College of Cardiology, 2012, Jul-17, Volume: 60, Issue:3

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro

2012
Angiographic and platelet reactivity outcomes with prasugrel 60 mg pretreatment and clopidogrel 600 mg pretreatment in primary percutaneous coronary intervention.
    Journal of thrombosis and thrombolysis, 2012, Volume: 34, Issue:4

    Topics: Adult; Aged; Asian People; Clopidogrel; Cohort Studies; Coronary Thrombosis; Female; Humans; Male; M

2012
Influence of CYP2C19 loss-of-function variants on the antiplatelet effects and cardiovascular events in clopidogrel-treated Chinese patients undergoing percutaneous coronary intervention.
    European journal of clinical pharmacology, 2013, Volume: 69, Issue:4

    Topics: Adolescent; Adult; Aged; Aryl Hydrocarbon Hydroxylases; Asian People; China; Clopidogrel; Coronary T

2013
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
    The New England journal of medicine, 2012, Nov-29, Volume: 367, Issue:22

    Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans;

2012
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
    The New England journal of medicine, 2012, Nov-29, Volume: 367, Issue:22

    Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans;

2012
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
    The New England journal of medicine, 2012, Nov-29, Volume: 367, Issue:22

    Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans;

2012
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
    The New England journal of medicine, 2012, Nov-29, Volume: 367, Issue:22

    Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans;

2012
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
    The New England journal of medicine, 2012, Nov-29, Volume: 367, Issue:22

    Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans;

2012
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
    The New England journal of medicine, 2012, Nov-29, Volume: 367, Issue:22

    Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans;

2012
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
    The New England journal of medicine, 2012, Nov-29, Volume: 367, Issue:22

    Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans;

2012
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
    The New England journal of medicine, 2012, Nov-29, Volume: 367, Issue:22

    Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans;

2012
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
    The New England journal of medicine, 2012, Nov-29, Volume: 367, Issue:22

    Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans;

2012
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
    The New England journal of medicine, 2012, Nov-29, Volume: 367, Issue:22

    Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans;

2012
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
    The New England journal of medicine, 2012, Nov-29, Volume: 367, Issue:22

    Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans;

2012
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
    The New England journal of medicine, 2012, Nov-29, Volume: 367, Issue:22

    Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans;

2012
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
    The New England journal of medicine, 2012, Nov-29, Volume: 367, Issue:22

    Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans;

2012
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
    The New England journal of medicine, 2012, Nov-29, Volume: 367, Issue:22

    Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans;

2012
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
    The New England journal of medicine, 2012, Nov-29, Volume: 367, Issue:22

    Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans;

2012
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
    The New England journal of medicine, 2012, Nov-29, Volume: 367, Issue:22

    Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans;

2012
Efficacy and safety of low-dose clopidogrel in Japanese patients after drug-eluting stent implantation: a randomized pilot trial.
    Heart and vessels, 2014, Volume: 29, Issue:1

    Topics: Aged; Asian People; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy

2014
Spaced administration of PA32540 and clopidogrel results in greater platelet inhibition than synchronous administration of enteric-coated aspirin and enteric-coated omeprazole and clopidogrel.
    American heart journal, 2013, Volume: 165, Issue:2

    Topics: Administration, Oral; Adult; Aspirin; Clopidogrel; Coronary Thrombosis; Cross-Over Studies; Dose-Res

2013
Sustained platelet activation following intracoronary beta irradiation.
    The American journal of cardiology, 2002, Dec-15, Volume: 90, Issue:12

    Topics: Angioplasty, Balloon, Coronary; Beta Particles; Blood Platelets; Brachytherapy; CD40 Ligand; Clopido

2002
Effects of diltiazem on platelet activation and cytosolic calcium during percutaneous transluminal coronary angioplasty.
    Postgraduate medical journal, 2003, Volume: 79, Issue:935

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Calcium; Calcium Channel Blockers; C

2003
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.
    Circulation, 2004, Mar-16, Volume: 109, Issue:10

    Topics: Aged; Anticoagulants; Aspirin; Catheterization; Clopidogrel; Combined Modality Therapy; Comorbidity;

2004
Effects of pretreatment with clopidogrel on platelet and coagulation activation in patients undergoing elective coronary stenting.
    Thrombosis research, 2003, Volume: 112, Issue:1-2

    Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; beta-Thromboglobulin; Blood Vessel Prosthesis; Clop

2003
Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study.
    Circulation, 2005, Mar-08, Volume: 111, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Angioplasty, Balloon, Coronary; Cardiovascular Agen

2005
Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study.
    Circulation, 2005, Mar-08, Volume: 111, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Angioplasty, Balloon, Coronary; Cardiovascular Agen

2005
Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study.
    Circulation, 2005, Mar-08, Volume: 111, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Angioplasty, Balloon, Coronary; Cardiovascular Agen

2005
Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study.
    Circulation, 2005, Mar-08, Volume: 111, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Angioplasty, Balloon, Coronary; Cardiovascular Agen

2005
Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study.
    Circulation, 2005, Mar-08, Volume: 111, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Angioplasty, Balloon, Coronary; Cardiovascular Agen

2005
Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study.
    Circulation, 2005, Mar-08, Volume: 111, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Angioplasty, Balloon, Coronary; Cardiovascular Agen

2005
Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study.
    Circulation, 2005, Mar-08, Volume: 111, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Angioplasty, Balloon, Coronary; Cardiovascular Agen

2005
Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study.
    Circulation, 2005, Mar-08, Volume: 111, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Angioplasty, Balloon, Coronary; Cardiovascular Agen

2005
Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study.
    Circulation, 2005, Mar-08, Volume: 111, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Angioplasty, Balloon, Coronary; Cardiovascular Agen

2005
What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention?: a meta-analysis.
    Journal of the American College of Cardiology, 2005, Mar-15, Volume: 45, Issue:6

    Topics: Aged; Angioplasty, Balloon, Coronary; Antineoplastic Agents, Phytogenic; Aspirin; Blood Vessel Prost

2005
Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 Trial.
    Circulation, 2005, Dec-20, Volume: 112, Issue:25

    Topics: Adolescent; Adult; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Drug Thera

2005
Angiographically evident thrombus following fibrinolytic therapy is associated with impaired myocardial perfusion in STEMI: a CLARITY-TIMI 28 substudy.
    European heart journal, 2006, Volume: 27, Issue:17

    Topics: Adolescent; Adult; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Double-Bli

2006
[Prevention of atherothrombotic incidents. CHARISMA Study (The Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance].
    Der Internist, 2006, Volume: 47, Issue:12

    Topics: Aged; Aspirin; Cause of Death; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Embolism

2006
Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents.
    Journal of the American College of Cardiology, 2006, Dec-19, Volume: 48, Issue:12

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug Deli

2006
Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents.
    Journal of the American College of Cardiology, 2006, Dec-19, Volume: 48, Issue:12

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug Deli

2006
Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents.
    Journal of the American College of Cardiology, 2006, Dec-19, Volume: 48, Issue:12

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug Deli

2006
Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents.
    Journal of the American College of Cardiology, 2006, Dec-19, Volume: 48, Issue:12

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug Deli

2006
Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents.
    Journal of the American College of Cardiology, 2006, Dec-19, Volume: 48, Issue:12

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug Deli

2006
Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents.
    Journal of the American College of Cardiology, 2006, Dec-19, Volume: 48, Issue:12

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug Deli

2006
Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents.
    Journal of the American College of Cardiology, 2006, Dec-19, Volume: 48, Issue:12

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug Deli

2006
Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents.
    Journal of the American College of Cardiology, 2006, Dec-19, Volume: 48, Issue:12

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug Deli

2006
Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents.
    Journal of the American College of Cardiology, 2006, Dec-19, Volume: 48, Issue:12

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug Deli

2006
Comparison of two antiplatelet regimens (aspirin alone versus aspirin + ticlopidine or clopidogrel) after intracoronary implantation of a carbofilm-coated stent.
    The American journal of cardiology, 2007, Apr-15, Volume: 99, Issue:8

    Topics: Aspirin; Carbon; Cause of Death; Clopidogrel; Coated Materials, Biocompatible; Coronary Disease; Cor

2007
Comparison of sarpogrelate and ticlopidine in bare metal coronary stent implantation.
    International journal of cardiology, 2008, May-07, Volume: 126, Issue:1

    Topics: Aged; Coronary Restenosis; Coronary Thrombosis; Coronary Vessels; Female; Follow-Up Studies; Humans;

2008
TAXUS VI 2-year follow-up: randomized comparison of polymer-based paclitaxel-eluting with bare metal stents for treatment of long, complex lesions.
    European heart journal, 2007, Volume: 28, Issue:21

    Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Coronary Thrombosis; Drug-Elutin

2007
Clopidogrel 600-mg double loading dose achieves stronger platelet inhibition than conventional regimens: results from the PREPAIR randomized study.
    Journal of the American College of Cardiology, 2008, Mar-18, Volume: 51, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Coronary Angiography; Coronary A

2008
Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance.
    Circulation, 1995, Mar-15, Volume: 91, Issue:6

    Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Catheterization; Coronary Angiography; Coronar

1995
Combined antiplatelet therapy with ticlopidine and aspirin. A simplified approach to intracoronary stent management.
    European heart journal, 1996, Volume: 17, Issue:9

    Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Chi-Square Distribution; Coronary Artery Disea

1996
High pressure assisted coronary stent implantation accomplished without intravascular ultrasound guidance and subsequent anticoagulation.
    Journal of the American College of Cardiology, 1997, Volume: 29, Issue:1

    Topics: Anticoagulants; Aspirin; Case-Control Studies; Coronary Angiography; Coronary Disease; Coronary Thro

1997
Coronary stenting (Cordis) without anticoagulation.
    The American journal of cardiology, 1997, Apr-01, Volume: 79, Issue:7

    Topics: Anticoagulants; Aspirin; Coronary Angiography; Coronary Disease; Coronary Thrombosis; Evaluation Stu

1997
Coronary stenting after rotational atherectomy in calcified and complex lesions. Angiographic and clinical follow-up results.
    Circulation, 1997, Jul-01, Volume: 96, Issue:1

    Topics: Aged; Aspirin; Atherectomy, Coronary; Calcinosis; Coronary Angiography; Coronary Disease; Coronary T

1997
Coronary stenting after rotational atherectomy in calcified and complex lesions. Angiographic and clinical follow-up results.
    Circulation, 1997, Jul-01, Volume: 96, Issue:1

    Topics: Aged; Aspirin; Atherectomy, Coronary; Calcinosis; Coronary Angiography; Coronary Disease; Coronary T

1997
Coronary stenting after rotational atherectomy in calcified and complex lesions. Angiographic and clinical follow-up results.
    Circulation, 1997, Jul-01, Volume: 96, Issue:1

    Topics: Aged; Aspirin; Atherectomy, Coronary; Calcinosis; Coronary Angiography; Coronary Disease; Coronary T

1997
Coronary stenting after rotational atherectomy in calcified and complex lesions. Angiographic and clinical follow-up results.
    Circulation, 1997, Jul-01, Volume: 96, Issue:1

    Topics: Aged; Aspirin; Atherectomy, Coronary; Calcinosis; Coronary Angiography; Coronary Disease; Coronary T

1997
Silicon carbide-coated stents: clinical experience in coronary lesions with increased thrombotic risk.
    Journal of endovascular surgery : the official journal of the International Society for Endovascular Surgery, 1998, Volume: 5, Issue:1

    Topics: Adult; Aged; Angioplasty, Balloon; Carbon Compounds, Inorganic; Coronary Disease; Coronary Thrombosi

1998
Clinical outcome at six months of coronary stenting followed by ticlopidine monotherapy.
    The American journal of cardiology, 1998, Jan-15, Volume: 81, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Coronary Angiography; Coronary Thrombosis; Coronary Vessels; Electro

1998
Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.
    Lancet (London, England), 1998, Jul-11, Volume: 352, Issue:9122

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Coronary Disease; Corona

1998
Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.
    Lancet (London, England), 1998, Jul-11, Volume: 352, Issue:9122

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Coronary Disease; Corona

1998
Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.
    Lancet (London, England), 1998, Jul-11, Volume: 352, Issue:9122

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Coronary Disease; Corona

1998
Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.
    Lancet (London, England), 1998, Jul-11, Volume: 352, Issue:9122

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Coronary Disease; Corona

1998
Low-molecular-weight heparins in coronary stenting (the ENTICES trial). ENoxaparin and TIClopidine after Elective Stenting.
    The American journal of cardiology, 1998, Sep-10, Volume: 82, Issue:5B

    Topics: Aged; Aspirin; Coronary Angiography; Coronary Thrombosis; Drug Therapy, Combination; Enoxaparin; Fem

1998
Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS).
    Circulation, 1998, Nov-17, Volume: 98, Issue:20

    Topics: Adult; Aged; Anticoagulants; Aspirin; Coronary Thrombosis; Female; Humans; Male; Middle Aged; Patien

1998
Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation.
    Circulation, 1999, May-11, Volume: 99, Issue:18

    Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Disease; Coronary Thrombosis; Diarrhea; D

1999
Comparison of cilostazol versus ticlopidine therapy after stent implantation.
    The American journal of cardiology, 1999, Sep-01, Volume: 84, Issue:5

    Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Coronary Disease; Coronary Thrombo

1999
Clopidogrel as adjunctive antiplatelet therapy during coronary stenting.
    Journal of the American College of Cardiology, 1999, Volume: 34, Issue:7

    Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiograp

1999
Clopidogrel versus ticlopidine after intracoronary stent placement.
    Journal of the American College of Cardiology, 1999, Volume: 34, Issue:7

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Thrombosi

1999
[Acute coronary syndrome, stent and cardiac insufficiency. Advances in thrombosis prevention].
    Der Internist, 1999, Volume: 40, Issue:12 Suppl F

    Topics: Acute Disease; Clopidogrel; Coronary Disease; Coronary Thrombosis; Coumarins; Humans; Platelet Aggre

1999
A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents.
    Circulation, 2000, Feb-15, Volume: 101, Issue:6

    Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Coronary Vessels; Drug Therapy, Combination; Female

2000
[Subacute thrombosis with antiplatelet treatment in a non-selected population of intracoronary stents: incidence and predictors].
    Revista espanola de cardiologia, 2000, Volume: 53, Issue:6

    Topics: Acute Disease; Aspirin; Coronary Thrombosis; Female; Humans; Male; Middle Aged; Platelet Aggregation

2000
Abciximab, ticlopidine, and concomitant abciximab-ticlopidine therapy: ex vivo platelet aggregation inhibition profiles in patients undergoing percutaneous coronary interventions.
    American heart journal, 2000, Volume: 140, Issue:3

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Thrombosis; Drug T

2000
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.
    Heart (British Cardiac Society), 2001, Volume: 85, Issue:1

    Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Ther

2001
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.
    Heart (British Cardiac Society), 2001, Volume: 85, Issue:1

    Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Ther

2001
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.
    Heart (British Cardiac Society), 2001, Volume: 85, Issue:1

    Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Ther

2001
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.
    Heart (British Cardiac Society), 2001, Volume: 85, Issue:1

    Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Ther

2001
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.
    Heart (British Cardiac Society), 2001, Volume: 85, Issue:1

    Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Ther

2001
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.
    Heart (British Cardiac Society), 2001, Volume: 85, Issue:1

    Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Ther

2001
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.
    Heart (British Cardiac Society), 2001, Volume: 85, Issue:1

    Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Ther

2001
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.
    Heart (British Cardiac Society), 2001, Volume: 85, Issue:1

    Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Ther

2001
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.
    Heart (British Cardiac Society), 2001, Volume: 85, Issue:1

    Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Ther

2001
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.
    Heart (British Cardiac Society), 2001, Volume: 85, Issue:1

    Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Ther

2001
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.
    Heart (British Cardiac Society), 2001, Volume: 85, Issue:1

    Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Ther

2001
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.
    Heart (British Cardiac Society), 2001, Volume: 85, Issue:1

    Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Ther

2001
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.
    Heart (British Cardiac Society), 2001, Volume: 85, Issue:1

    Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Ther

2001
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.
    Heart (British Cardiac Society), 2001, Volume: 85, Issue:1

    Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Ther

2001
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.
    Heart (British Cardiac Society), 2001, Volume: 85, Issue:1

    Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Ther

2001
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.
    Heart (British Cardiac Society), 2001, Volume: 85, Issue:1

    Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Ther

2001
A safe and effective regimen without heparin therapy after successful primary coronary stenting in patients with acute myocardial infarction.
    Japanese heart journal, 2000, Volume: 41, Issue:6

    Topics: Aged; Aspirin; Combined Modality Therapy; Coronary Angiography; Coronary Thrombosis; Coronary Vessel

2000
Randomized comparison of ticlopidine and clopidogrel after intracoronary stent implantation in a broad patient population.
    Circulation, 2001, Jul-31, Volume: 104, Issue:5

    Topics: Abciximab; Antibodies, Monoclonal; Clopidogrel; Coronary Disease; Coronary Thrombosis; Eptifibatide;

2001
Inhibition by combined therapy with ticlopidine and aspirin of enhanced platelet aggregation during physical exercise in patients with coronary artery disease.
    American heart journal, 2001, Volume: 142, Issue:2

    Topics: Adenine Nucleotides; Adult; Aged; Aspirin; Coronary Disease; Coronary Thrombosis; Drug Administratio

2001
A randomized, placebo-controlled trial of enoxaparin after high-risk coronary stenting: the ATLAST trial.
    Journal of the American College of Cardiology, 2001, Nov-15, Volume: 38, Issue:6

    Topics: Aged; Analysis of Variance; Anticoagulants; Aspirin; Coronary Disease; Coronary Thrombosis; Double-B

2001
Safety and efficacy of only 2 weeks of ticlopidine therapy in patients at increased risk of coronary stent thrombosis: results from the Antiplatelet Therapy alone versus Lovenox plus Antiplatelet therapy in patients at increased risk of Stent Thrombosis (
    American heart journal, 2002, Volume: 143, Issue:5

    Topics: Coronary Thrombosis; Enoxaparin; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Platelet Ag

2002

Other Studies

320 other studies available for ticlopidine and Coronary Thrombosis

ArticleYear
Dual antiplatelet therapy after percutaneous coronary intervention: entering the final chapter?
    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2019, Aug-09, Volume: 15, Issue:6

    Topics: Coronary Restenosis; Coronary Thrombosis; Drug Therapy, Combination; Humans; Percutaneous Coronary I

2019
Stent thrombosis: prevention is the only effective treatment.
    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2020, Jul-17, Volume: 16, Issue:4

    Topics: Coronary Thrombosis; Humans; Platelet Aggregation Inhibitors; Stents; Thrombosis; Ticlopidine

2020
Stent thrombosis in patients undergoing coronary stenting after return of spontaneous circulation. Does the choice of antiplatelet drug matter?
    Resuscitation, 2017, Volume: 114

    Topics: Aspirin; Coronary Thrombosis; Drug-Eluting Stents; Humans; Platelet Aggregation Inhibitors; Stents;

2017
Potentially increased incidence of scaffold thrombosis in patients treated with Absorb BVS who terminated DAPT before 18 months.
    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2017, Jun-02, Volume: 13, Issue:2

    Topics: Absorbable Implants; Aged; Aspirin; Cardiovascular Agents; Clopidogrel; Coated Materials, Biocompati

2017
Cost-effectiveness analysis of 30-month vs 12-month dual antiplatelet therapy with clopidogrel and aspirin after drug-eluting stents in patients with acute coronary syndrome.
    Clinical cardiology, 2017, Volume: 40, Issue:10

    Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Computer Simulation; Coronary Thrombosis; Cost-Benefi

2017
Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Report From the PROMETHEUS Study.
    JACC. Cardiovascular interventions, 2017, 10-23, Volume: 10, Issue:20

    Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Chi-Square Distribution; Clopidogrel; Coronary Thr

2017
Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated With Drug-Eluting Stents: 2-Year Results of a Prospective, Multicenter Registry Study.
    JACC. Cardiovascular interventions, 2017, 08-28, Volume: 10, Issue:16

    Topics: Aged; Aspirin; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Thrombosis; Drug Resi

2017
Associations Between Complex PCI and Prasugrel or Clopidogrel Use in Patients With Acute Coronary Syndrome Who Undergo PCI: From the PROMETHEUS Study.
    The Canadian journal of cardiology, 2018, Volume: 34, Issue:3

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Cohort Studies; Combined Modal

2018
Long-term outcome after angiographically proven coronary stent thrombosis.
    The American journal of cardiology, 2013, May-01, Volume: 111, Issue:9

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Drug-E

2013
Safety and efficacy of intense antithrombotic treatment and percutaneous coronary intervention deferral in patients with large intracoronary thrombus.
    The American journal of cardiology, 2013, Jun-15, Volume: 111, Issue:12

    Topics: Acute Coronary Syndrome; Angiography; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopi

2013
Thrombocytosis as a potential cause of a very late stent thrombosis in the left main coronary artery.
    Kardiologia polska, 2013, Volume: 71, Issue:3

    Topics: Adult; Clopidogrel; Coronary Angiography; Coronary Stenosis; Coronary Thrombosis; Drug-Eluting Stent

2013
Antiplatelet therapy. Cangrelor succeeds, at last, in PCI.
    Nature reviews. Cardiology, 2013, Volume: 10, Issue:6

    Topics: Adenosine Monophosphate; Administration, Intravenous; Administration, Oral; Blood Platelets; Clopido

2013
Relationship between aspirin/clopidogrel resistance and intra-stent thrombi assessed by follow-up optical coherence tomography after drug-eluting stent implantation.
    European heart journal. Cardiovascular Imaging, 2013, Volume: 14, Issue:12

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Cohort Studies; Confidence Intervals; Co

2013
Abciximab bolus with optional infusion in intervention for ST-elevation myocardial infarction.
    Scandinavian cardiovascular journal : SCJ, 2013, Volume: 47, Issue:4

    Topics: Abciximab; Aged; Aged, 80 and over; Antibodies, Monoclonal; Clopidogrel; Coronary Thrombosis; Cost S

2013
[Relevance of CYP2C19 2 regarding platelet reactivity in patients with acute coronary syndrome treated with clopidogrel].
    Medicina clinica, 2014, Jul-07, Volume: 143, Issue:1

    Topics: Acute Coronary Syndrome; Aged; Alleles; Angina, Unstable; Aryldialkylphosphatase; Biotransformation;

2014
P2Y12 Receptor Blockade and Myocardial Perfusion.
    JACC. Cardiovascular interventions, 2013, Volume: 6, Issue:7

    Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Coronary Angiography; Coronary Stenosis; Coronary T

2013
The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation.
    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2013, Volume: 9, Issue:3

    Topics: Acute Coronary Syndrome; Aged; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subf

2013
Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA study (predictor of bleedings with antiplatelet drugs).
    JACC. Cardiovascular interventions, 2013, Volume: 6, Issue:8

    Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Area Under Curve; Biomarkers; Cell Adhesion Molecu

2013
Efficacy and safety of aspirin, clopidogrel, and warfarin after coronary artery stenting in Korean patients with atrial fibrillation.
    Heart and vessels, 2014, Volume: 29, Issue:5

    Topics: Aged; Anticoagulants; Asian People; Aspirin; Atrial Fibrillation; Blood Coagulation; Clopidogrel; Co

2014
[The CHAMPION PHOENIX study].
    Giornale italiano di cardiologia (2006), 2013, Volume: 14, Issue:10

    Topics: Adenosine Monophosphate; Clopidogrel; Coronary Restenosis; Coronary Stenosis; Coronary Thrombosis; D

2013
Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease.
    JACC. Cardiovascular interventions, 2013, Volume: 6, Issue:11

    Topics: Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Biotransformation; Clopidogrel; Coronary Artery Diseas

2013
Impact of mild hypothermia on platelet responsiveness to aspirin and clopidogrel: an in vitro pharmacodynamic investigation.
    Journal of cardiovascular translational research, 2014, Volume: 7, Issue:1

    Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Female;

2014
Fixed-dose aspirin-clopidogrel combination enhances compliance to aspirin after acute coronary syndrome.
    International journal of cardiology, 2014, Mar-01, Volume: 172, Issue:1

    Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Thrombosis; Dose-Re

2014
A cautionary tale on the use of antiplatelet treatment following TURP.
    BMJ case reports, 2014, Apr-04, Volume: 2014

    Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Hematuria; Humans; Male; Myoca

2014
A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity. Results of the ISAR-HPR registry.
    Thrombosis and haemostasis, 2014, Volume: 112, Issue:2

    Topics: Aged; Aged, 80 and over; Blood Platelets; Case-Control Studies; Clopidogrel; Coronary Thrombosis; Dr

2014
Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome.
    Annals of internal medicine, 2014, Feb-18, Volume: 160, Issue:4

    Topics: Acute Coronary Syndrome; Adenosine; Alleles; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Th

2014
Subacute bioresorbable vascular scaffold thrombosis: a report of 2 cases.
    Heart and vessels, 2015, Volume: 30, Issue:4

    Topics: Absorbable Implants; Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Stenosis;

2015
Thrombotic and bleeding events after coronary stenting according to clopidogrel and aspirin platelet reactivity: VerifyNow French Registry (VERIFRENCHY).
    Archives of cardiovascular diseases, 2014, Volume: 107, Issue:4

    Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Female; France; Hemorrha

2014
Fixed combination dual antiplatelet therapy and the risk of stent thrombosis.
    International journal of cardiology, 2014, Jun-15, Volume: 174, Issue:2

    Topics: Aged, 80 and over; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Drug-Elutin

2014
Acute coronary thrombosis and multiple coronary aneurysms in a 22-year-old man with the human immunodeficiency virus.
    Texas Heart Institute journal, 2014, Volume: 41, Issue:2

    Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Aneurysm; Coronary An

2014
Letter by Roguin and Musallam regarding article, "Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial".
    Circulation, 2014, May-13, Volume: 129, Issue:19

    Topics: Acute Coronary Syndrome; Adenosine; Coronary Thrombosis; Female; Humans; Internationality; Male; Ste

2014
Response to letter regarding article, "Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial".
    Circulation, 2014, May-13, Volume: 129, Issue:19

    Topics: Acute Coronary Syndrome; Adenosine; Coronary Thrombosis; Female; Humans; Internationality; Male; Ste

2014
An atypical presentation of an extremely late stent thrombosis after more than 7 years (2634 days) of DES implantation in a patient without obvious risk factors on regular dual antiplatelet therapy.
    BMJ case reports, 2014, Jul-15, Volume: 2014

    Topics: Aspirin; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Drug Therapy, Combination; Drug-Elu

2014
Clopidogrel discontinuation within the first year after coronary drug-eluting stent implantation: an observational study.
    BMC cardiovascular disorders, 2014, Aug-13, Volume: 14

    Topics: Aged; Clopidogrel; Coronary Thrombosis; Denmark; Drug Administration Schedule; Drug Prescriptions; D

2014
Prasugrel vs clopidogrel in cardiogenic shock patients undergoing primary PCI for acute myocardial infarction. Results of the ISAR-SHOCK registry.
    Thrombosis and haemostasis, 2014, Volume: 112, Issue:6

    Topics: Aged; Aged, 80 and over; Blood Platelets; Clopidogrel; Coronary Thrombosis; Female; Germany; Hemorrh

2014
Changes in thrombus composition and profilin-1 release in acute myocardial infarction.
    European heart journal, 2015, Apr-21, Volume: 36, Issue:16

    Topics: Analysis of Variance; Blood Platelets; Clopidogrel; Coronary Thrombosis; Female; Fibrinogen; Humans;

2015
Impact of gene polymorphisms, platelet reactivity, and the SYNTAX score on 1-year clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention: the GEPRESS study.
    JACC. Cardiovascular interventions, 2014, Volume: 7, Issue:10

    Topics: Acute Coronary Syndrome; Aged; Biotransformation; Blood Platelets; Clopidogrel; Coronary Angiography

2014
Optimising pharmacotherapy for secondary prevention of non-invasively managed acute coronary syndrome.
    The Medical journal of Australia, 2014, Nov-17, Volume: 201, Issue:10

    Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti

2014
Tailored antiplatelet therapy in a patient with ITP and clopidogrel resistance.
    Thrombosis and haemostasis, 2015, Volume: 113, Issue:3

    Topics: Adenosine; Clopidogrel; Coronary Thrombosis; Drug Resistance; Drug Substitution; Humans; Male; Middl

2015
Intrastent thrombus – what you see is what you get?
    Circulation journal : official journal of the Japanese Circulation Society, 2015, Volume: 79, Issue:1

    Topics: Angioscopy; Clopidogrel; Coronary Thrombosis; Cytochrome P-450 CYP2C19; Drug-Eluting Stents; Female;

2015
Biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent in patients with acute myocardial infarction.
    International journal of cardiology, 2015, Mar-15, Volume: 183

    Topics: Absorbable Implants; Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Everolimu

2015
Thrombotic complications associated with early and late nonadherence to dual antiplatelet therapy.
    JACC. Cardiovascular interventions, 2015, Volume: 8, Issue:3

    Topics: Aged; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; D

2015
Plasma fibrin clot phenotype independently affects intracoronary thrombus ultrastructure in patients with acute myocardial infarction.
    Thrombosis and haemostasis, 2015, Volume: 113, Issue:6

    Topics: Aged; Aspirin; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Thrombosis; Coronary

2015
Characterization of patients with angioscopically-detected in-stent mural thrombi – genetics of clopidogrel responsiveness and generations of drug-eluting stents.
    Circulation journal : official journal of the Japanese Circulation Society, 2015, Volume: 79, Issue:1

    Topics: Activation, Metabolic; Aged; Alleles; Angina Pectoris; Angioscopy; Aspirin; Clopidogrel; Coronary An

2015
A case of repetitive and simultaneous stent thromboses.
    International journal of cardiology, 2015, Volume: 186

    Topics: Coronary Angiography; Coronary Thrombosis; Diagnosis, Differential; Electrocardiography; Graft Occlu

2015
Effects of Rivaroxaban on Platelet Activation and Platelet-Coagulation Pathway Interaction: In Vitro and In Vivo Studies.
    Journal of cardiovascular pharmacology and therapeutics, 2015, Volume: 20, Issue:6

    Topics: Adenosine; Adult; Animals; Arteriovenous Shunt, Surgical; Aspirin; Blood Coagulation; Clopidogrel; C

2015
Cardioembolic acute myocardial infarction associated with apical ballooning: Considerations.
    International journal of cardiology, 2015, Aug-01, Volume: 192

    Topics: Aged, 80 and over; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Echocardiog

2015
Very late bioresorbable vascular scaffold thrombosis: a new clinical entity.
    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2015, May-19, Volume: 11, Issue:1

    Topics: Absorbable Implants; Aged, 80 and over; Anterior Wall Myocardial Infarction; Brachytherapy; Clopidog

2015
Cytochrome P450 CYP 2C19*2 Associated with Adverse 1-Year Cardiovascular Events in Patients with Acute Coronary Syndrome.
    PloS one, 2015, Volume: 10, Issue:7

    Topics: Activation, Metabolic; Acute Coronary Syndrome; Aged; Alleles; Angina Pectoris; Aspirin; Clopidogrel

2015
Prasugrel in Clopidogrel Nonresponders: A Way to Improve Secondary Prevention in Patients After Percutaneous Coronary Intervention?
    JACC. Cardiovascular interventions, 2015, Volume: 8, Issue:12

    Topics: Coronary Artery Disease; Coronary Thrombosis; Drug Substitution; Female; Humans; Male; Percutaneous

2015
Successful Prasugrel Therapy for Recurrent Left Main Stent Thrombosis in a Clopidogrel Hyporesponder.
    Texas Heart Institute journal, 2015, Volume: 42, Issue:5

    Topics: Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Thrombosis; Drug Resis

2015
Very late scaffold thrombosis of everolimus-eluting bioresorbable scaffold following implantation in STEMI after discontinuation of dual antiplatelet therapy.
    Cardiovascular intervention and therapeutics, 2017, Volume: 32, Issue:1

    Topics: Absorbable Implants; Adult; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Coronary Vessels

2017
Impact of Cytochrome P450 2C19*2 and *3 on Clopidogrel Loading Dose in Saudi Patients with Acute Coronary Syndrome.
    Drug metabolism letters, 2016, Volume: 10, Issue:1

    Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Coronary Thrombosis; Cytochrome P-450 CYP2C19; Drug Dosa

2016
Stent thrombosis after primary percutaneous coronary intervention in comatose survivors of out-of-hospital cardiac arrest: Are the new P2Y12 inhibitors really more effective than clopidogrel?
    Resuscitation, 2016, Volume: 98

    Topics: Adenosine; Aspirin; Clopidogrel; Coma; Coronary Angiography; Coronary Thrombosis; Drug Therapy, Comb

2016
Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: "Window" Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents).
    JACC. Cardiovascular interventions, 2015, Dec-28, Volume: 8, Issue:15

    Topics: Aged; Aspirin; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Disease; Coronary Thr

2015
Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: "Window" Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents).
    JACC. Cardiovascular interventions, 2015, Dec-28, Volume: 8, Issue:15

    Topics: Aged; Aspirin; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Disease; Coronary Thr

2015
Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: "Window" Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents).
    JACC. Cardiovascular interventions, 2015, Dec-28, Volume: 8, Issue:15

    Topics: Aged; Aspirin; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Disease; Coronary Thr

2015
Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: "Window" Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents).
    JACC. Cardiovascular interventions, 2015, Dec-28, Volume: 8, Issue:15

    Topics: Aged; Aspirin; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Disease; Coronary Thr

2015
Personalized Antiplatelet Therapy: The Odyssey Continues.
    JACC. Cardiovascular interventions, 2016, Jan-11, Volume: 9, Issue:1

    Topics: Coronary Artery Disease; Coronary Thrombosis; Drug Substitution; Female; Humans; Male; Percutaneous

2016
Reply: Personalized Antiplatelet Therapy: The Odyssey Continues.
    JACC. Cardiovascular interventions, 2016, Jan-11, Volume: 9, Issue:1

    Topics: Coronary Artery Disease; Coronary Thrombosis; Drug Substitution; Female; Humans; Male; Percutaneous

2016
Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS.
    Journal of the American College of Cardiology, 2016, May-17, Volume: 67, Issue:19

    Topics: Acute Coronary Syndrome; Age Factors; Aged; Anemia; Aspirin; Body Mass Index; Clopidogrel; Cohort St

2016
The Impact of Timing of Ischemic and Hemorrhagic Events on Mortality After Percutaneous Coronary Intervention: The ADAPT-DES Study.
    JACC. Cardiovascular interventions, 2016, 07-25, Volume: 9, Issue:14

    Topics: Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; D

2016
CASE 11-2016 Perioperative Coronary Thrombosis in a Patient With Multiple Second-Generation Drug-Eluting Stents: Is It Time for a Paradigm Shift?
    Journal of cardiothoracic and vascular anesthesia, 2016, Volume: 30, Issue:6

    Topics: Analgesics, Opioid; Anti-Arrhythmia Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopid

2016
Increased Platelet-leukocyte Aggregates Are Associated With Myocardial No-reflow in Patients With ST Elevation Myocardial Infarction.
    The American journal of the medical sciences, 2016, Volume: 352, Issue:3

    Topics: Aspirin; Blood Platelets; Clopidogrel; Coronary Angiography; Coronary Circulation; Coronary Thrombos

2016
Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2017, Jun-01, Volume: 89, Issue:7

    Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Administration Schedule; Drug Antagonism; Drug

2017
Platelet aggregation and the risk of stent thrombosis or bleeding in elective percutaneous coronary intervention patients.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2017, Volume: 28, Issue:5

    Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Thrombosis; Elective Surgical Procedures; Fema

2017
Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention.
    Circulation. Cardiovascular interventions, 2017, Volume: 10, Issue:1

    Topics: Adenosine Monophosphate; Aged; Brain Ischemia; Chi-Square Distribution; Clopidogrel; Coronary Artery

2017
Sex Differences in the Clinical Impact of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
    Circulation. Cardiovascular interventions, 2017, Volume: 10, Issue:2

    Topics: Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; D

2017
Out-of-hospital cardiac arrest and stent thrombosis: Ticagrelor versus clopidogrel in patients with primary percutaneous coronary intervention under mild therapeutic hypothermia.
    Resuscitation, 2017, Volume: 114

    Topics: Adenosine; Aged; Clopidogrel; Coronary Thrombosis; Humans; Hypothermia, Induced; Male; Middle Aged;

2017
Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of Drug-Eluting Stents in Subjects With Peripheral Arterial Disease: Analysis From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
    Circulation. Cardiovascular interventions, 2017, Volume: 10, Issue:3

    Topics: Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; D

2017
Very late stent thrombosis after drug-eluting stent implantation in a patient without aspirin and clopidogrel resistance.
    Journal of Korean medical science, 2008, Volume: 23, Issue:3

    Topics: Aged; Angina Pectoris; Aspirin; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Drug Resista

2008
The optimal threshold of high post-treatment platelet reactivity could be defined by a point-of-care VerifyNow P2Y12 assay.
    European heart journal, 2008, Volume: 29, Issue:17

    Topics: Angioplasty, Balloon, Coronary; Coronary Stenosis; Coronary Thrombosis; Female; Humans; Male; Platel

2008
A threshold of platelet reactivity for ischaemic events?
    European heart journal, 2008, Volume: 29, Issue:17

    Topics: Angioplasty, Balloon, Coronary; Coronary Stenosis; Coronary Thrombosis; Female; Humans; Male; Platel

2008
Efficient tirofiban infusion resulting in resolution of intracoronary thrombus.
    Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2008, Volume: 36, Issue:3

    Topics: Anticholesteremic Agents; Aspirin; Atorvastatin; Clopidogrel; Coronary Angiography; Coronary Thrombo

2008
Reversible clopidogrel resistance due to right ventricular myocardial infarction: risk factor of recurrent stent thrombosis?
    Clinical research in cardiology : official journal of the German Cardiac Society, 2008, Volume: 97, Issue:11

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug R

2008
Very late stent thrombosis after discontinuation of clopidogrel therapy.
    The Medical journal of Australia, 2008, Aug-18, Volume: 189, Issue:4

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Follow-Up Studi

2008
Safety and efficacy of low-dose clopidogrel in Japanese patients undergoing coronary stenting: preliminary 30-day clinical outcome.
    Circulation journal : official journal of the Japanese Circulation Society, 2008, Volume: 72, Issue:10

    Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Restenosis; Coronary Thrombosis; Female; Huma

2008
Clopidogrel in a pediatric population: prescribing practice and outcomes from a single center.
    Pediatric cardiology, 2009, Volume: 30, Issue:2

    Topics: Adolescent; Child; Child Welfare; Child, Preschool; Clopidogrel; Coronary Thrombosis; Drug Prescript

2009
What to do with patients receiving long-term clopidogrel: reload or relax?
    Circulation, 2008, Sep-16, Volume: 118, Issue:12

    Topics: Clopidogrel; Coronary Thrombosis; Drug Administration Schedule; Humans; Platelet Aggregation; Random

2008
[Severe myocardial infarction due to late and very late stent thrombosis after coronary artery stenting with drug-eluting stents].
    Deutsche medizinische Wochenschrift (1946), 2008, Volume: 133, Issue:40

    Topics: Aged; Aspirin; Cardiac Catheterization; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Crea

2008
Identifying clopidogrel resistance during chronic therapy: the case for a biochemical approach.
    Thrombosis and haemostasis, 2008, Volume: 100, Issue:4

    Topics: Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Resistance; Humans; Platelet Aggrega

2008
Overcoming "resistance" to aspirin and clopidogrel with tirofiban: fact or fiction?
    Thrombosis and haemostasis, 2008, Volume: 100, Issue:4

    Topics: Aspirin; Clopidogrel; Coronary Thrombosis; Drug Resistance; Humans; Platelet Aggregation Inhibitors;

2008
The challenge of monitoring platelet response after clopidogrel.
    European heart journal, 2008, Volume: 29, Issue:23

    Topics: Blood Platelets; Clopidogrel; Coronary Disease; Coronary Thrombosis; Humans; Platelet Aggregation In

2008
Impact of clopidogrel resistance on thrombotic events after percutaneous coronary intervention with drug-eluting stent.
    Thrombosis research, 2009, Volume: 124, Issue:1

    Topics: Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Drug Resist

2009
Death caused by simultaneous subacute stent thrombosis of sirolimus-eluting stents in left anterior descending artery and left circumflex artery.
    International journal of cardiology, 2010, Apr-01, Volume: 140, Issue:1

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Occ

2010
Very late stent thrombosis after discontinuation of clopidogrel therapy.
    The Medical journal of Australia, 2009, Feb-02, Volume: 190, Issue:3

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Humans; Plate

2009
Knowledge of coronary stents, thrombosis and dual antiplatelet therapy among Spanish dentists.
    Revista espanola de cardiologia, 2009, Volume: 62, Issue:2

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Thrombosis; Coronary Vessels; Cross-S

2009
Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis.
    The American journal of cardiology, 2009, Mar-15, Volume: 103, Issue:6

    Topics: Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Thromb

2009
Very late stent thrombosis after discontinuation of clopidogrel therapy.
    The Medical journal of Australia, 2009, Feb-02, Volume: 190, Issue:3

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Humans; Plate

2009
Very late drug-eluting stent thrombosis after nonsteroidal anti-inflammatory drug treatment despite dual antiplatelet therapy.
    The Canadian journal of cardiology, 2009, Volume: 25, Issue:4

    Topics: Adult; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Thrombosis; Cyclooxygenase Inh

2009
Combined, superselective pharmacological management of large coronary thrombus burden.
    The Journal of invasive cardiology, 2009, Volume: 21, Issue:4

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Clopidog

2009
Bridging with GP IIb/IIIa inhibitors after abdominal surgery in a patient presenting with late stent thrombosis of a drug-eluting stent and who cannot receive oral antiplatelet treatment.
    The Journal of invasive cardiology, 2009, Volume: 21, Issue:4

    Topics: Administration, Oral; Aged; Aspirin; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; Drug-Elu

2009
Assessment of sirolimus-eluting coronary stent implantation with aspirin plus low dose ticlopidine administration: one year results from CYPHER Stent Japan Post-Marketing Surveillance Registry (J-PMS).
    Circulation journal : official journal of the Japanese Circulation Society, 2009, Volume: 73, Issue:6

    Topics: Aged; Aspirin; Combined Modality Therapy; Coronary Angiography; Coronary Thrombosis; Coronary Vessel

2009
[Late thrombosis in paclitaxel-eluting stent after discontinuation of clopidogrel medication - a case report with 2-year follow-up].
    Kardiologia polska, 2009, Volume: 67, Issue:3

    Topics: Angioplasty, Balloon, Coronary; Blood Vessel Prosthesis Implantation; Clopidogrel; Coronary Angiogra

2009
Preliminary results of the hydroxyapatite nonpolymer-based sirolimus-eluting stent for the treatment of single de novo coronary lesions a first-in-human analysis of a third-generation drug-eluting stent system.
    JACC. Cardiovascular interventions, 2008, Volume: 1, Issue:5

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Angiogra

2008
A volumetric intravascular ultrasound comparison of early drug-eluting stent thrombosis versus restenosis.
    JACC. Cardiovascular interventions, 2009, Volume: 2, Issue:5

    Topics: Analysis of Variance; Aspirin; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; Drug-Eluting S

2009
Local determinants of thrombus formation following sirolimus-eluting stent implantation assessed by optical coherence tomography.
    JACC. Cardiovascular interventions, 2009, Volume: 2, Issue:5

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosis; Coronary Thrombosis

2009
Coronary aneurysms after drug-eluting stent implantation: clinical, angiographic, and intravascular ultrasound findings.
    Journal of the American College of Cardiology, 2009, Jun-02, Volume: 53, Issue:22

    Topics: Adult; Aged; Clopidogrel; Confidence Intervals; Coronary Aneurysm; Coronary Angiography; Coronary Re

2009
Future of oral antiplatelet therapy: four challenged hypotheses.
    Thrombosis and haemostasis, 2009, Volume: 101, Issue:6

    Topics: Adenosine; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Cost-Benefit Analysis; Hemorr

2009
Tailored medical and interventional therapy against recurrent stent thrombosis after drug-eluting stenting.
    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2010, Volume: 16, Issue:5

    Topics: Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Thrombosis; Drug-Eluting Stents; Humans; Male

2010
Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Circulation, 2009, Jun-30, Volume: 119, Issue:25

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Combined Modality Therapy; C

2009
New coating stent design for patients with high-risk coronary lesions for thrombotic events: early and long-term results of the Camouflage registry.
    The Journal of invasive cardiology, 2009, Volume: 21, Issue:8

    Topics: Aged; Argentina; Clopidogrel; Coated Materials, Biocompatible; Coronary Angiography; Coronary Diseas

2009
Drug-specific thienopyridine resistance in patient with recurrent coronary stent thrombosis.
    The Journal of invasive cardiology, 2009, Volume: 21, Issue:8

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Drug Resistance; Humans; Male; Mid

2009
Prevalence of aspirin and clopidogrel resistance among patients with and without drug-eluting stent thrombosis.
    The American journal of cardiology, 2009, Aug-15, Volume: 104, Issue:4

    Topics: Aged; Aspirin; Case-Control Studies; Clopidogrel; Cohort Studies; Coronary Thrombosis; Drug Resistan

2009
Early stent thrombosis in patients undergoing primary coronary stenting for acute myocardial infarction: incidence, a simple risk score, and prognosis.
    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2010, Volume: 16, Issue:1

    Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Female; Humans; Incid

2010
Platelet antiaggregants in pregnancy.
    Revista espanola de cardiologia, 2009, Volume: 62, Issue:10

    Topics: Abciximab; Adult; Antibodies, Monoclonal; Clopidogrel; Coronary Thrombosis; Female; Humans; Immunogl

2009
Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients.
    The American journal of cardiology, 2009, Oct-15, Volume: 104, Issue:8

    Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Blood Proteins

2009
Time does not heal every wound: coronary stent thrombosis of a bare-metal stent more than one decade after its implantation.
    Platelets, 2009, Volume: 20, Issue:8

    Topics: Adenosine Diphosphate; Angioplasty, Balloon, Coronary; Blood Vessel Prosthesis; Clopidogrel; Coronar

2009
Effectiveness of two-year clopidogrel + aspirin in abolishing the risk of very late thrombosis after drug-eluting stent implantation (from the TYCOON [two-year ClOpidOgrel need] study).
    The American journal of cardiology, 2009, Nov-15, Volume: 104, Issue:10

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combi

2009
Perioperative management of the patient with a coronary stent.
    Current opinion in anaesthesiology, 2010, Volume: 23, Issue:1

    Topics: Algorithms; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Drug-Eluting Stent

2010
High residual platelet reactivity after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease.
    Circulation, 2009, Dec-01, Volume: 120, Issue:22

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Cor

2009
Potential Interaction between clopidogrel and proton pump inhibitors.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2009, Volume: 9, Issue:6

    Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Thrombosis; Drug Interactions; Drug Therapy, Combinat

2009
Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?: Dual antiplatelet therapy after drug-eluting stents should be continued for more than one year and preferably indefinitely.
    Circulation. Cardiovascular interventions, 2008, Volume: 1, Issue:3

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosis;

2008
Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?: Dual antiplatelet therapy after drug-eluting stents should not be continued for more than 1 year and preferably indefinitely.
    Circulation. Cardiovascular interventions, 2008, Volume: 1, Issue:3

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Loss, Surgical; Clopidogrel; Coronary Restenosis; Cor

2008
Guidelines for the management of antiplatelet therapy in patients with coronary stents undergoing non-cardiac surgery.
    Heart, lung & circulation, 2010, Volume: 19, Issue:1

    Topics: Anticoagulants; Aspirin; Australia; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Heparin;

2010
[Antiplatelet therapy and urgent surgical procedures. Acute appendicitis two days after stent implantation--a case report].
    Kardiologia polska, 2009, Volume: 67, Issue:12

    Topics: Appendicitis; Clopidogrel; Coronary Thrombosis; Dobutamine; Humans; Intraoperative Complications; Ma

2009
Subacute coronary stent thrombosis in a patient with angina treated with double antiplatelet drugs for six days.
    Chinese medical journal, 2009, Oct-05, Volume: 122, Issue:19

    Topics: Adult; Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Thrombosis; D

2009
Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.
    Circulation, 2010, Feb-02, Volume: 121, Issue:4

    Topics: Aged; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Cyto

2010
Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.
    Circulation, 2010, Feb-02, Volume: 121, Issue:4

    Topics: Aged; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Cyto

2010
Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.
    Circulation, 2010, Feb-02, Volume: 121, Issue:4

    Topics: Aged; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Cyto

2010
Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.
    Circulation, 2010, Feb-02, Volume: 121, Issue:4

    Topics: Aged; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Cyto

2010
Genotyping, clopidogrel metabolism, and the search for the therapeutic window of thienopyridines.
    Circulation, 2010, Feb-02, Volume: 121, Issue:4

    Topics: Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Thrombosis; Cytochrome P-450 CYP2C19; Gene Freq

2010
Efficacy of modified dual antiplatelet therapy combined with warfarin following percutaneous coronary intervention with drug-eluting stents.
    The Journal of invasive cardiology, 2010, Volume: 22, Issue:2

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Combi

2010
Very late drug-eluting stent thrombosis in the perioperative period of endoscopic choledocholithotomy.
    Acta cardiologica, 2009, Volume: 64, Issue:6

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis;

2009
Long-term effectiveness and safety of sirolimus stent implantation for coronary in-stent restenosis results of the TRUE (Tuscany Registry of sirolimus for unselected in-stent restenosis) registry at 4 years.
    Journal of the American College of Cardiology, 2010, Feb-16, Volume: 55, Issue:7

    Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Restenosis; Coronary

2010
Acute myocardial infarction related to very late sirolimus-eluting stent thrombosis 6 months after discontinuation of dual antiplatelet therapy.
    Journal of cardiovascular medicine (Hagerstown, Md.), 2011, Volume: 12, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Angiogra

2011
The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response.
    Thrombosis and haemostasis, 2010, Volume: 103, Issue:5

    Topics: Aged; Amlodipine; Angioplasty; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood Platel

2010
[Recurrent stent thrombosis in a patient with non-ST-segment elevation acute coronary syndrome].
    Kardiologia polska, 2010, Volume: 68, Issue:3

    Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Drug Resistance; El

2010
[Thrombosis of pharmacoactive coronary endoprothesis after stopping antiplatelet treatment].
    La Tunisie medicale, 2010, Volume: 88, Issue:1

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Cholecystectomy, Laparoscopic; Cholecystolithiasis; Clopido

2010
Thrombus too big for pharmacology alone?
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2010, May-01, Volume: 75, Issue:6

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Coronary Thrombosis; Humans;

2010
Dual low response to acetylsalicylic acid and clopidogrel is associated with myonecrosis and stent thrombosis after coronary stent implantation.
    American heart journal, 2010, Volume: 159, Issue:5

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery

2010
Late and very late stent thrombosis after polymer-based sirolimus- or paclitaxel-eluting stent implantation in real-world clinical practice.
    Chinese medical journal, 2010, Apr-05, Volume: 123, Issue:7

    Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug-Eluting Stents; Humans; Paclitaxel

2010
Comparison of the incidence of late stent thrombosis after implantation of different drug-eluting stents in the real world coronary heart disease patients: three-year follow-up results.
    Chinese medical journal, 2010, Apr-05, Volume: 123, Issue:7

    Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug-Eluting Stents; Female; Huma

2010
Impact of inflammatory state and metabolic control on responsiveness to dual antiplatelet therapy in type 2 diabetics after PCI: prognostic relevance of residual platelet aggregability in diabetics undergoing coronary interventions.
    Clinical research in cardiology : official journal of the German Cardiac Society, 2010, Volume: 99, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; Blood Glucose; C-Reactive Protein; Clopid

2010
The evidence base for platelet function testing in patients undergoing percutaneous coronary intervention.
    Circulation. Cardiovascular interventions, 2010, Jun-01, Volume: 3, Issue:3

    Topics: Acute Coronary Syndrome; Atherectomy; Clopidogrel; Coronary Thrombosis; Coronary Vessels; Diagnostic

2010
Management of perioperative stent thrombosis in patients undergoing surgery.
    Platelets, 2010, Volume: 21, Issue:7

    Topics: Aged; Aspirin; Cardiac Surgical Procedures; Clopidogrel; Coronary Thrombosis; Humans; Male; Perioper

2010
Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window.
    Journal of the American College of Cardiology, 2010, Jul-20, Volume: 56, Issue:4

    Topics: Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Hemorrhage; Humans; Platelet Aggregation; Pur

2010
Initial experience with an institutional bridging protocol for patients with recent coronary stent implantation requiring discontinuation of dual antiplatelet therapy resulting from urgent surgery.
    American journal of therapeutics, 2011, Volume: 18, Issue:6

    Topics: Antithrombins; Aspirin; Blood Loss, Surgical; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents;

2011
Recurrent acute stent thrombosis due to allergic reaction secondary to clopidogrel therapy.
    American journal of therapeutics, 2011, Volume: 18, Issue:4

    Topics: Acute Disease; Adult; Clopidogrel; Coronary Thrombosis; Drug Hypersensitivity; Humans; Male; Platele

2011
Platelet response to clopidogrel and restenosis in patients treated predominantly with drug-eluting stents.
    American heart journal, 2010, Volume: 160, Issue:2

    Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Coronary

2010
Adjunctive treatment with ticagrelor, but not clopidogrel, added to tPA enables sustained coronary artery recanalisation with recovery of myocardium perfusion in a canine coronary thrombosis model.
    Thrombosis and haemostasis, 2010, Volume: 104, Issue:3

    Topics: Adenosine; Animals; Bleeding Time; Blood Coagulation; Clopidogrel; Coronary Circulation; Coronary Th

2010
Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate.
    Journal of the American College of Cardiology, 2010, Sep-14, Volume: 56, Issue:12

    Topics: Adenosine Diphosphate; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Coronary Artery

2010
Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate.
    Journal of the American College of Cardiology, 2010, Sep-14, Volume: 56, Issue:12

    Topics: Adenosine Diphosphate; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Coronary Artery

2010
Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate.
    Journal of the American College of Cardiology, 2010, Sep-14, Volume: 56, Issue:12

    Topics: Adenosine Diphosphate; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Coronary Artery

2010
Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate.
    Journal of the American College of Cardiology, 2010, Sep-14, Volume: 56, Issue:12

    Topics: Adenosine Diphosphate; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Coronary Artery

2010
Frequency of left ventricular thrombus in patients with anterior wall acute myocardial infarction treated with percutaneous coronary intervention and dual antiplatelet therapy.
    The American journal of cardiology, 2010, Nov-01, Volume: 106, Issue:9

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Chi-Square Distribution; Clopidogrel; Combined Modali

2010
Frequency of left ventricular thrombus in patients with anterior wall acute myocardial infarction treated with percutaneous coronary intervention and dual antiplatelet therapy.
    The American journal of cardiology, 2010, Nov-01, Volume: 106, Issue:9

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Chi-Square Distribution; Clopidogrel; Combined Modali

2010
Frequency of left ventricular thrombus in patients with anterior wall acute myocardial infarction treated with percutaneous coronary intervention and dual antiplatelet therapy.
    The American journal of cardiology, 2010, Nov-01, Volume: 106, Issue:9

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Chi-Square Distribution; Clopidogrel; Combined Modali

2010
Frequency of left ventricular thrombus in patients with anterior wall acute myocardial infarction treated with percutaneous coronary intervention and dual antiplatelet therapy.
    The American journal of cardiology, 2010, Nov-01, Volume: 106, Issue:9

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Chi-Square Distribution; Clopidogrel; Combined Modali

2010
[Between thrombosis and bleeding - a case of paroxysmal nocturnal hemoglobinuria].
    Therapeutische Umschau. Revue therapeutique, 2010, Volume: 67, Issue:12

    Topics: Aged; Anticoagulants; Aspirin; Cerebral Hemorrhage; Clopidogrel; Coronary Thrombosis; Drug Therapy,

2010
Significant increase in clopidogrel use across U.S. children's hospitals.
    Pediatric cardiology, 2011, Volume: 32, Issue:2

    Topics: Adolescent; Child; Child, Preschool; Clopidogrel; Coronary Thrombosis; Databases, Factual; Drug Ther

2011
[Efficacy and safety of concomitant use of rabeprazole during dual-antiplatelet therapy with clopidogrel and aspirin after drug-eluting stent implantation: a retrospective cohort study].
    Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2010, Volume: 130, Issue:12

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel;

2010
What is the optimal duration of triple anti-platelet therapy in patients with acute myocardial infarction undergoing drug-eluting stent implantation?
    Journal of cardiology, 2011, Volume: 57, Issue:1

    Topics: Aspirin; Cilostazol; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Female; Follow-Up Studie

2011
Clinical and angiographic outcomes with sirolimus-eluting stent for coronary bifurcation lesions. The J-PMS study.
    Circulation journal : official journal of the Japanese Circulation Society, 2011, Volume: 75, Issue:2

    Topics: Angioplasty; Aspirin; Calcinosis; Coronary Angiography; Coronary Restenosis; Coronary Stenosis; Coro

2011
Behind the paper: stepping up to the antiplatelet.
    Nature medicine, 2011, Volume: 17, Issue:1

    Topics: Amino Acid Sequence; Aryldialkylphosphatase; Aspirin; Clopidogrel; Coronary Thrombosis; Cytochrome P

2011
Management of clopidogrel hypersensitivity without drug interruption.
    The American journal of cardiology, 2011, Mar-15, Volume: 107, Issue:6

    Topics: Adrenal Cortex Hormones; Cardiac Catheterization; Clopidogrel; Coronary Thrombosis; Drug Hypersensit

2011
Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding St
    The American journal of cardiology, 2011, Apr-01, Volume: 107, Issue:7

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Dos

2011
Recurrent myocardial infarction due to one subacute and two very late thrombotic events of drug-eluting stent associated with clopidogrel resistance.
    The Journal of invasive cardiology, 2011, Volume: 23, Issue:2

    Topics: Adult; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Drug

2011
Recurrent episodes of very late stent thrombosis in a patient with aspirin hypersensitivity, stent fracture and malapposition.
    Acute cardiac care, 2011, Volume: 13, Issue:1

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Occlusion; Coronary Thrombosis; Drug

2011
Treatment patterns in acute coronary syndrome patients in the United Kingdom undergoing PCI.
    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2011, Volume: 6, Issue:8

    Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Thromb

2011
[Coronary stent thrombosis in concurrent clopidogrel and proton pump inhibitor therapy].
    Ugeskrift for laeger, 2011, Feb-28, Volume: 173, Issue:9

    Topics: Clopidogrel; Coronary Thrombosis; Drug Interactions; Drug Therapy, Combination; Humans; Platelet Agg

2011
Oral antiplatelet therapy for atherothrombotic disease: current evidence and new directions.
    American heart journal, 2011, Volume: 161, Issue:3

    Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary A

2011
Lack of impact of calcium-channel blockers on the pharmacodynamic effect and the clinical efficacy of clopidogrel after drug-eluting stenting.
    American heart journal, 2011, Volume: 161, Issue:3

    Topics: Aged; Calcium Channel Blockers; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary

2011
Effective management of acute coronary thrombosis in a young woman with lupus using aggressive medical therapy.
    Cardiology, 2011, Volume: 118, Issue:1

    Topics: Adult; Aspirin; Clopidogrel; Coronary Thrombosis; Eptifibatide; Female; Fibrinolytic Agents; Heparin

2011
Serial angioscopic evaluation of neointimal coverage and incidence of thrombus formation after Paclitaxel-eluting stent implantation: comparison between 6- and 18-month follow-up.
    Clinical cardiology, 2011, Volume: 34, Issue:5

    Topics: Aged; Angioscopy; Coronary Artery Disease; Coronary Thrombosis; Drug-Eluting Stents; Female; Health

2011
Comparison of two murine models of thrombosis induced by atherosclerotic plaque injury.
    Thrombosis and haemostasis, 2011, Volume: 105 Suppl 1

    Topics: Animals; Apolipoproteins E; Blood Platelets; Carotid Arteries; Clopidogrel; Coronary Thrombosis; Dis

2011
[Multiple arterial thrombosis and resistance to conventional antiaggregation].
    Revista espanola de cardiologia, 2011, Volume: 64, Issue:9

    Topics: Aged; Angiography; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Resistance; Electrocardiography;

2011
Increased platelet turnover in patients with previous definite stent thrombosis.
    Journal of thrombosis and haemostasis : JTH, 2011, Volume: 9, Issue:7

    Topics: Aspirin; Blood Platelets; Coronary Thrombosis; Female; Humans; Male; Ticlopidine

2011
Massive thrombus burden with recurrence of intracoronary thrombosis early after stenting and delayed onset of prasugrel action in a patient with ST-elevation myocardial infarction and cardiac shock.
    Thrombosis and haemostasis, 2011, Volume: 106, Issue:3

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiopulmonary Resuscitation; Catecholamines; Clopidogrel; Co

2011
Reduced antiplatelet therapy after drug-eluting stenting: multicenter Janus Flex carbostent implantation with short dual antiplatelet treatment for 2 or 6 months-MATRIX study.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2012, Sep-01, Volume: 80, Issue:3

    Topics: Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; D

2012
Influence of low-dose aspirin (81 mg) on the incidence of definite stent thrombosis in patients receiving bare-metal and drug-eluting stents.
    Clinical cardiology, 2011, Volume: 34, Issue:9

    Topics: Aspirin; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; Drug Therapy, Combination; Drug-Elut

2011
Recent trends in Australian percutaneous coronary intervention practice: insights from the Melbourne Interventional Group registry.
    The Medical journal of Australia, 2011, Aug-01, Volume: 195, Issue:3

    Topics: Age Factors; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Australia; Clopidogrel; Comorb

2011
Influence of platelet reactivity on outcome of patients with acute myocardial infarction undergoing primary angioplasty.
    Circulation journal : official journal of the Japanese Circulation Society, 2011, Volume: 75, Issue:9

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Female; Humans; Male; Myocardial I

2011
Antiplatelet therapy in percutaneous coronary intervention: is variability of response clinically relevant?
    Heart (British Cardiac Society), 2011, Volume: 97, Issue:17

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Thrombosis

2011
Stent-related cardiac events beyond three years after implantation of the sirolimus-eluting stent (from the EVASTENT Patients).
    The American journal of cardiology, 2011, Nov-15, Volume: 108, Issue:10

    Topics: Clopidogrel; Cohort Studies; Coronary Artery Disease; Coronary Thrombosis; Diabetes Mellitus; Drug-E

2011
Optical coherence tomography findings during "evolving" stent thrombosis.
    The Journal of invasive cardiology, 2011, Volume: 23, Issue:9

    Topics: Abciximab; Antibodies, Monoclonal; Anticoagulants; Aspirin; Cardiopulmonary Resuscitation; Clopidogr

2011
Intravascular ultrasound and angiographic demonstration of left main stem thrombus-high-risk presentation in a young adult with anabolic steroid abuse.
    The American heart hospital journal, 2010,Winter, Volume: 8, Issue:2

    Topics: Abciximab; Anabolic Agents; Antibodies, Monoclonal; Aspirin; Clopidogrel; Coronary Angiography; Coro

2010
Prognostic implications of early and long-term bleeding events in patients on one-year dual antiplatelet therapy following drug-eluting stent implantation.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2012, Sep-01, Volume: 80, Issue:3

    Topics: Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; D

2012
Relationship between cytochrome P450 2C19*2 polymorphism and stent thrombosis following percutaneous coronary intervention in Chinese patients receiving clopidogrel.
    The Journal of international medical research, 2011, Volume: 39, Issue:5

    Topics: Aged; Aged, 80 and over; Amplified Fragment Length Polymorphism Analysis; Angioplasty, Balloon, Coro

2011
Renal function assessed using cystatin C and antiplatelet efficacy of clopidogrel assessed using the vasodilator-stimulated phosphoprotein index in patients having percutaneous coronary intervention.
    The American journal of cardiology, 2012, Mar-01, Volume: 109, Issue:5

    Topics: Aged; Angioplasty, Balloon, Coronary; Blood Proteins; Cell Adhesion Molecules; Clopidogrel; Coronary

2012
Low mean corpuscular hemoglobin level is a predictor of discontinuation of antiplatelet therapy in patients with acute coronary syndrome.
    Internal medicine (Tokyo, Japan), 2011, Volume: 50, Issue:24

    Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Cl

2011
"Conversations in cardiology": How do you pick the best antiplatelet drug--clopidogrel, prasugrel, ticagrelor for your PCI patient?
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2012, Feb-01, Volume: 79, Issue:2

    Topics: Adenosine; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Decision Making; Humans

2012
The safety of major head and neck surgery in patients taking clopidogrel (Plavix).
    Plastic and reconstructive surgery, 2012, Volume: 129, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Clopidogrel; Coronary Thrombosis; Female; Head and Neck

2012
Acute stent thrombosis: technical complication or inadequate antithrombotic therapy? An optical coherence tomography study.
    JACC. Cardiovascular interventions, 2012, Volume: 5, Issue:2

    Topics: Acute Disease; Aged; Antithrombins; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Eptifibat

2012
Short thromboelastography and the identification of high platelet reactivity while on and off therapy.
    Heart (British Cardiac Society), 2012, Volume: 98, Issue:9

    Topics: Clopidogrel; Coronary Thrombosis; Drug Resistance; Female; Graft Occlusion, Vascular; Humans; Male;

2012
Personalised antiplatelet therapy in stent thrombosis: observations from the Clopidogrel Resistance in Stent Thrombosis (CREST) registry.
    Heart (British Cardiac Society), 2012, Volume: 98, Issue:9

    Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Dose-Response Relationship, Drug; Drug Resistance;

2012
Very late thrombosis of a paclitaxel-eluting stent after 72 months in a patient on dual anti-platelet therapy.
    Cardiovascular journal of Africa, 2012, Apr-12, Volume: 23, Issue:3

    Topics: Aspirin; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Echocardiography; Electrocardiograph

2012
Pharmacodynamic effect of clopidogrel therapy and switching to cilostazol in patients with the CYP2C19 loss-of-function allele (ACCEL-SWITCH) study.
    Journal of thrombosis and haemostasis : JTH, 2012, Volume: 10, Issue:8

    Topics: Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Asian People; Aspirin; Cilostazol; Cl

2012
Simultaneous subacute thrombosis of bare metal coronary stents in two different arteries early after clopidogrel cessation.
    Cardiology journal, 2012, Volume: 19, Issue:3

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Stenosis; Coron

2012
Simultaneous thromboses of two coronary arteries in a heavy smoker woman: a singular case of acute myocardial infarction.
    Minerva cardioangiologica, 2012, Volume: 60, Issue:4

    Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Anti-Inflammatory Agents, Non-Steroidal; Antibodies

2012
Atopaxar: a review of its mechanism of action and role in patients with coronary artery disease.
    Future cardiology, 2012, Volume: 8, Issue:4

    Topics: Acute Coronary Syndrome; Animals; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Humans;

2012
Early and late outcome associated with bleeding events in the setting of dual antiplatelet therapy following stent placement.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2012, Sep-01, Volume: 80, Issue:3

    Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug-Eluting Stents; Female; Hem

2012
Less may be more: insights on dual antiplatelet therapy duration after drug-eluting stent implantation from the MATRIX registry.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2012, Sep-01, Volume: 80, Issue:3

    Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug-Eluting Stents; Female; Hum

2012
Value of platelet pharmacogenetics in common clinical practice of patients with ST-segment elevation myocardial infarction.
    International journal of cardiology, 2013, Sep-10, Volume: 167, Issue:6

    Topics: Aged; Aged, 80 and over; Aryl Hydrocarbon Hydroxylases; Blood Platelets; Clopidogrel; Cohort Studies

2013
Understand the power of Plavix. This antiplatelet drug prevents in-stent clots in women as well as men.
    Heart advisor, 2010, Volume: 13, Issue:4

    Topics: Angioplasty, Balloon; Clopidogrel; Coronary Thrombosis; Drug Administration Schedule; Drug-Eluting S

2010
Predictors of early, late, and very late stent thrombosis after primary percutaneous coronary intervention with bare-metal and drug-eluting stents for ST-segment elevation myocardial infarction.
    JACC. Cardiovascular interventions, 2012, Volume: 5, Issue:10

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Confidence Intervals; Coronary Restenosis; Corona

2012
Effects of pre-hospital clopidogrel administration on early and late residual platelet reactivity in ST-segment elevation myocardial infarction patients undergoing primary intervention.
    Journal of thrombosis and haemostasis : JTH, 2013, Volume: 11, Issue:1

    Topics: Aged; Belgium; Blood Platelets; Clopidogrel; Coronary Thrombosis; Drug Administration Schedule; Emer

2013
A new generation of biodegradable polymer-coated sirolimus-eluting stents for the treatment of coronary artery disease: final 5-year clinical outcomes from the CREATE study.
    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2012, Nov-22, Volume: 8, Issue:7

    Topics: Absorbable Implants; Aged; Aspirin; Cardiovascular Agents; China; Clopidogrel; Coronary Artery Disea

2012
Current antiplatelet therapy for Japanese patients with ST elevation acute myocardial infarction: J-AMI registry.
    Cardiovascular intervention and therapeutics, 2013, Volume: 28, Issue:2

    Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Femal

2013
Cardiovascular risk among patients on clopidogrel anti-platelet therapy after placement of drug-eluting stents is modified by genetic variants in both the CYP2C19 and ABCB1 genes.
    Thrombosis and haemostasis, 2013, Volume: 109, Issue:4

    Topics: Aged; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cass

2013
A case of in-stent thrombosis in a patient with drug eluting stents during perioperative management with glycoprotein IIb/IIIa inhibitors.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2013, Dec-01, Volume: 82, Issue:7

    Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Thrombosis; Drug

2013
Ambulatory use of ticlopidine and clopidogrel in association with percutaneous coronary revascularization procedures in a national managed care organization.
    Journal of interventional cardiology, 2002, Volume: 15, Issue:3

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Female;

2002
Clopidogrel as an antiplatelet agent in transplant heart coronary stenting.
    Journal of interventional cardiology, 2002, Volume: 15, Issue:3

    Topics: Aspirin; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Heart Transplantation; Humans;

2002
Large intracoronary thrombi with good TIMI flow during acute myocardial infarction: four cases of successful aggressive medical management in patients without angiographically detectable coronary atherosclerosis.
    Heart (British Cardiac Society), 2002, Volume: 88, Issue:5

    Topics: Abciximab; Adult; Antibodies, Monoclonal; Anticoagulants; Aspirin; Clopidogrel; Coronary Circulation

2002
Frequency and correlates of coronary stent thrombosis in the modern era: analysis of a single center registry.
    Journal of the American College of Cardiology, 2002, Nov-06, Volume: 40, Issue:9

    Topics: Aged; Aged, 80 and over; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Cor

2002
Influence of residual stenosis after percutaneous coronary intervention with stent implantation on development of restenosis and stent thrombosis.
    The American journal of cardiology, 2003, Jan-15, Volume: 91, Issue:2

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Coronary Restenosis; Coronary T

2003
Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial.
    American heart journal, 2003, Volume: 145, Issue:2

    Topics: Aged; Angioplasty, Balloon, Coronary; Antigens, CD; Clopidogrel; Collagen; Coronary Disease; Coronar

2003
Introduction to "Optimizing management of non-ST-segment elevation acute coronary syndromes". Harmonizing advances in mechanical and pharmacologic intervention.
    Journal of the American College of Cardiology, 2003, Feb-19, Volume: 41, Issue:4 Suppl S

    Topics: Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Cardiac Catheterization; Clopidogre

2003
Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2003, Volume: 59, Issue:3

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Case-Control Studies; Cell Adhesio

2003
[Effects of antiaggregants on concentration of plasma cytokines in patients with acute coronary syndrome].
    Klinicheskaia meditsina, 2003, Volume: 81, Issue:6

    Topics: Acute Disease; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Cytokines; Female

2003
Clopidogrel versus ticlopidine after the placement of coronary artery stents.
    Journal of the American College of Cardiology, 2003, Aug-20, Volume: 42, Issue:4

    Topics: Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Dose-Response Relationship, Drug; Humans

2003
Influence of residual stenosis after coronary stent implantation on development of restenosis and stent thrombosis.
    The American journal of cardiology, 2003, Oct-15, Volume: 92, Issue:8

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Coronary Restenosis; Coronary Thrombo

2003
Incidence, mechanism, predictors, and long-term prognosis of late stent malapposition after bare-metal stent implantation.
    Circulation, 2004, Feb-24, Volume: 109, Issue:7

    Topics: Aged; Aspirin; Atherectomy, Coronary; Catheterization; Cilostazol; Combined Modality Therapy; Corona

2004
Are we making efficient use of clopidogrel?
    European heart journal, 2004, Volume: 25, Issue:6

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Humans; Platelet Aggregation Inhib

2004
Limited early antiplatelet effect of 300 mg clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions.
    European heart journal, 2004, Volume: 25, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disea

2004
Resistance to antiplatelet drugs: is it real or relevant?
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2004, Volume: 62, Issue:1

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Vessel Prosthesis Implantation; Brachytherapy; Clopid

2004
Late stent thrombosis (> 1 year) following clopidogrel withdrawal after brachytherapy treatment: need to assess aspirin resistance?
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2004, Volume: 62, Issue:1

    Topics: Adult; Angioplasty, Balloon, Coronary; Aspirin; Blood Vessel Prosthesis Implantation; Brachytherapy;

2004
PlA polymorphism and platelet reactivity following clopidogrel loading dose in patients undergoing coronary stent implantation.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2004, Volume: 15, Issue:1

    Topics: Abciximab; Adenosine Diphosphate; Aged; Amino Acid Substitution; Antibodies, Monoclonal; Aspirin; Bl

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
    Circulation, 2004, Jun-29, Volume: 109, Issue:25

    Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor

2004
[New antiplatelet agents (platelet receptor blockers): has aspirin come out of place?].
    Praxis, 2004, Jun-02, Volume: 93, Issue:23

    Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Huma

2004
[What should one pay attention to during surgery shortly after brachytherapy with coated stents?].
    Deutsche medizinische Wochenschrift (1946), 2004, Jul-09, Volume: 129, Issue:28-29

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Brachytherapy; Clopidogrel; Contraindications; Coronary Thr

2004
Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
    Chest, 2004, Volume: 126, Issue:3 Suppl

    Topics: Administration, Oral; Aspirin; Clopidogrel; Coronary Thrombosis; Evidence-Based Medicine; Humans; My

2004
Late coronary thrombosis after drug-eluting stent: stent vs patient-driven prescription of aspirin-clopidogrel combination.
    Thrombosis and haemostasis, 2004, Volume: 92, Issue:3

    Topics: Aspirin; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Female; Humans; Middle Aged; P

2004
[Antiplatelet strategies in the acute and chronic therapy of cardiovascular disease].
    Medizinische Klinik (Munich, Germany : 1983), 2004, Aug-15, Volume: 99 Suppl 1

    Topics: Aspirin; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Humans; Long-Term Care; Myocar

2004
Antiplatelet therapy in non-ST-segment elevation acute coronary syndromes.
    JAMA, 2004, Oct-20, Volume: 292, Issue:15

    Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery B

2004
A case of life-saving pharmacologic and mechanical coronary dethrombosis.
    Italian heart journal : official journal of the Italian Federation of Cardiology, 2004, Volume: 5, Issue:11

    Topics: Angioplasty, Balloon; Aspirin; Combined Modality Therapy; Coronary Angiography; Coronary Thrombosis;

2004
Subacute coronary stent thrombosis in a patient developing clopidogrel associated thrombotic thrombocytopenic purpura.
    Heart (British Cardiac Society), 2005, Volume: 91, Issue:2

    Topics: Aged; Angina, Unstable; Blood Vessel Prosthesis; Clopidogrel; Coronary Restenosis; Coronary Stenosis

2005
Dual antiplatelet therapy for coronary stenting: a clear path for a research agenda.
    Circulation, 2005, Mar-08, Volume: 111, Issue:9

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug A

2005
[Exercise-induced left arm pain and thrombocytosis].
    Praxis, 2005, Apr-13, Volume: 94, Issue:15

    Topics: Angioplasty, Balloon, Coronary; Bone Marrow Examination; Clopidogrel; Coronary Angiography; Coronary

2005
Very late thrombosis after implantation of sirolimus eluting stent.
    Heart (British Cardiac Society), 2005, Volume: 91, Issue:6

    Topics: Adult; Aspirin; Blood Vessel Prosthesis; Catheterization; Clopidogrel; Coronary Angiography; Coronar

2005
Validation of predictors of intraprocedural stent thrombosis in the drug-eluting stent era.
    The American journal of cardiology, 2005, Jun-15, Volume: 95, Issue:12

    Topics: Acute Disease; Anticoagulants; Antineoplastic Agents, Phytogenic; Blood Vessel Prosthesis Implantati

2005
Increased long term rates of stent thrombosis and mortality in patients given clopidogrel as compared to ticlopidine following coronary stent implantation.
    International journal of cardiology, 2005, Sep-01, Volume: 103, Issue:3

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; D

2005
What is the best measure of thrombotic risks--pretreatment platelet aggregation, clopidogrel responsiveness, or posttreatment platelet aggregation?
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2005, Volume: 66, Issue:4

    Topics: Blood Vessel Prosthesis Implantation; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Humans; P

2005
Optimal antiplatelet treatment for percutaneous coronary intervention: clopidogrel vs. ticlopidine.
    International journal of cardiology, 2007, Jan-02, Volume: 114, Issue:1

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Drug Interactions; Drug Resistance

2007
Antiplatelet therapy after percutaneous coronary intervention.
    Cerebrovascular diseases (Basel, Switzerland), 2006, Volume: 21 Suppl 1

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Coronary Thrombosis; Drug Resistan

2006
Potent low dose platelet inhibitory effects of clopidogrel and aspirin on coronary thrombus formation in an animal model of acute unstable angina.
    Thrombosis and haemostasis, 2006, Volume: 95, Issue:2

    Topics: Acute Disease; Angina, Unstable; Animals; Aspirin; Clopidogrel; Coronary Thrombosis; Disease Models,

2006
Successful lysis of coronary thrombi by long term warfarin treatment after a failed course of tirofiban infusion.
    International journal of cardiology, 2006, Mar-22, Volume: 108, Issue:1

    Topics: Angina Pectoris; Anticoagulants; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combinatio

2006
Pharmacologic inhibition of platelet vWF-GPIb alpha interaction prevents coronary artery thrombosis.
    Thrombosis and haemostasis, 2006, Volume: 95, Issue:3

    Topics: Animals; Bleeding Time; Clopidogrel; Coronary Thrombosis; Disease Models, Animal; Dogs; Dose-Respons

2006
Suspected clopidogrel resistance in a patient with acute stent thrombosis.
    Nature clinical practice. Cardiovascular medicine, 2006, Volume: 3, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Coronary Stenosis; Coronary

2006
Combined aspirin and clopidogrel resistance associated with recurrent coronary stent thrombosis.
    Clinical research in cardiology : official journal of the German Cardiac Society, 2006, Volume: 95, Issue:2

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Rest

2006
Late in-stent thrombosis in a patient with systemic lupus erythematosus and hyperhomocysteinemia while on clopidogrel and aspirin.
    The Journal of invasive cardiology, 2006, Volume: 18, Issue:6

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Coagulation Disorders; Clopidogrel; Coronary Artery D

2006
Subacute thrombosis after coronary stenting occurring with resistance to ticlopidine.
    Internal medicine (Tokyo, Japan), 2006, Volume: 45, Issue:10

    Topics: Aged; Angioplasty, Balloon, Coronary; Atherectomy, Coronary; Coronary Thrombosis; Drug Resistance; H

2006
Clopidogrel-associated thrombotic thrombocytopenic purpura presenting with coronary artery thrombosis.
    American journal of hematology, 2006, Volume: 81, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Female; Humans; L-Lactate De

2006
Use of ticlopidine and cilostazol after intracoronary drug-eluting stent placement in a patient with previous clopidogrel-induced thrombotic thrombocytopenic purpura: a case report.
    The Journal of invasive cardiology, 2006, Volume: 18, Issue:7

    Topics: ADAM Proteins; ADAMTS1 Protein; Aged; Apoptosis; Aspirin; Autoantibodies; Cilostazol; Clopidogrel; C

2006
[Combination of clopidogrel and aspirin was no better than aspirin alone for prevention of atherothrombotic events in stable patients. Results of CHARISMA].
    Kardiologiia, 2006, Volume: 46, Issue:5

    Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug T

2006
Documented subacute stent thrombosis within thirty days after stenting with sirolimus-eluting stent (Cypher) for acute myocardial infarction: a Japanese single center retrospective non-randomized study.
    Circulation journal : official journal of the Japanese Circulation Society, 2006, Volume: 70, Issue:8

    Topics: Aged; Aspirin; Coronary Restenosis; Coronary Thrombosis; Disease Progression; Female; Humans; Immuno

2006
Clinical, biochemical and genetical resistance to clopidogrel in a patient with recurrent stent thrombosis.
    International journal of cardiology, 2007, Mar-02, Volume: 116, Issue:1

    Topics: Clopidogrel; Coronary Thrombosis; Dose-Response Relationship, Drug; Drug Monitoring; Drug Resistance

2007
The CHARISMA trial and the REACH registry outcomes.
    Journal of the National Medical Association, 2006, Volume: 98, Issue:10

    Topics: Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Humans; Inciden

2006
Clinical and angiographic outcomes of sirolimus-eluting stents implantation in Japanese patients in daily practice.
    Circulation journal : official journal of the Japanese Circulation Society, 2006, Volume: 70, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Disease; Coronary Restenosis; C

2006
Late thrombosis of drug-eluting stents after discontinuation of clopidogrel: report of two cases and review of the literature.
    Connecticut medicine, 2006, Volume: 70, Issue:8

    Topics: Aged, 80 and over; Aspirin; Clopidogrel; Coronary Thrombosis; Humans; Male; Middle Aged; Myocardial

2006
Late angiographic stent thrombosis in a drug-eluting stent that occurred 20 months after premature discontinuation of clopidogrel administration.
    International heart journal, 2006, Volume: 47, Issue:5

    Topics: Adult; Clopidogrel; Coronary Angiography; Coronary Stenosis; Coronary Thrombosis; Humans; Male; Plat

2006
A current problem in cardiology: very late thrombosis after implantation of sirolimus eluting stent.
    Cardiology, 2007, Volume: 108, Issue:4

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Huma

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.
    European heart journal, 2007, Volume: 28, Issue:8

    Topics: Aged; Aspirin; Catheterization; Cell Proliferation; Coronary Restenosis; Coronary Thrombosis; Drug T

2007
Late ischemic events after clopidogrel cessation following drug-eluting stenting: should we be worried?
    Journal of the American College of Cardiology, 2006, Dec-19, Volume: 48, Issue:12

    Topics: Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug Delivery Systems; Humans; Immunosuppressiv

2006
A new caution for patients with drug-coated stents.
    Heart advisor, 2006, Volume: 9, Issue:8

    Topics: Clopidogrel; Coronary Disease; Coronary Thrombosis; Humans; Platelet Aggregation Inhibitors; Stents;

2006
Stent thrombosis: consider also low response to antiplatelets.
    BMJ (Clinical research ed.), 2007, Jan-13, Volume: 334, Issue:7584

    Topics: Aspirin; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; Drug Implants; Humans; Platelet Aggr

2007
Stent thrombosis: patient card on discontinuing clopidogrel is available.
    BMJ (Clinical research ed.), 2007, Jan-13, Volume: 334, Issue:7584

    Topics: Clopidogrel; Coronary Restenosis; Coronary Thrombosis; Drug Implants; Humans; Medical Records; Plate

2007
Response to letter of Dr van Werkum et al.
    International journal of cardiology, 2007, Jun-25, Volume: 119, Issue:1

    Topics: Clopidogrel; Coronary Thrombosis; Drug Resistance; Humans; Platelet Aggregation Inhibitors; Ticlopid

2007
Incidence of side-effects of ticlopidine after sirolimus-eluting stent implantation.
    Circulation journal : official journal of the Japanese Circulation Society, 2007, Volume: 71, Issue:4

    Topics: Aged; Blood Vessel Prosthesis Implantation; Chemical and Drug Induced Liver Injury; Coronary Thrombo

2007
Double-trouble: three cases with simultaneous stent thrombosis in different coronary arteries.
    Journal of interventional cardiology, 2007, Volume: 20, Issue:2

    Topics: Aged; Angioplasty, Balloon; Angioplasty, Balloon, Coronary; Aspirin; Blood Vessel Prosthesis; Clopid

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.
    Circulation, 2007, May-08, Volume: 115, Issue:18

    Topics: Aged; Angioplasty, Balloon, Coronary; Anthropometry; Aspirin; Clopidogrel; Coronary Restenosis; Coro

2007
A case report of simultaneous thrombosis of two coronary artery stents in association with clopidogrel resistance.
    Clinical cardiology, 2007, Volume: 30, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug Resi

2007
Late thrombosis of a drug-eluting stent during combined anti-platelet therapy in a clopidogrel nonresponsive diabetic patient: shall we routinely test platelet function?
    Thrombosis and haemostasis, 2007, Volume: 97, Issue:5

    Topics: Aged; Clopidogrel; Coronary Thrombosis; Coronary Vessels; Diabetic Angiopathies; Drug Resistance; Hu

2007
Increased incidence of stent thrombosis in patients with cocaine use.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2007, Jun-01, Volume: 69, Issue:7

    Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Cocaine-Related Disorders; Co

2007
[Treatment of intrastent restenosis by drug eluting stents: experience from one cardiology centre].
    Archives des maladies du coeur et des vaisseaux, 2007, Volume: 100, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Aspirin; Clopidogrel; Coronary Angiography; Coronar

2007
Timing of thrombotic events in patients receiving 2 weeks of clopidogrel therapy post bare metal coronary artery stenting: a New Zealand retrospective study.
    The New Zealand medical journal, 2007, Jun-01, Volume: 120, Issue:1255

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Coronary Disease; Coronary

2007
Clopidogrel and stent thrombosis after percutaneous coronary intervention.
    The New Zealand medical journal, 2007, Jun-01, Volume: 120, Issue:1255

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Coronary Restenosis; Coronary Thrombo

2007
Long-term safety and efficacy of drug-eluting stents: two-year results of the REAL (REgistro AngiopLastiche dell'Emilia Romagna) multicenter registry.
    Circulation, 2007, Jun-26, Volume: 115, Issue:25

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Angi

2007
Residual platelet activity is increased in clopidogrel- and ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease.
    Heart (British Cardiac Society), 2008, Volume: 94, Issue:6

    Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Cohort Studies; Coronary Artery Disease; Corona

2008
Confined late stent thrombosis following clopidogrel withdrawal in a patient with multi-segment sirolimus-eluting stent implants.
    Journal of cardiovascular medicine (Hagerstown, Md.), 2007, Volume: 8, Issue:7

    Topics: Abciximab; Aged; Angioplasty, Balloon; Antibodies, Monoclonal; Anticoagulants; Clopidogrel; Coronary

2007
Comparison of drug-eluting stents with bare metal stents in unselected patients with acute myocardial infarction.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2007, Jul-01, Volume: 70, Issue:1

    Topics: Aged; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Cardiovascular Diseases; Clopidogrel; C

2007
Very late paclitaxel-eluting stent thrombosis despite 21 months of clopidogrel treatment after percutaneous coronary intervention.
    Journal of cardiovascular medicine (Hagerstown, Md.), 2007, Volume: 8, Issue:8

    Topics: Acute Disease; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Clopidogrel; Coronary Angiogra

2007
[Suspected clopidogrel resistance associated with recurrent coronary stent thrombosis--a case report].
    Kardiologia polska, 2007, Volume: 65, Issue:7

    Topics: Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombos

2007
Perioperative thrombotic risk of coronary artery stents: possible role for intravenous platelet blockade.
    Anesthesiology, 2007, Volume: 107, Issue:3

    Topics: Aspirin; Clopidogrel; Coronary Thrombosis; Humans; Injections, Intravenous; Perioperative Care; Plat

2007
Sirolimus-eluting stent thrombosis several years after clopidogrel discontinuation.
    The Journal of invasive cardiology, 2007, Volume: 19, Issue:9

    Topics: Adult; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Thrombosis; Drug Deliver

2007
Angiographic and procedural correlates of stent thrombosis after intracoronary implantation of drug-eluting stents.
    Journal of interventional cardiology, 2007, Volume: 20, Issue:5

    Topics: Clopidogrel; Coronary Angiography; Coronary Restenosis; Coronary Thrombosis; Drug-Eluting Stents; He

2007
Triple antithrombotic therapy with aspirin, clopidogrel and warfarin--a persisting dilemma.
    Internal and emergency medicine, 2007, Volume: 2, Issue:3

    Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Fibrinoly

2007
Clopidogrel versus aspirin in patients with atherothrombosis: CAPRIE-based calculation of cost-effectiveness for Germany.
    Current medical research and opinion, 2008, Volume: 24, Issue:1

    Topics: Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Clopidogrel; Cohort Studies; Coronary Thrombosis;

2008
[Prasugrel, a new thienopyridine].
    Hamostaseologie, 2007, Volume: 27, Issue:5

    Topics: Clinical Trials, Phase II as Topic; Clopidogrel; Coronary Thrombosis; Humans; Piperazines; Platelet

2007
Perioperative complications in patients with drug-eluting stents: a three-year audit at Geelong Hospital.
    Anaesthesia and intensive care, 2007, Volume: 35, Issue:6

    Topics: Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Humans; Intraoperative Complications; Male; M

2007
The success of clopidogrel treatment for recurrent coronary thrombosis in a patient with aortic and mitral valve replacement.
    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2008, Volume: 14, Issue:4

    Topics: Aortic Valve; Clopidogrel; Coronary Thrombosis; Female; Heart Valve Prosthesis; Humans; Middle Aged;

2008
[Four years of circulatory support with the INCOR axial pump from Berlin Heart].
    Archives des maladies du coeur et des vaisseaux, 2007, Volume: 100, Issue:11

    Topics: Clopidogrel; Coronary Thrombosis; Enoxaparin; Fibrinolytic Agents; Heart Failure; Heart-Assist Devic

2007
Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation.
    European heart journal, 2008, Volume: 29, Issue:8

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug-Elut

2008
Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation.
    European heart journal, 2008, Volume: 29, Issue:8

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug-Elut

2008
Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation.
    European heart journal, 2008, Volume: 29, Issue:8

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug-Elut

2008
Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation.
    European heart journal, 2008, Volume: 29, Issue:8

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug-Elut

2008
Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation.
    European heart journal, 2008, Volume: 29, Issue:8

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug-Elut

2008
Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation.
    European heart journal, 2008, Volume: 29, Issue:8

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug-Elut

2008
Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation.
    European heart journal, 2008, Volume: 29, Issue:8

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug-Elut

2008
Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation.
    European heart journal, 2008, Volume: 29, Issue:8

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug-Elut

2008
Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation.
    European heart journal, 2008, Volume: 29, Issue:8

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug-Elut

2008
Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation.
    European heart journal, 2008, Volume: 29, Issue:8

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug-Elut

2008
Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation.
    European heart journal, 2008, Volume: 29, Issue:8

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug-Elut

2008
Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation.
    European heart journal, 2008, Volume: 29, Issue:8

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug-Elut

2008
Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation.
    European heart journal, 2008, Volume: 29, Issue:8

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug-Elut

2008
Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation.
    European heart journal, 2008, Volume: 29, Issue:8

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug-Elut

2008
Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation.
    European heart journal, 2008, Volume: 29, Issue:8

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug-Elut

2008
Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation.
    European heart journal, 2008, Volume: 29, Issue:8

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug-Elut

2008
Very late thrombosis in a bare metal stent: an under-recognized problem.
    The Canadian journal of cardiology, 2008, Volume: 24, Issue:2

    Topics: Aspirin; Clopidogrel; Coronary Angiography; Coronary Restenosis; Coronary Thrombosis; Humans; Male;

2008
Which patients receiving warfarin can be treated safely with a drug-eluting stent?
    Heart (British Cardiac Society), 2008, Volume: 94, Issue:3

    Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Restenosis; Cor

2008
Clinical outcomes after multilesion percutaneous coronary intervention: comparison between exclusive and selective use of drug-eluting stents.
    The Journal of invasive cardiology, 2008, Volume: 20, Issue:3

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Cor

2008
Drug-eluting versus bare-metal stents: when and for whom?
    The Journal of invasive cardiology, 2008, Volume: 20, Issue:3

    Topics: Angioplasty, Balloon, Coronary; Canada; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; D

2008
Very very late thrombosis of a sirolimus-eluting stent: does suboptimal stent expansion take its toll even after three years?
    Journal of cardiovascular medicine (Hagerstown, Md.), 2008, Volume: 9, Issue:4

    Topics: Aspirin; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Humans; Male; Middle Aged; Platelet

2008
Simultaneous subacute coronary drug-eluting stent thrombosis in two different vessels of a patient with factor V Leiden mutation.
    Journal of cardiovascular medicine (Hagerstown, Md.), 2008, Volume: 9, Issue:4

    Topics: Angioplasty, Balloon; Anticoagulants; Aspirin; Clopidogrel; Coronary Angiography; Coronary Thrombosi

2008
Resistance to what, does it matter? How do we study it?
    European heart journal, 2008, Volume: 29, Issue:8

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug Resistance

2008
Clinical, procedural, and pharmacologic correlates of acute and subacute stent thrombosis: results of a multicenter case-control study with 145 thrombosis events.
    American heart journal, 2008, Volume: 155, Issue:4

    Topics: Acute Disease; Aged; Analysis of Variance; Case-Control Studies; Clopidogrel; Coronary Angiography;

2008
Stent thrombosis--a complication best avoided.
    The Journal of invasive cardiology, 2008, Volume: 20, Issue:4

    Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Coronary Th

2008
Percutaneous coronary intervention in neurosurgical patients.
    The Journal of invasive cardiology, 2008, Volume: 20, Issue:4

    Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Thrombos

2008
Resistance to platelet antiaggregants: an important cause of very late thrombosis of drug eluting stents? Observations from five cases.
    Archives of cardiovascular diseases, 2008, Volume: 101, Issue:2

    Topics: Aged; Aged, 80 and over; Aspirin; Cell Adhesion Molecules; Clopidogrel; Coronary Thrombosis; Drug Re

2008
Acute stent thrombosis in a patient with giant cell arteritis.
    The Canadian journal of cardiology, 2008, Volume: 24, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Di

2008
Commentary for "Comparison of drug eluting stents with bare metal stents in unselected patients with acute myocardial infarction".
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2008, May-01, Volume: 71, Issue:6

    Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Humans; Metal

2008
Antithrombotic effect of ticlopidine on occlusive thrombi of small coronary arteries in (NZWxBXSB)F1 male mice with myocardial infarction and systemic lupus erythematosus.
    Journal of cardiovascular pharmacology, 1995, Volume: 25, Issue:1

    Topics: Analysis of Variance; Animals; Antigen-Antibody Complex; Blood Urea Nitrogen; Coronary Disease; Coro

1995
[Pilot study of the efficacy of ticlopidine in early patency of coronary endoprostheses].
    Archives des maladies du coeur et des vaisseaux, 1994, Volume: 87, Issue:11

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Coronary Disease; Coron

1994
Relation of thrombotic occlusion of coronary stents to the indication for stenting, stent size, and anticoagulation.
    The American journal of cardiology, 1995, Jan-01, Volume: 75, Issue:1

    Topics: Angioplasty, Balloon, Coronary; Coronary Disease; Coronary Thrombosis; Female; Heparin; Humans; Male

1995
Prevention of intra-coronary thrombosis in the anaesthetised dog: the importance of thromboxane A2 and thrombin.
    Thrombosis and haemostasis, 1994, Volume: 71, Issue:3

    Topics: Anesthesia; Animals; Aspirin; Biphenyl Compounds; Blood Coagulation Tests; Coronary Circulation; Cor

1994
Clopidogrel is more effective than aspirin in preventing coronary artery reocclusion after thrombolysis.
    Transactions of the Association of American Physicians, 1993, Volume: 106

    Topics: Animals; Aspirin; Blood Coagulation; Clopidogrel; Coronary Thrombosis; Disease Models, Animal; Dogs;

1993
Ticlopidine and subcutaneous heparin as an alternative regimen following coronary stenting.
    Catheterization and cardiovascular diagnosis, 1994, Volume: 32, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Coronary Thrombosis; Female; Heparin

1994
Clopidogrel is more effective than aspirin as adjuvant treatment to prevent reocclusion after thrombolysis.
    The American journal of physiology, 1994, Volume: 267, Issue:2 Pt 2

    Topics: Animals; Aspirin; Clopidogrel; Coronary Thrombosis; Dogs; Drug Therapy, Combination; Fibrinolytic Ag

1994
Improved outcome of coronary stenting by utilizing a modified treatment protocol.
    Israel journal of medical sciences, 1996, Volume: 32, Issue:9

    Topics: Aged; Angioplasty, Balloon, Coronary; Clinical Protocols; Combined Modality Therapy; Coronary Diseas

1996
Reduction of thrombotic and hemorrhagic complications after stent implantation.
    American heart journal, 1996, Volume: 132, Issue:6

    Topics: Acute Disease; Aged; Anticoagulants; Coronary Angiography; Coronary Thrombosis; Female; Follow-Up St

1996
Subacute stent thrombosis in the era of intravascular ultrasound-guided coronary stenting without anticoagulation: frequency, predictors and clinical outcome.
    Journal of the American College of Cardiology, 1997, Volume: 29, Issue:1

    Topics: Anticoagulants; Aspirin; Case-Control Studies; Causality; Coronary Angiography; Coronary Disease; Co

1997
Ticlopidine in the prevention of thrombus formation after percutaneous transluminal coronary angioplasty (PTCA).
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 1997, Volume: 80, Issue:2

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Coronary Disease; Coronary Thrombosis

1997
Antiplatelet therapy alone is safe and effective after coronary stenting: observations of a transition in practice.
    The Canadian journal of cardiology, 1997, Volume: 13, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Ar

1997
Neutropenia with ticlopidine plus aspirin.
    Lancet (London, England), 1997, May-24, Volume: 349, Issue:9064

    Topics: Aspirin; Chemoprevention; Coronary Thrombosis; Coronary Vessels; Drug Combinations; Fibrinolytic Age

1997
Micro stent implantation in patients with acute myocardial infarction without anticoagulation: clinical experience with two different antithrombotic protocols.
    Catheterization and cardiovascular diagnosis, 1998, Volume: 44, Issue:2

    Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Blood Vessel Prosthesis Implantation; Coronary Angiograp

1998
[Thrombocyte aggregation inhibition].
    Der Internist, 1998, Volume: 39, Issue:8

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Coronary Thrombosis; Humans; Intracranial Embolism

1998
Emergency coronary artery bypass grafting (CABG) after failed coronary artery intervention--caution regarding the combined use of aspirin, ticlopidine and abciximab.
    Australian and New Zealand journal of medicine, 1998, Volume: 28, Issue:4

    Topics: Abciximab; Adult; Angina Pectoris; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin;

1998
Fatal neutropenia and thrombocytopenia associated with ticlopidine after stenting.
    The American journal of cardiology, 1999, Jan-01, Volume: 83, Issue:1

    Topics: Aged; Coronary Disease; Coronary Thrombosis; Fatal Outcome; Female; Humans; Male; Middle Aged; Neutr

1999
Preliminary experience with intravascular ultrasound guided Palmaz-Schatz coronary stenting: the acute and short-term results on a consecutive series of patients.
    Journal of interventional cardiology, 1994, Volume: 7, Issue:2

    Topics: Aged; Coronary Angiography; Coronary Artery Disease; Coronary Thrombosis; Evaluation Studies as Topi

1994
Toward the elimination of stent thrombosis.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 1999, Volume: 46, Issue:1

    Topics: Coronary Thrombosis; Fibrinolytic Agents; Humans; Registries; Stents; Ticlopidine

1999
[Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation].
    Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology, 1999, Volume: 18, Issue:6

    Topics: Aspirin; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Humans; Platelet Aggregation I

1999
Effectiveness of aspirin and clopidogrel combination therapy in coronary stenting.
    The American journal of cardiology, 1999, Sep-15, Volume: 84, Issue:6

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Dise

1999
Vale, warfarin: a stentorian farewell.
    American heart journal, 1999, Volume: 138, Issue:4 Pt 1

    Topics: Animals; Anticoagulants; Aspirin; Coronary Thrombosis; Dogs; Humans; Platelet Aggregation Inhibitors

1999
Studies published on clopidogrel-aspirin for coronary stent placement.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2000, Jan-15, Volume: 57, Issue:2

    Topics: Aspirin; Clopidogrel; Coronary Thrombosis; Coronary Vessels; Drug Combinations; Humans; Platelet Agg

2000
[Imputable cutaneous eruption caused by ticlopidine after implantation of a coronary endoprosthesis: why not continue treatment?].
    Presse medicale (Paris, France : 1983), 2000, Feb-19, Volume: 29, Issue:6

    Topics: Angioplasty, Balloon, Coronary; Coronary Disease; Coronary Thrombosis; Dose-Response Relationship, D

2000
Ticlopidine plus aspirin for coronary thrombosis in Kawasaki disease.
    Pediatrics, 2000, Volume: 105, Issue:5

    Topics: Aspirin; Coronary Thrombosis; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Infant; Male;

2000
Incidence of thrombocytopenia following coronary stent placement using abciximab plus clopidogrel or ticlopidine.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2000, Volume: 50, Issue:4

    Topics: Abciximab; Adult; Aged; Antibodies, Monoclonal; Blood Vessel Prosthesis Implantation; Cardiac Cathet

2000
Extensive thrombus prior to elective percutaneous coronary intervention.
    The Journal of invasive cardiology, 2001, Volume: 13, Issue:7

    Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Clopidogrel; Coronary Thrombosis; Elective Surgical

2001
Late acute thrombosis after paclitaxel eluting stent implantation.
    Heart (British Cardiac Society), 2001, Volume: 86, Issue:3

    Topics: Acute Disease; Angiogenesis Inhibitors; Aspirin; Coronary Disease; Coronary Thrombosis; Drug Implant

2001
Adjunctive therapies in the cath lab. Subacute stent thrombosis developing twelve days after discontinuation of ticlopidine treatment.
    The Journal of invasive cardiology, 2001, Volume: 13, Issue:9

    Topics: Acute Disease; Aged; Coronary Thrombosis; Female; Humans; Platelet Aggregation Inhibitors; Stents; S

2001
Coronary stent thrombosis: insights from the porcine coronary stent model.
    Thrombosis and haemostasis, 2001, Volume: 86, Issue:3

    Topics: Animals; Anticoagulants; Aspirin; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Coronary Vess

2001
Aspirin plus clopidogrel for everyone: panacea comes true in the 21st century.
    The Journal of invasive cardiology, 2001, Volume: 13, Issue:12

    Topics: Aspirin; Clopidogrel; Coronary Thrombosis; Humans; Platelet Aggregation Inhibitors; Postoperative Co

2001
Thrombostatin inhibits cyclic flow variations in stenosed canine coronary arteries.
    Thrombosis and haemostasis, 2001, Volume: 86, Issue:5

    Topics: Animals; Aspirin; Blood Coagulation Tests; Bradykinin; Clopidogrel; Coronary Stenosis; Coronary Thro

2001
Thrombus formation on guide wires during routine PTCA procedures: a scanning electron microscopic evaluation.
    The Canadian journal of cardiology, 2002, Volume: 18, Issue:3

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Coated Materials, Biocompatible; Coronary Thrombosis;

2002
[Two platelet inhibitors after acute coronary syndrome. Many colleagues are not aware of this].
    MMW Fortschritte der Medizin, 2002, Mar-28, Volume: 144, Issue:13

    Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug T

2002
[A case of hypertrophic obstructive cardiomyopathy with left atrial giant thrombus during anti-platelet therapy].
    Kokyu to junkan. Respiration & circulation, 1989, Volume: 37, Issue:3

    Topics: Aged; Cardiomyopathy, Hypertrophic; Coronary Disease; Coronary Thrombosis; Echocardiography; Female;

1989
Intracoronary thrombodynamics in the early phase of acute myocardial infarction.
    Japanese circulation journal, 1988, Volume: 52, Issue:7

    Topics: Animals; Blood Pressure; Coronary Circulation; Coronary Disease; Coronary Thrombosis; Death, Sudden;

1988